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Almost every process in the cell involves proteins, each serving their own particular function. 
This functionality can however be expanded by covalent attachments to their chain of amino 
acids: posttranslational modifications (PTMs). After transcription and folding the protein can 
be subjected to a wide variety of alterations, including the conjugation of hydroxyl-, methyl-, 
or phosphate groups with certain residues. The attachment of such a molecular identifier 
can have a very specific effect on the function of this protein, changing its cellular location 
and its ability to interact with other proteins amongst others1. 
Such PTMs not only broaden the functionality of proteins, it can also account for a layer of 
regulation. By controlling the target protein function, the modification can prevent the need 
for the target to be degraded and the need to synthesise a new protein with only a minor 
difference. Furthermore, the modification can alter the three-dimensional conformation 
of the target, mediate protein-protein interactions and change the intrinsic activity of the 
target. Through these functions, PTMs can activate and inhibit cell processes, allowing for 
quickly fine-tuning the delicate balance necessary at a certain stage in the cell’s lifecycle2,3.
Ubiquitin
One of these modifications is the conjugation of ubiquitin to the target protein (Fig. 1). 
Ubiquitin is a protein of 76 residues (Fig. 2a), identified in 1975 as “ubiquitous immunopoietic 
peptide”4. The peptide has been found in all eukaryotic cells with strong sequence 
conservation: between mammals, plants and yeast only three of the 76 amino acids change. 
After the discovery of ubiquitin as a PTM, a vast amount of research into the function has 
been published5,6. Ubiquitination has since then been recognised to be critical for many 
cellular processes, ranging from DNA damage response to proteasomal degradation and from 
transcription to modulating protein activity6,7. The findings resulted in a better understanding 
of how the cell controls biochemical processes such as the cell cycle. The importance of 
ubiquitin-driven proteolysis is underscored by the Nobel Prize in Chemistry awarded in 20048.
Ubiquitination pathway
The conjugation of ubiquitin to a target protein (ubiquitination, or ubiquitylation) is the best 
studied part of the ubiquitin pathway (Fig. 1). Ubiquitin is attached to an amino group on 
the target with its C-terminus (Fig. 2b), and requires three successive enzyme activities for 
creating this covalent isopeptide bond (Fig. 1). The first step is executed by the ubiquitin-
activating enzyme E19. The enzyme activates the C-terminal glycine of ubiquitin, using ATP10. 
The adenylated ubiquitin then forms a thioester bond with a cysteine of the E1 enzyme, 
releasing AMP. In the second step the activated ubiquitin is transferred to a ubiquitin-
conjugating enzyme, E211. In the third step the final transfer of ubiquitin from the active site 
cysteine to the amino group, most often the ε-amino group of a lysine, is carried out (Fig. 1). 
This transfer can occur directly from the E2 to the target, or through a covalent E3-ubiquitin 
intermediate12. The latter case requires a ubiquitin ligase E3 with the HECT domain that takes 
over the active ubiquitin from the E2 and subsequently transfers it to the target protein13. 
Direct transfer, however, is catalysed by an E3 that contains a RING domain. This brings the 
E2 in close proximity to the target14,15 and catalyses the reaction16,17. Some E3 classes display 
a mix of these two methods, as is seen for example in ubiquitin transfer mediated by Cullin-
RING ligases18,19 or the RING-in-between RING family of E3s20.
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This last step, where the ubiquitin is attached to the target lysine, determines a change of 
fate for this target. Specificity can be achieved by the spatial arrangement of the target, E3 
and E2, induced by their specific interactions21. This orients the ubiquitin and lysines within 
reach can all be ubiquitinated22. Whereas only two E1 enzymes have been found, the amount 
of E2s is in the dozens and so far about five hundred E3s are discovered23. This large amount 
of ubiquitin ligases expands the targeted proteins greatly and makes sure various processes 
can be regulated specifically through the ubiquitination pathway24,25.
Ubiquitin chains
The ubiquitination pathway is more versatile than just mono-ubiquitination, where ubiquitin is 
specifically attached to a target protein. Chains of ubiquitin, with various linkage types can be 
built onto the target-conjugated ubiquitin, as ubiquitin itself has multiple amino groups that 
can be ubiquitinated. There are seven lysines that can be modified and the N-terminus also has 
an amino group that can be targeted, resulting in linear ubiquitin chains (Fig. 2a). These eight 
ubiquitin attachment points allow for a variety of ubiquitin chains that can be formed (M1, 
K6, K11, K27, K29, K33, K48 and K63), and since mixed chains are possible26–28 a large variety 
of ubiquitin signals can be encoded onto a target protein29,30. These individual modifications 
may assign a different fate to the protein targeted. Usage of chemically generated chains31,32 
can help to identify their specific interactors33 and investigate the effect of the linkage type.
The effects of these different ubiquitin chains on proteins have been studied to various 
degrees34. K48-linked ubiquitin chains have been found to be the most abundant type 
of chains and have been studied extensively35. The K48 mark targets the substrate for 
proteasomal degradation, as the three-dimensional structure of these chains is recognised 
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Figure 1. Ubiquitination pathway. Ubiquitination is carried out in an E1-E2-E3 enzyme cascade, requiring 
ATP in the process. DUBs can reverse this post-translational modification.
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by the proteasome subunits Rpn10 and Rpn1336,37. Other compacted ubiquitin chains (Fig. 
2c), such as K11-linked ones38, change the substrate’s fate similarly39,40, indicating that the 
downstream effect of these chains is dependent on the three-dimensional conformation41,42. 
Ubiquitin chains that exhibit a more extended conformation (Fig. 2c) are recognised by 
different proteins, and therefore have a different effect38. For instance linear chains (M1), 
that are recognised to act predominantly in the NF-κB pathway43. Or K63-linked chains which 
serve as a mark for signalling, is also important in this NF-κB pathway44, but is also important 
in the DNA damage response45,46.
This variety of chains, with their specific outcomes, is further complicated by the existence of 
mixed chains26,47. These chains can contain multiple ubiquitin molecules linked with different 
linkages, but can also be supplemented with other PTMs48,49 such as phosphorylation50 or 
inclusion of ubiquitin-like modifiers51 like SUMO52,53, FAT1054 or ISG1555.
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Figure 2. The ubiquitin structure in A. (from PDB: 1UBQ109) shows the C-terminus that can get covalently 
linked to the target lysine (K) via an isopeptide bond. Figure B. depicts such an isopeptide bond, for clarity 
the C-terminal residues of Ub are marked as well. Ubiquitin itself has the N-terminus and 7 lysines available 
for ubiquitination (see colouring legend on the sequence at the bottom of A.) to generate ubiquitin chains. 
The different chain options can lead to different outcomes, based on the adopted three-dimensional 
architecture. In C. and D. the difference between a compacted chain (K63, PDB: 5GOK) and an extended 
one (K48, PDB: 3M3J) is visualised.
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Deubiquitination
Just like with other PTMs, proper regulation can only be performed if it is possible to 
remove the signal from the target protein. In the case of ubiquitination this is carried out 
by deubiquitinating enzymes (DUBs or deubiquitinases)56,57. These enzymes hydrolyse the 
isopeptide bond between ubiquitin and the targeted protein (Fig. 1). 
Some DUBs exhibit a strict target specificity56,58,59, just like the E3 ligases. There are also more 
promiscuous DUBs and there are DUBs that recognise a specific ubiquitin chain type. These 
DUBs distinguish between the various linkages by observing the specifics of the (iso)peptide 
bond, such as distances and angles between two moieties in the chain (Fig. 2c) or the presence 
of an aiding residue on the substrate60. 
This specificity is narrowed down even more for deubiquitinases that only recognise and 
cleave off the last ubiquitin in a chain61. This cleaving of the distal ubiquitin, also known as exo-
deubiquitination, depends greatly on the ubiquitin binding pocket and whether or not it can 
accommodate an extra ubiquitin linkage. Contrary to this mechanism is endo-deubiquitination 
which can only break the isopeptide bond within a ubiquitin chain, or to the substrate. This 
could allow for direct release of the whole ubiquitin chain.
Next to DUBs that only recognise poly-ubiquitin62, there are substrate-specific ones63. These 
enzymes recognise the targeted protein with the ubiquitin attachment. The hydrolysis then 
often cleaves off an entire ubiquitin chain (if present), i.e. after the proximal ubiquitin28,64. These 
latter enzymes need both the substrate and the attached ubiquitin moieties for recognition 
and subsequent hydrolysis to revert the substrate to a mono- or unubiquitinated one.
DUBs play a role similar to the phosphatases in pathways regulated by phosphorylation. 
They serve as a regulatory layer, making the ubiquitination pathway a reversible and more 
finely tuned process. However, the role of deubiquitinases is more than just antagonising the 
ubiquitination pathway, it is essential in the very first steps of ubiquitination as well. Ubiquitin 
is always expressed as an immature proprotein, a linear polyubiquitin that must be cleaved 
(Fig. 1) to yield the mature ubiquitin monomers. DUBs carry out this function and are therefore 
responsible for the pool of available ubiquitin60. The deubiquitinases also supply to this pool 
by degrading ubiquitin chains, leaving the free ubiquitin monomers. 
Furthermore, DUBs can rescue ubiquitin from aberrant covalent adducts. Along the 
ubiquitination pathway there are various points at which the thiol ester intermediates can 
get attacked by small nucleophiles. Some DUBs are able to recognise this aberration and rescue 
the trapped ubiquitin65. With these described functions deubiquitination not only antagonises 
the ubiquitination pathway, it also maintains the available pool of ubiquitin monomers.
Ubiquitin and diseases: regulation of E3’s and DUBs
Many cellular processes require spatial or temporal regulation, which can be achieved by 
posttranslational modification of the proteins involved. This also means that, if the fine 
regulatory balance of ubiquitination is disturbed, certain dependent pathways may be 
disturbed. Malfunction in the ubiquitin pathway itself could therefore lead to a plethora of 
dysregulated cellular pathways66–68. For instance, proteasomal degradation is heavily linked 
to ubiquitination and its dysregulation has been implied in various neurological disorders69. 
As various pathways could lead to various diseases, ubiquitination can be involved in diseases 
linked to these processes. 
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One way to keep these (de)ubiquitination enzymes in check is to regulate them. 
Deubiquitinating enzyme abundance can be tuned by increased transcription or degradation 
of the DUB, but interestingly ubiquitination of DUBs itself is not confirmed as a trigger for 
their proteasomal degradation70. The post-translational modifications with ubiquitin, likewise 
to phosphorylation or SUMOylation, can have other effects on the DUB. It can change its 
localisation, allow for complex formation, or even adapt the intrinsic activity71. Other external 
factors that regulate DUB activity are binding partners that can help recruit a target or even 
the substrate itself. In chapter 3 we investigate the effect of a ubiquitinated p53-substrate 
on the activity of USP7.
Some DUBs however also have intramolecular regulatory domains. Their three-dimensional 
build-up can be such that they possess a self-inhibiting or self-activating ability72. Such intrinsic 
self-regulation could allow for fine-tuning of the DUB activity, and have a potential for specific 
human intervention in the form of drugs73,74. As the self-activation of DUBs is the main theme 
of this thesis we will discuss this in more detail.
Various families of DUBs 
There are seven different classes of DUBs72, based on the ubiquitin protease domain (Fig. 3). 
Six of these classes are cysteine proteases, using the cysteine thiol group in the active site to 
mediate the hydrolysis of the ubiquitin bond75, whilst the other class are metalloproteases. 
Below we discuss these separate classes and some of their hallmarks concisely. The main topic 
of this thesis, USP7, is a member of the Ubiquitin Specific Protease (USP) class, warranting a 
more extensive, separate description for the USP class. 
The metalloprotease DUBs use Zn2+ in the interaction with the substrate56,59, where a JAMM 
(JAB1/MPN/Mov34) domain (Fig. 3a) coordinates the Zn ion by an aspartic acid, histidine and 
serine residue76. The zinc ion can activate a water molecule which subsequently performs a 
nucleophilic attack, breaking the peptide bond between the ubiquitin moiety and its target. 
So far about a dozen putative deubiquitinases of this family have been found, although not 
all zinc-coordinating amino acids are conserved between them. This could imply that some 
of them are inactive, awaiting experimental confirmation of their function77.
The class of the Ubiquitin C-terminal Hydrolases (UCHs) (Fig. 3b) encompasses four members 
with an UCH domain containing the active site cysteine78. In hydrolysis this cysteine is aided 
by an aspartic acid, a histidine and a glutamine79. UCH enzymes seem unable to process 
diubiquitin conjugates80 and are well-known for processing relatively small protein substrates81. 
This has long been attributed to its hallmark cross-over loop82, but since UCHs have been 
shown to cleave ubiquitin off of SUMO-(chains) the role of this loop is debated81.
The second smallest class are the Machado-Joseph Disease Protein Domain Proteases (MJDs) 
with five members. Although the domain fold differs from the other classes, the catalytic triad 
residues are still a cysteine, histidine and aspartate. The only protein of the family of which 
structural information is available83, Ataxin-3 (Fig. 3c), is mutated in the Machado-Josephin 
disease, giving the class its name. The protein structure shows a misaligned catalytic triad, 
which transforms into an active conformation upon ubiquitin binding. An interesting feature 
found in this MJD structure is an α-helix that blocks access to the active site, but whether this 
is conserved throughout the class still needs experimental validation84. It has been implied 
that this helix is stabilized in an open conformation when Ataxin-3 itself gets ubiquitinated, 
making the active site available85.
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For a third class of DUBs, Ovarian Tumour Proteases (OTUs), several structures (Fig. 3d) have 
been elucidated86–88. These structures indicate that the active site residues are cysteine, 
histidine, aspartate or asparagine, and threonine. Further analysis of the OTU catalytic core 
indicates an unproductive conformation and remodelling of the site is necessary for actual 
isopeptidase activity, a feature that is shared with some other members of the cysteine-
protease DUBs89,90. Interestingly, some deubiquitinases already show a regulatory function 
independent of their protease activity. OTUB1, for instance, can inhibit the E2 UBC13 
without performing a deubiquitination event91. This indicates non-canonical functions for 
deubiquitinating enzymes, adding to their functionality, even if the active site remains in an 
inactive configuration.
A relatively new class of cysteine protease DUBs is MINDY (motif interacting with ubiquitin 
(MIU) containing novel DUB family)92. This class (Fig. 3e) currently contains four members that 
share a MINDY domain with the active site cysteine helped by a histidine and a glutamate 
in catalysis. Again, for this DUB the triad is in an inactive conformation that rearranges upon 
binding of ubiquitin92. Inquiries into biological roles for MINDY DUBs are still ongoing, but 
these DUBs seem to be specific for K48 ubiquitin chains93.
JAMM: AMSH-LP
MJD: 
Ataxin-3
OTU: 
Otulin1
UCH: 
UCHL5
MINDY: 
MINDY-1 ZUFSP: ZUFSP
A B C
D E F
Figure 3. The structures of deubiquitinating enzyme types in complex with ubiquitin. The bound 
ubiquitin is coloured purple and kept in the same orientation, while the DUB is coloured yellow. Other 
ubiquitin molecules, members of a chain, are depicted in magenta and secondary, modulating proteins 
in red. For each class a representative is chosen: A. AMSH-LP in complex with a K63-linked diubiquitin 
(PDB: 2ZNV171), B. UCHL5 with an activating fragment of INO80G (4UF680), C. Ataxin-3 in complex with 
K48 diubiquitin (2JRI83), D. Otulin-1 (3BY487), E. MINDY-1 (5JQS92) and F. ZUFSP (6EI195)
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The newest class of ZUFSP DUBs (Fig. 3f) was identified with activity-based profiling using a 
K63-specific probe94–97. This class, with currently one confirmed member, share their fold with 
Ufm1 and Atg8 proteases98 having an active site cysteine that is aided in catalysis by a histidine 
and aspartate. ZUFSP binds RPA and is involved in genomic stability, with its specificity for 
K63-linked ubiquitin chains induced by the ubiquitin-binding domain MIU.
Ubiquitin Specific Proteases (USPs)
The focus of this thesis is on USP7 and USP40, two members of the Ubiquitin Specific Protease 
(USP) family. This is the largest class of DUBs with currently over 60 identified members. This 
family is the best studied one, although many functions and substrates remain unknown. 
Nevertheless, both knowledge about USP structures as well as their functionality increases.
The USP family is characterized by the papain-like USP domain (Fig. 4), which is responsible for 
binding the distal ubiquitin and subsequent hydrolysis of the isopeptide bond. The domain has 
a papain-like fold90 and is structurally very well conserved, although inserts99 can be present 
within the USP domain. Globally, the USP domain consists of a fingers region, a palm and a 
thumb region (Fig. 4a). The ubiquitin that gets hydrolysed can bind between the fingers and 
the thumb where a lot of acidic residues can accommodate the positively charged ubiquitin90. 
Its C-terminal tail with which it is attached to a substrate, will then be positioned between 
the palm and thumb regions, close to the catalytic residues (Fig. 4c).
A B
R74
His Asp
Cys
G76
G75
Figure 4. Structure of the USP domain of USP12 (PDB: 5L8W172) reveals three separate subdomains: the 
Fingers region (orange), the Palm (brown) and the Thumb (yellow) in A. Furthermore, the five common 
insertions points, where the USP domain can have small loops or even domains inserted99, are marked 
in black spheres. In B. the ubiquitin-bound structure is depicted, using the same colouring scheme with 
ubiquitin in purple, supplemented with a zoom of the active site (residues in red) where the catalytic 
cysteine is bound to the C-terminus of Ub.
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The catalytic residues are cysteine, histidine and aspartate, although for some USPs asparagine 
substitutes the latter99,100. The catalytic cysteine needs to be deprotonated in the catalysis101, 
which is carried out by the histidine that can act as a general base when it is coordinated by 
the aspartic acid (Fig. 5). Now the cysteine can perform a nucleophilic attack on the isopeptide 
bond that link the ubiquitin molecule to the substrate, forming a tetrahedral intermediate59,101. 
This ‘oxyanion’ state will then collapse, resulting in the release of the substrate (Fig. 5) and 
a ubiquitin-bound protease. For the DUB to return to its basal state a second nucleophilic 
attack, this time performed by a water molecule, is necessary. This will generate a second 
oxyanion state that will collapse similarly, resulting in the release of the ubiquitin molecule 
and a regenerated enzyme59 (Fig. 5).
Structural analyses of various USP domains however have shown that these catalytic 
residues are, for some USPs, not in a catalytically competent configuration90. Furthermore, 
biochemical assays indicate that most USP catalytic domains are able to digest any type 
of ubiquitin-chain linkage102, a feature that is not always valid in full-length and/or in 
vivo studies62. These apparent discrepancies indicate that the catalytic domain requires a 
secondary domain or protein interaction for full, physiological activity. As both the potential 
regulation and specificity of a deubiquitinating enzyme can provide insight into its biological 
function, research into the activation has gathered interest103,104. On top of that, structural 
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Figure 5. Reaction mechanism of cysteine DUBs, like USPs, shows how the active site residues need to be 
in close proximity to allow for an active state and start the hydrolysis cycle resulting in deubiquitination 
of the target lysine.
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and mechanical insight on enzymes can allow for the development of more potent and 
more specific inhibitors leading to potential clinical drug development105–107. 
In this thesis we focus specifically on the activity mechanism of a subclass of USPs, containing 
both USP7 and USP40, and how this deubiquitinating activity can be modulated. USP7 has 
been described to have seven different domains. N-terminally of the catalytic domain, it has 
a TRAF domain (Fig. 6) that mediates many of its target interactions. On the C-terminus USP7 
has five Ubiquitin-like (Ubl) domains that are important for full activity and can also serve 
as an interaction hotspot108. These Ubl domains resemble the ubiquitin fold109, having the 
β-grasp structure, but have very little sequence homology (<12% identity)110. They could be 
artefacts from the development of the pathway throughout evolution, or serve a direct role: 
the ubiquitin resemblance could be a way to inhibit the enzymes, or even enhance them102,111. 
In this thesis we look specifically at the effect of the ancillary domains on the activity of USP7.
11021
TRAF USP7CD 1 2 3 4 5
Ubl12: interactor binding Ubl45: self-activationTarget recognition
A
Ubiquitin binding and hydrolysis
B
TR
A
F
1
234
5
Cys
His Asp
Ub
Figure 6. USP7 consists of seven different domains with each a different physiological function. In A. the 
protein is schematically depicted with the TRAF domain, Catalytic domain (CD) and the five Ubl domains 
marked (numbers). The very C-terminal tail (purple) is not a separate domain, but plays a major role in 
the self-activation. The colouring scheme of the domains is carried over in panel B. which depicts the 
structural model of full-length USP7. This model is built from various crystal structures (PDB: 1NBF, 2YLM 
and 5FWI), with bound ubiquitin in grey90,108,173. 
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USP7 in disease
The main subject of this thesis is the enzyme USP7 (Fig. 6), and specifically its mode of action. 
The enzyme has originally been identified as ‘herpes virus associated ubiquitin specific 
protease’ (HAUSP) for its interaction with the herpes protein ICP0112,113, but its multiple 
physiological roles and links to various diseases earned USP7 its medical attention.
USP7 is implicated in various cancers114–116, and is frequently mutated in specific childhood 
leukaemias117,118. In other cancers119 it is found to be rarely mutated, but rather up- or 
downregulated120,121. This suggests that USP7 is essential for cell survival, as is further illustrated 
by the embryonic lethality of a full gene-loss122. Also, having only a single (working) allele can 
already have dramatic consequences for neurodevelopment123. Haploinsufficiency causes a 
disease that stems from a dysfunctional interaction of USP7 with MAGE-L2 and TRIM27 in the 
cytosol, where only a small fraction of USP7 is found124,125. Most USP7 is found in the nucleus126, 
where it interacts with many proteins127. It stabilises both the ‘guardian of the genome’ 
p53128, as well as its E3 ligase MDM2, dictating the balance through its deubiquitinating 
activity122,129–131. Furthermore, USP7 has also been described to bind DNMT1 and UHRF132,133 
and PCNA and Rad18134,135, illustrating a USP7 link to DNA maintenance and DNA damage 
repair as well. Through these various interactions, USP7 is involved in multiple pathways, 
ranging from transcription regulation and DNA replication136,137 to apoptosis138. The plethora 
of USP7 functions makes the protein an important player and good material to further the 
understanding of the human cell139.
At the same time, the broad spectrum of interacting proteins makes it difficult to define the 
full function of USP7. Causality relations are not always obvious, e.g. USP7 both stabilises 
p53 as well as mediating its ubiquitination through MDM263,140. The complexity of USP7 
as a node in various pathways still remains elusive, although its individual interactions are 
becoming increasingly better mapped. In chapter 1 we describe the biochemically validated 
interactions of USP7, through which domains these take place (Fig. 6a) and what role these 
may have in the cell141.
USP7 regulation: external factors
A high number of the described interactions are direct E3-USP7 complexes. In such a complex, 
the DUB can protect the associated E3 from auto-ubiquitination and subsequent proteasomal 
degradation142,143. Such direct regulation has been found for USP9X which prevents the E3 
Itch from becoming ubiquitinated144. The direct interaction with E3s can also serve a second 
role. By associating with the E3 ligase, the DUB is able to directly deubiquitinate and stabilise 
the protein targeted by the E3. By forming such an ‘on/off’ switch, the targeted protein 
can be tightly regulated145. In the review on regulation of the DUB USP7 in chapter 1141, we 
will discuss such interactions of USP7, sketching the importance and possible outcomes of 
USP7-E3 complexes124.
Both E3 and other interactors often recruit USP7 for its main feature; the deubiquitinating 
activity. The recruitment of a DUB can protect the target from proteasomal degradation, but 
the DUB activity of USP proteins can also be influenced by secondary factors. The factors 
could be external factors, like these interacting proteins, or intramolecular factors, such 
as internal domains146. By association with a USP these interactors can change the DUBs 
localisation, thereby influencing where it can perform its deubiquitinating activity, like in 
the case for USP14147. 
18
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Such interactors can also be substrates, as they possess affinity for their deubiquitinating 
enzyme. But substrates can do more than just recruiting; they may even aid in the ubiquitin 
hydrolysis as they can induce a catalytically competent conformation in the DUB90,148, through 
so-called induced fit149,150. Similarly, other external factors like PTMs or secondary binders (like 
e.g. in Fig. 3b) could influence the DUB activity. In chapter 1, we review interactors of USP7 
and their potential effect on USP7 activity, while the activation mechanism of USP7 will be 
discussed in chapters 2 and 3. 
Internal factors in USP7 activation
The main properties of a USP enzyme that can be affected by its internal domains are the 
intrinsic DUB activity and the recruitment of the target protein and binding of ubiquitin. For 
the selection of the right substrate, like a poly-ubiquitin chain, the USP can have a Ubiquitin-
binding domain (UBD)151 or a loop insertion to distinguish specific chains152. For the recruitment 
of particular substrates the USP protein can have a separate domain with affinity for a specific 
target, like the DUSP-Ubl domain (Domain in USP - Ubiquitin-like domain) of USP15153, which 
increases the chance to find this target. Both can increase the DUB activity on this particular 
substrate, also by aiding in substrate-induced rearrangement60 of the catalytic core. For USP7 
this function is carried out by the N-terminal TRAF domain (Fig. 6) as it recognises substrates 
p53140, MDM263 and viral proteins154,155. In chapter 3 we show how the recognition of a 
ubiquitinated substrate by the TRAF domain affects the deubiquitinating activity of USP7. 
The other ancillary domains of USP7 are located downstream of the catalytic domain (Fig. 
6a) and can also affect the activity on a substrate156. A crystal structure of USP7-CD123 (Fig. 
6a) provided essential information to generate a full-length structural model of the protein 
(Fig. 6b (Chapter 2)) and also showed how the catalytic domain connects to the downstream 
Ubl domains and how the connection influences the activity. The final three-dimensional 
structure illustrates the possibilities of USP7 self-activation, in terms of steric hindrance, but 
also where the three Ubl domains fit in. These domains are an anchoring point for various 
interactors, for instance the allosteric activator GMPS (Guanosine monophosphate Synthetase) 
that can hyperactivate USP7108. 
The last two Ubl domains and the very C-terminal tail are essential for full activity of USP7 
and both perform an important, but different function in the self-activation (chapter 3). Our 
findings, based on biophysical methods, NMR (Nuclear Magnetic Resonance) spectroscopy 
and molecular modelling, show that these domains fulfil a distinct part and collaborate to 
ensure effective hydrolysis of USP7 targets. Furthermore, we investigate the effects of the TRAF 
domain on USP7 activity using a realistic substrate. Our findings show that the ubiquitinated 
substrate can play a major role in the activity of the enzyme.
C-terminal Ubl domains in other USPs
USP7 is not the only protein containing integrated Ubl domains. Within the USP class of 
DUBs, various members harbour Ubl domains110,157 (Fig. 7). Our studies on USP7 indicated 
an interesting role for the Ubl domains located C-terminally of the catalytic domain, but thus 
far it is not known whether this is protein-specific. To investigate whether activity-regulation 
by C-terminal Ubl domains represents a general mechanism we look at one other member 
of this particular USP subgroup, USP40 (Fig. 7).
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Figure 7. Ubl domains occur often in USPs. USP proteins (USP CD in yellow) that contain one or more 
Ubiquitin-like domains (Ubl domain in blue) can be grouped by the position of the Ubl in relation to the 
CD. The Ubl domains annotated here have been predicted110 and in few cases structurally confirmed. The 
other domains (in brown) such as the domain in USPs (DUSP; magenta) are depicted for completeness’ 
sake and taken from UniProt annotation174.
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Using sequence analysis with Phyre158, four members could be identified that contain a Ubl 
domain located C-terminally of their catalytic domain: USP7, USP40, USP47 and USP48110. Apart 
from USP7 very little is known on the activation mechanisms of these proteins. Production of 
USP47 for in vitro assays has been described159, but no in-depth studies have been undertaken. 
The fact that USP47 cross-reacts with inhibitors developed for USP7160 could be a hint at a 
similar activity mechanism. USP48 is not closely related to USP7, although it seems to share 
the protective function of the E3 MDM2161 and it has a Ubl domain at its C-terminus162. Our lab 
described an H2A-specific role for this DUB163, showing that deletion resulted in a decreased 
intrinsic activity of USP48.
For USP40 little is known about its activity or biological role. Next to USP40 binding to nestin164 
and a Single Nucleotide Polymorphism (SNP) possibly relating it to Parkinson’s disease165, a 
mass spectrometry (MS) screen has found the protein to interact specifically with K27-linked 
ubiquitin chains35. In chapter 4 we show that USP40 is a bona fide DUB and that its C-terminal 
Ubl domains have an activating role in the deubiquitinating activity. Next to biochemical 
characterisation of the enzyme, we investigate USP40 ubiquitin-linkage preference and present 
initial steps towards a mechanical and structural model of USP40.
Investigation of mechanisms of action
In this thesis we utilise structural biology, biochemistry and biophysics166,167 to gain insights into 
the mechanisms of the USP7 class of deubiquitinating enzymes. These efforts towards detailed 
understanding on the mode of action of USP7 and USP40 can aid to better comprehend 
their biological function and can provide essential insight into the development of specific 
inhibitors168–170.
In chapter 1 we describe an overview of the structure of USP7 as well as a basic mechanism 
of action. Furthermore, we discuss the identified and verified interactors of this DUB and 
speculate on how their interaction affects USP7 activity.
Chapter 2 describes our structural studies on the CD123 construct (Fig. 6) of USP7. We show 
that a long, uncommon helix connects CD to the Ubl domains and that it has a function in 
the intrinsic activity, possibly by arranging the Ubl domains spatially.
In chapter 3 we go deeper into the activation mechanism of USP7. We show that USP7 
works in cis and has an induced fit mode of action with a major role for the Ubl45 domain. 
Furthermore, we extend our study from a minimal substrate to  to a more realistic one and 
show that the target recognition plays a major role in the deubiquitination cycle. 
Chapter 4 then describes our biochemical analysis of USP40, a close paralogue of USP7. We 
show that it has a similar activation mechanism and has preferred binding to certain diubiquitin 
chains. Our studies also annotated six new Ubl domains and allow for the speculation of a 
new subgroup in the USP class of enzymes.
In chapter 5 we will discuss the findings presented in this thesis and their implications for 
the future.
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List of abbreviations
ADP  Adenosine diphosphate
AI  Auto-induction
AMP  Adenosine monophosphate
Asp  Aspartic acid, Aspartate
ATP  Adenosine triphosphate
Cys  Cysteine
DTT  Dithiothreitol
DUB  Deubiquitinating enzyme
EDTA  Ethylenediaminetetraacetic acid
FAT10  HLA-F-adjacent transcript 10
GMPS  Guanosine monophosphate Synthetase
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His  Histidine
IEX  Ion exchange chromatography
ISG15  Interferon-stimulated gene 15
JAMM  Jab1/Mov34/Mpr1 protease
kDa  Kilodalton
MALLS  Multi-angle laser light scattering
MINDY  Motif interacting with ubiquitin domain
MIU  Motif interacting with ubiquitin
MJD  Machado-Josephin domain protease
MS  Mass Spectrometry
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OTU  Ovarian tumour protease
PDB  Protein Data Bank
PTM  Post-translational modification
RING  Really Interesting New Gene
SAXS  Small-angle X-ray scattering
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEC  Size-exclusion chromatography
SNP  Single Nucleotide Polymorphism
SUMO  Small Ubiquitin-like Modifier
TB  Terrific Broth
TCEP  tris(2-carboxyethyl)phosphine
TRAF  TNF receptor-associated factor
Ub  Ubiquitin
UBD  Ubiquitin-binding domain
Ubl  Ubiquitin-like
UCH  Ubiquitin C-terminal hydrolase
USP  Ubiquitin Specific Protease
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Abstract
Ubiquitin conjugation is a critical signalling process in eukaryotic cells. The precise regulation 
of deubiquitination is an important component of this signalling cascade. Here we discuss how 
USP7 (or HAUSP), one of the most abundant deubiquitinating enzymes (DUBs) is regulated 
by complex formation with regulatory proteins and targets. 
Full activity of USP7 requires that its C-terminal ubiquitin-like domains fold back onto the 
catalytic domain, to allow remodelling of the active site to a catalytically competent state by 
the very C-terminal peptide. This regulatory mode can be modulated by complex formation 
with other proteins. 
USP7 is found in a large number of relatively stable complexes with different possible functions. 
Complex formation can provide recruitment of a target, bring in an E3 ubiquitin ligase or 
modulate the activation of the DUB activity. These complexes make up potential cellular 
‘switches’, using their (de)ubiquitination ability to switch pathways on or off upon cellular 
signals. Here we summarize what is known for USP7 complexes, focussing on the prevalence 
of E3 ubiquitin ligases and how complex formation can affect ubiquitin switches. 
Introduction
Ubiquitin (Ub) conjugation is important in virtually every eukaryotic cellular pathway1,2. By 
conjugation of a ubiquitin molecule to amino-groups in lysines or the N-terminus of a target, 
a signal for downstream ubiquitin binding proteins is provided. Since ubiquitin itself contains 
seven lysines that can be ubiquitinated and an amino-terminus, allowing for different types 
of ubiquitin chains and leading to a particularly rich variety in outcomes3. In the ubiquitin 
signalling cascade, control and trimming of ubiquitin marks by deubiquitination play important 
roles4. Ongoing analysis is starting to show that these deubiquitinating enzymes (DUBs) are 
themselves very carefully regulated5,6. 
A particularly interesting example of complex regulation is found in USP7, a member of the 
Ubiquitin Specific Protease (USP) subgroup of DUBs7. USP7 is highly expressed and was found 
to have many interactors8. Among these interactors are a large number of target proteins, 
which are regulated through the USP7 deubiquitinating activity. Not all of the interacting 
proteins are targets however, and several of these proteins form stable protein complexes. 
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Some of them could serve as scaffolds, localising USP7 to the correct place, but a subset of 
these could be activity modulators, altering USP7 conformation and thereby regulating USP7 
activity. 
USP7 functions in various pathways9; from apoptosis10 and transcription regulation11 to DNA 
replication12 and neuronal development13. USP7 knockout has been shown to be lethal in 
mice, even in the absence of p5314,15. To function selectively, USP7 requires careful regulation 
of activity. A first layer of regulation is intrinsic in USP7’s multi-domain architecture; USP7 
requires its C-terminal region for full activity, as the catalytic domain (CD) is 120-fold less 
active than the full-length protein16,17. Furthermore, post-translational modification (PTM) of 
USP7 may change its enzymatic activity, or its ability to form complexes18. A second layer of 
regulation is the ability of USP7 to form multiple complexes that modulate its function. Such 
a complex could make USP7 switch from being target-associated to interact with another 
protein like an E3 ubiquitin ligase. In this review we discuss the current knowledge of USP7 
interactors, focussing on crystallographic and biochemical data that describe how USP7 is 
regulated by itself and its interactors.
USP7 is self-activated by its C-terminal region
USP7 is a multi-domain protein of 1102 amino acids and although no full-length structure is 
available, a lot of information could be derived from individual domains and partial structures 
(Fig. 1a-b). The catalytic domain (CD; res. 208-560) contains the ubiquitin hydrolase activity. 
Structure analysis showed how it exists in an inactive empty state, where the active site 
cysteine, C223, is located 10 Å away from the deprotonating histidine H464 and aspartate 
D481 (PDB: 1NB8; Fig. 1b)19. In the crystal structure of the ubiquitin-bound state (PDB: 1NBF), 
conformational changes result in an active conformation of the catalytic triad (Fig. 1b)19 and 
rearrangement of a loop around W285, dubbed the ‘switching loop’16.
Intriguingly, the USP7CD is much less active than full-length USP7. The C-terminal half, which 
has five ubiquitin-like (Ubl) domains (PDB: 2YLM)16,20, is necessary for full activity of USP717. 
In particular the very C-terminal tail is sufficient for activation, but requires Ubl4516 or an 
artificial linker21 for recruitment to the CD. A recent structure showed how this C-terminal 
tail, with essential residues I1098 and I1100, binds onto a groove of CD (PDB: 5JTV; Fig. 1c)21. 
Ubl45 binds CD close to where the C-terminus of Ub is bound by the catalytic domain (PDB: 
5JTV21), bringing the C-terminal tail close enough to reach the ‘switching loop’ (Fig. 3a)16. 
The binding of the tail remodels the CD and stabilizes the ‘switching loop’ in a catalytically 
competent configuration16,21.
The crystal structure (PDB: 5JTV) shows dimer formation and thereby hints at in trans activation 
of the CD by the C-terminal tail21. Although this peptide is essential for activation, it binds 
with only 1 mM affinity in trans, a concentration far higher than present in the cell or used 
in in vitro experiments that show full activity16,21,22. The ambiguity is further illustrated when 
trying to merge the existing structures into a full-length model (Fig. 1b): the gap between 
Ubl3 and the CD can be bridged by Ubl45 and the flexible tail, but this would require large 
movements, compared to the Ubl45-bound structure (PDB: 5JTV, Fig. 1c)21. Whether USP7 
functions as a dimer or monomer is still one of the open questions in the field.
36
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USP7 domain architecture
The N-terminus of USP7, contains an unstructured 50 amino-acid region with poly-Q stretch, 
followed by a TNF receptor associated factor domain (TRAF; res. 50-208) that is required 
for the nuclear localisation (Fig. 1c)17. The TRAF domain is important for recognition of 
target proteins23, but does not affect deubiquitinating activity on a minimal Ub-substrate16. 
Co-crystal structures of the TRAF domain with peptides from target proteins (p53, MDM2, 
EBNA, MCM-BP) show that TRAF binds its targets in the groove on one side of the β-sheet, 
extending the sheet with a fifth β-strand (PDB: 1YY6, 2F1Y, 2FOO, 4KG9; Fig. 2a)23–25, in contrast 
to the perpendicular binding commonly observed in other proteins with a TRAF domain. 
Consequently, the interacting residues of the TRAF domain are different from ‘canonical’ 
TRAF binding26 and TRAF recognizes its targets through a P/A-x-x-S motif (Fig. 2b)27,28. This 
broad motif allows for many different interactors and could explain the promiscuity of USP7 
in screens8. Although TRAF has been shown to interact with other TRAF domains29, there have 
been no reports of self-association of USP7 through this domain or functional interactions 
between USP7 and other TRAF proteins. The absence of TRAF domains in other USPs indicates 
A
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Figure 1. Structure model of USP7. A. Schematic figure of USP7 domain architecture, with important 
residues and established PTM sites highlighted. Colours are as used throughout figure 1. B. A model of the 
full-length USP7 structure, generated by superposition of overlapping regions in partial crystal structures 
(2F1Z, 1NBF, 5FWI, 2YLM). Colours as in A., ubiquitin in grey. A zoom depicts the active site residues of 
inactive USP7 (dark red) and active USP7 (beige).  C. The crystal structure of USP7 in activated state (5JTV) 
illustrating how Ubl45 and the activating peptide bind onto CD.
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this mode of target recognition is unique to USP75.
The C-terminal half of USP7 contains five ubiquitin-like domains, connected to the CD by an 
α-helix of 26 residues (PDB: 5FWI; Fig. 1b)16,22. This helical element is proposed to have some 
influence on the positioning of the following Ubl domains, thereby altering the enzyme’s 
activity22. The Ubl domains have the typical ubiquitin β-grasp fold, where five strands straddle 
the α-helix30,31. Despite their very low sequence similarity, either to Ub or to each other 
(max 20%), the Ubls resemble each other with r.m.s.d.’s of maximal 2.9 Å16, similar to more 
conserved Ubl domains32. Their frequent occurrence in USPs 20 suggests regulatory roles, 
although the specific function may vary between different USPs33. 
Figure 2: Co-crystal structures indicate conserved binding motifs. A. Interaction between TRAF and 
interacting peptides from EBNA1 (1YY6), p53 (2FOO), MDM2 (2F1Y), MDM4 (3MQR), UbE2E1 (4JJQ), 
MCM-BP (4KG9), vIRF-1 (4YSI) and vIRF-4 (2XXN). Structures were superposed by SSM, showing the surface 
of the TRAF domain in brown with the main interacting residues in a lighter shade. The co-crystallized 
peptides are displayed as ribbons, with binding residues shown as sticks, colours as in B.; the conserved 
serine makes hydrogen bonds to R104 and D164 on the TRAF; the upstream residues have their backbone 
stabilized by W165. B. A TRAF recognition motif, although not very strict, is found upon alignment of 
interacting peptides found in crystal structures (in colours corresponding to A.) or affinity assays. C. 
Interaction between Ubl12 and interacting peptides from DNMT1, ICP0, RNF169 and UHRF1 show how 
the interaction is anchored by insertion of positively charged amino acid onto a negative patch of Ubl12 
(PDB codes: 4Z96, 4WPI, 5GG4, 5CD6). Electrostatic surface was generated using APBS Plugin for PyMol. D. 
Sequence alignment, aided by crystal structures (colours correspond to C.), of tested interacting peptides 
reveal Ubl12 recognition motif. Shown peptides were confirmed with ITC for interaction with Ubl12 with 
K
D
-values of maximally 10 µM16,34,37,81. Residues in bold are confirmed anchors in the crystal structures, 
note that ICP0 and RNF169 seem to be reversed sequence-wise.
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The five Ubl domains of USP7 have a 2+1+2 structure, where Ubl12 (res. 562-771) and Ubl45 
(res. 894-1102) combine to stable structural regions (Fig. 1a). Whereas the latter has a tail 
important for self-activation, Ubl12 serves as a binding spot for interactors16,34. Crystallographic 
studies have identified DNMT1, UHRF1 and ICP0 to bind in an acidic pocket of Ubl2 (PDB: 4YOC, 
4Z96, 5C6D, 4WPH; Fig. 2c)34–37. Using sequence alignment and affinity studies with derived 
peptides consensus binding motifs for Ubl12 (R/K-x-K or K-x-x-x-K) could be identified (Fig. 
2d)34,35. The site of binding, although far from the activating C-terminal tail, could modulate 
USP7 activity through allostery (Fig. 3a). The linker between Ubl12 and Ubl3 adopts variable 
conformations in crystal structures22,34. Furthermore, flexibility between Ubl3 and Ubl45 is 
deduced from SAXS analysis 16 and is required for successful folding back of the Ubl45 domain 
onto CD (Fig. 1b)21,22. Binding of proteins within the Ubl region could stabilise these linkers, 
promoting either an active or inactive conformation of USP7.
Alterations like post-translational modifications (PTM) in the Ubl region could modulate 
USP7 activity. Several PTMs have been described for USP7; phosphorylation of S18 and S963, 
ubiquitination of K443 and K869 and acetylation of K1084 and K1099 among others (Fig. 
1a)17,38–40. Their effect on activity has not been described, except for the ubiquitination on K443, 
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Figure 3: Ways of USP7 regulation. A. The allosteric activation by GMPS and the potential allosteric 
inhibition by DNMT1 of USP7 are both mediated through the Ubl domains. The active site residues (C, H, 
D) are highlighted in red (inactive conformation) or green (active). B. Model, based on the structure of 
DNMT1, solved in complex with Ubl12345 (4YOC) superposed on the CD123 structure (5FWI), suggests 
a relative position of DNMT1 (soft pink) and CD. In this conformation, DNMT1 may affect the ability of 
Ubl45 to interact with the CD (modelled here as in figure 1b), which would cause inhibition of activity.
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within CD. This creates a binding scaffold for CBP, that can recruit HIF1-α for deubiquitination 
by USP738.
Modifications in the Ubl region, like K869Ub in Ubl3 or S963 phosphorylation in Ubl4, could 
potentially interfere with the folding back ability of Ubl45 to bind the CD, while acetylation 
in the C-terminal peptide40 could prevent binding to the CD, modulating USP7 self-activation. 
The phosphorylation sites at S18 and S963 are located near protein-protein interaction regions 
and could affect interaction17. Further analysis of these PTMs is required to assess the extent 
of change of USP7 activity.
Aside from PTMs that could potentially modulate USP7 activity, a plethora of interacting 
proteins is described that could assert some USP7 modulation8,9. Among the various regions 
of USP7: there are two interaction hotspots predominantly used by protein-USP7 interactions. 
The TRAF domain is predominantly used for target recognition (Fig. 2a), whereas the site on 
Ubl12 seems to be used for recruitment of interaction partners (Fig. 2c). 
Among these interaction partners a surprisingly large number of E3 ubiquitin ligases is found, 
enzymes with the opposite activity to USP71. Such a DUB-E3 interaction may result in a 
complex that is protected from auto-ubiquitination, with predominant E3 ligase activity. 
Upon an external signal, the DUB may ‘switch’, shifting its activity from the E3 to its target, 
allowing the E3 to be degraded and protection of the target from degradation. This creates 
a rapid response to a signal, such as e.g. cellular stress. Throughout the text we will refer to 
this type of response as a ‘switch’: USP7 switches from being target-associated to forming a 
complex with the E3 ubiquitin ligase, or vice versa.. Here we discuss the E3-USP7 interactions 
on a biochemical level as well as the potential of these complexes to form a molecular switch.
The MDM2/p53 switch
The E3 ubiquitin ligase MDM2 targets the tumour suppressor p53 for degradation by the 
proteasome41. Levels of p53 are critical for transcriptional regulation of cellular fate after 
stress42. Both p53 and its E3 ubiquitin ligase MDM2 are thought to be targets of USP743,44. 
Under normal circumstances, USP7 associates with MDM2, possibly with help of adaptor 
protein DAXX45 and/or acetylation of MDM246, to protect the E3 ubiquitin ligase from auto-
ubiquitination. This allows MDM2 to ubiquitinate p53 for proteasomal degradation47. Upon 
stress signals like DNA damage however, USP7 preferentially binds p53, stabilizing it through 
deubiquitination and allowing induction of the apoptosis pathway (Fig. 4a)45,48. 
Both MDM2 and p53 bind USP7 on the TRAF domain and co-crystal structures with peptides 
of both targets are available (PDB: 2FOJ, 2F1Y; Fig. 2a-b)23,24. A secondary interaction site has 
been reported in USP7’s Ubl region for both p53 and MDM249, but this interaction is hard 
to capture21. The shared binding site and cell biological data 43 indicate that USP7 regulates 
both MDM2 and p53 in a ‘switch-like’ manner (Fig. 4a)50. 
Other regulatory proteins can make USP7 switch from one complex to the other51. TSPYL5, 
known as a breast cancer risk protein, has been shown to disrupt the p53-USP7 complex52 
and in vivo results suggest that ABRO1 (FAM175B), a member of the DUB complex BRISC, 
promotes the p53-USP7 complex, stabilising p5353. On the other side of this molecular switch 
are proteins that affect the MDM2-USP7 interaction. Ras association domain-containing protein 
RASSF1A is a potential tumour suppressor that disrupts the association of USP7 to MDM2, 
allowing the latter to self-ubiquitinate and stabilising p5354. The deacetylase SIRT1 has been 
shown to affect the interaction similarly; by deacetylating MDM2, the DUB USP7 can dissociate 
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and deubiquitinate p5346. A positive regulator of the MDM2-USP7 complex, and thus p53 
degradation, is the aforementioned DAXX45, a protein that also has been found to sequester 
USP7 away from the target PTEN, resulting in higher levels of ubiquitinated PTEN55. This set 
of proteins balances the p53/MDM2 axis through USP751 and it would be interesting to see 
how these interactions change by modifications through, for instance, DNA damage signals.
USP7 forms an E3/target switch with DNMT1 and UHRF1
Another E3 ubiquitin ligase that interacts with USP7 is UHRF1, involved in DNA methylation 
maintenance36. A recent crystal structure of USP7 with a peptide of UHRF1 (PDB: 5C6D) shows 
how UHRF1 binds onto a negative patch of Ubl12 (Fig. 2c)36. Interestingly, a ubiquitination 
target of UHRF1, the methyltransferase DNMT1, also interacts with USP735. The crystal 
structure of the C-terminal part of DNMT1 in complex with Ubl12345 (PDB: 4YOC) shows that 
DNMT1 binds on the same patch of Ubl12, but also binds the third Ubl and has van der Waals 
contacts with Ubl4535. The stability of DNMT1 depends on the E3 ubiquitin ligase UHRF1, 
that binds and ubiquitinates DNMT156,57. USP7 in turn, protects both UHRF1 and DNMT1 
from ubiquitination, which stabilizes these proteins and promotes chromatin binding35,58. 
The shared binding site on USP7 however indicates that DNMT1 and UHRF1 bind mutually 
exclusive to USP7 and suggests competition for this binding site on USP759.
Combining proteins with seemingly reciprocal activity together in a complex could indicate 
a cellular switch (Fig. 4b). USP7 controls both UHRF1 and DNMT1 via protection from 
proteasomal degradation, through the seemingly mutually exclusive binding site. Breaking 
up these USP7 complexes could therefore allow for degradation of the DNA methylation 
maintenance complex. This feature comes into play when cell cycle events require, for instance 
in late S-phase60. This switch could be similar to that proposed for MDM2 and p53, with 
USP7 shifting from protection of the E3 ubiquitin ligase to protection of the target protein 
DNMT1 (Fig. 4b). 
One potentially complicating factor comes to light when superposing the crystal structure of 
the USP7/DNMT1 complex (PDB: 4YOC) to that of Ubl45 bound to CD (PDB: 5JTV): Ubl4 clashes 
with DNMT1 in this position. This could potentially indicate that the DNMT1 is incompatible 
with USP7 activation, although the activation groove on CD is not blocked by DNMT1 (Fig. 3b). 
Therefore flexibility between Ubl domains and the tail could allow activation in the presence 
of DNMT121. Analysis of the effect of DNMT1 interaction on USP7 activity will be interesting 
to study. Furthermore, whether UHRF1 has multiple interaction sites as well, and if this has 
any effect on USP7 activity remains unknown. 
It has been shown that UHRF1/DNMT1/USP7 complexes are regulated through cell cycle-
dependent phosphorylation61, acetylation by the histone acetyltransferase Tip60 (KAT5)56 
or association of DNA glycosylase, the methyl-CpG-binding domain protein MBD462. These 
modifications could disrupt the complex and thereby allow modulation of USP7 function, 
making it a cell-cycle dependent USP7/E3/target complex. Nevertheless, many questions 
remain: a) how USP7 chooses between UHRF1 or DNMT1, b) whether they exist as a feedback 
complex and c) how the decision is made to promote degradation or protection of DNMT1.
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Cytoplasmic USP7 complex with TRIM27
The processes mentioned above reside in the nucleus, USP7’s predominant localisation13,17. 
A minor fraction of USP7 can also form complexes in the cytosol, like the recently identified 
complex with the RING-type E3 ubiquitin ligase TRIM2739. The C-terminal domains of TRIM27 
are required for interaction with CD13. Recently, a binding partner stabilizing this complex was 
found: MAGE-L263. MAGE family proteins are known for binding RING E3 ubiquitin ligases64, 
but MAGE-L2/TRIM27 requires the DUB USP7 for stability13. MAGE-L2 binds the TRAF domain 
with its C-terminus and Ubl123 with a central region13.
Disruption of this MAGE-L2/TRIM27/USP7 complex can lead to serious neurological 
disorders65,66, probably through control of WASH63. The actin nucleating protein WASH is a 
regulator of endosomal trafficking and is under tight control by the (de)ubiquitinating activity 
of TRIM27/USP7. TRIM27 is protected from auto-ubiquitination by USP7, enabling K63-linked 
ubiquitination of WASH, which in turn is kept in check by USP7 (Fig. 4c)13. The K63-linked 
polyubiquitination is not a signal for proteasomal degradation, but rather activates WASH63. 
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This E3/DUB cooperativity allows for great control to keep optimal WASH activity.
Thus far no secondary interactors that influence this regulatory complex are known. The 
TRIM27/USP7 complex however has also been implicated in apoptosis, where TRIM27’s 
ubiquitin ligase activity was shown to target USP7 at K869, with poly-ubiquitin chains of 
various linkage types. This probably creates a binding platform as it stabilizes the interaction 
with the cytoplasmic RIP1, allowing its subsequent deubiquitination39. This ties the TRIM27/
USP7 complex to TNF-α induced apoptosis67. 
It is not clear whether the functions of the TRIM27/USP7 complex are separated between 
control of WASH and stabilization of RIP1 or whether these two pathways influence each 
other. It would be interesting to see whether secondary interactors influence these tight 
balances, and the viral factor ICP0 seems a major candidate, as it was shown to interact with 
both TRIM2768 and USP769.
USP7 complexes with a viral E3 ubiquitin ligase
Viruses, known for their hijacking of human proteins, also can create such E3/USP7 complexes. 
ICP0, is an E3 ubiquitin ligase from herpes simplex. Its interaction with USP7 gave it its original 
name, Herpes-Associated Ubiquitin-Specific Protease or HAUSP70. ICP0 residues 617-629 
interact with Ubl1234,69, at the potential allosteric binding site also used by DNMT1 and 
UHRF1 (Fig. 2c-d). 
The N-terminal region of ICP0 contains a RING-type E3 ubiquitin ligase domain71. USP7 
prevents ICP0 auto-ubiquitination72 and suppresses viral infection responses73. As ICP0 binds 
Ubl12 with a C-terminal part, it leaves both the E3 ubiquitin ligase domain of ICP0 and the 
USP domain of USP7 available for enzymatic action; indeed ICP0 does not modulate USP7-
activity74. Interestingly, the E3 ubiquitin ligase activity of ICP0 is directed towards TRIM2768, 
possibly interfering with the aforementioned TRIM27/USP7 complex (Fig. 4c). The hijacking 
of USP7 by ICP0 evidently suppresses viral infection response, but doesn’t seem to have 
major effects on other USP7 complexes75. This modulation is apparently subtle enough to 
not disturb the other functions of USP7, leaving a functioning host cell.
USP7/E3 complexes in DNA damage signalling and repair
USP7 has been implicated in DNA repair through its interaction with E3 ubiquitin ligase 
Rad18 and PCNA76,77. USP7 can deubiquitinate both PCNA78 and RAD1876, the E3 ubiquitin 
ligase responsible for this ubiquitination79. The exact interaction with PCNA hasn’t been 
characterized, but for RAD18 it seems that the TRAF domain recognizes a PSTS motif (Fig. 2b) 
at residues 191-19476. This way USP7 protects the E3 ubiquitin ligase from auto-ubiquitination, 
allowing ubiquitination of PCNA77. As the DUB targets both the E3 ubiquitin ligase and its 
target, it makes this triad look like a cellular switch similar to p53/MDM2/USP7 (Fig. 4d). The 
details are however less defined, as we don’t know whether RAD18 or PCNA can alter the 
deubiquitinating activity or what triggers the switching. Additional modulators might be in 
place to tip this balance upon DNA damage.
Furthermore, USP7 interacts with the E3 ubiquitin ligase RNF168, responsible for ubiquitination 
on H2A in DNA damage response80. Although the binding site on RNF168 is still unknown, this 
interaction is mediated through the Ubl12 domain of USP7 and is shown to stabilize RNF168, 
protecting it from auto-ubiquitination (Fig. 4e)80. During submission of this review a paper was 
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published describing the interaction of USP7 with RNF169, a paralogue of RNF168, resulting 
in protection from auto-ubiquitination of this E3 ubiquitin ligase81. This crystal structure (PDB: 
5GG4) showed that RNF169 uses the conserved binding motif for interaction with Ubl12 (Fig. 
2c-d), which could help to pinpoint the interaction site for RNF168 as well.
It would be interesting to see if the USP7/E3 complex functions as a type of ‘switch’, for 
instance after a DNA damage signal. For such a switch both components require the same 
target, but thus far there is no evidence showing that H2A K13 and K15, the target of RNF168, 
can be deubiquitinated by USP7. Furthermore, it is unknown whether RNF168 affects USP7 
activity and what signals are required to engage these two proteins.
USP7 and polycomb group proteins
USP7 stabilizes E3 ubiquitin ligases in the polycomb repressive complex 1 (PRC1)82,83. The 
PRC1 complex can be made up with various components84, but USP7 seemingly interacts 
directly with the common PRC1 component RING1B (RNF2)82. The interacting domain of 
USP7 is still unknown, but the complex seems to require the intact RING domain of the 
PRC1 protein RING1B83. However, if RING1B is complexed to BMI1 or MEL18 (PCGF2), this 
direct interaction seems very unlikely85. For these PRC1 complexes the interaction with 
USP7 is bridged by SCML286. SCML2 binds the TRAF domain through its N-terminal MBT-DUF 
domain85 and bridges between USP7 and PRC1 complex components BMI1 and MEL18 via 
PHC187. SCML2 is reported to co-purify with all components of PRC1 and seems required for 
the co-localisation of USP7 to the polycomb complex85. However, it doesn’t recruit USP7 to 
RING1B-only PRC complexes, so perhaps another bridging protein may be involved here85, 
or the RING1B-USP7 interaction is direct83.
The association of USP7 to PRC1 does not have the exact same characteristics of the MDM2/
USP7 switch: the target of PRC1, H2A K119, does not seem to be deubiquitinated by USP788,89. 
Rather, USP7 promotes the placement of this mark as it protects the RING domains from self-
ubiquitination (Fig. 4e) 83 and depletion of USP7 lowers the levels of H2A ubiquitination85. That 
said, disruption of the PRC1-USP7 interaction could function as a switch90. Further research 
will most probably find factors that disturb this complexation, inhibiting PRC1-mediated 
gene repression.
BRISC and/or BRCA1-A complex
USP7 can also interact with another DUB, the metalloprotease BRCC36 (BRCC3), part of 
the larger, BRISC complex91. Consequently, USP7 has been found to interact with proteins 
from this cytoplasmic complex (BABAM1, BRE, BRCC36 and ABRO1) in a mass spectroscopy 
screen8, but through which domains remains unclear. Only for ABRO1 interactions with USP7 
have been shown in vitro, resulting in an effect on p53-deubiquitination by USP753. Where in 
the cell the USP7 interaction with the cytoplasmic ABRO1 takes place and how it affects the 
nuclear p53 protein requires further research. The nuclear counterpart of BRISC, the BRCA1-A 
complex, with ABRO1 substituted with the nuclear Abraxas (FAM175A)92, could be involved. 
This complex would entail two DUB moieties (USP7 and BRCC36) as well as ubiquitin ligase 
activity in the subunit BRCA193. Further investigation is required to find out whether USP7 
is required at a BRCA1-associated DNA break94. These interactions may indicate yet another 
way in which USP7 is involved the DNA damage response.
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Activity modulation by GMPS
One USP7 interactor that directly influences USP7 activity is the metabolic enzyme Guanine 
MonoPhosphate Synthetase (GMPS)16,95. GMPS interacts with Ubl12 (Fig. 2d) with two 
conserved lysines (K321, K326)34 and thereby allosterically activates the enzyme. By binding 
onto Ubl12 it is thought to positively influence the folding back of Ubl45 onto the CD16,34. 
This favours the active conformation where Ubl45 can activate the catalytic domain, resulting 
in an increase in catalytic efficiency. As GMPS doesn’t affect K
M
-values, a model has been 
proposed where it shifts the active/inactive equilibrium of USP7 towards the catalytically 
competent state (Fig. 3a)16. 
This ‘hyperactivation’ (an extra activation over the self-activation) by GMPS could have a 
regulatory role in cells. Indeed, for proper deubiquitination of nuclear targets, such as H2B 
or p53, GMPS is required88,96. Studies have shown that not the enzymatic activity of GMPS 
is essential for this hyperactivation, but rather its cellular location96. The cellular location of 
GMPS is controlled through its ubiquitination by the E3 ubiquitin ligase TRIM21, but there is 
no evidence this E3 ubiquitin ligase also complexes with USP7. It merely retains GMPS in the 
cytoplasm under normal conditions through ubiquitination, with genomic stress however, 
GMPS can accumulate in the nucleus and influence USP7 activity in the MDM2/p53 complex. 
This cytoplasmic-nuclear partitioning of GMPS can be considered a switch for activity of 
nuclear USP796, where GMPS hyperactivates through the interaction with Ubl12.
Furthermore USP7 interacts with the UV-stimulated scaffold protein A (UVSSA) in transcription-
coupled nucleotide excision repair (TC-NER)97,98, via its TRAF domain. This protects UVSSA 
from proteasomal degradation99, but interestingly the association of the two factors has an 
effect on the deubiquitinating activity of USP7 in vitro99. Although the affinity for a minimal 
substrate remains the same, the catalytic turnover drops: a hint that USP7 activity needs 
modulation in TC-NER.
A long, yet undefined list of USP7 interactors
Besides the complexes and interactors mentioned above, there is a long list of proteins that 
have been implicated to interact with USP78. These proteins could of course be targets of 
USP7, but could also make up new, yet unknown, complexes. 
Many of these are E3 ubiquitin ligases, including MARCH7 that uses USP7 to prevent 
auto-ubiquitination100, and RNF220 that complexes with the TRAF domain, promoting 
deubiquitination of β-catenin in the Wnt pathway101. HECTH9/HUWE1 ubiquitinates USP7 itself 
under hypoxia, and thereby allows for CBP binding and subsequent HIF1-α deubiquitination8,38. 
Similar to E3 ubiquitin ligase complexes that have been studied in more detail, these ubiquitin 
ligase interactions could use USP7 for protection against self-ubiquitination or to recruit them 
into a switch-like complex, having both ubiquitination and deubiquitination at the ready in 
stressful circumstances.
In addition to the E3 ubiquitin ligase complexes there are also other USP7 interactors 
with functions in the ubiquitin pathway, such as UbE2E1102 and USP1182. USP7 binds 
UbE2E1 N-terminal part with its TRAF domain (PDB: 4JJQ), suggesting it is a target for 
deubiquitination28. Indeed, USP7 attenuates UbE2E1 by counteracting its poly-ubiquitin 
chains28. Interestingly, this E2 is also implied in PRC1 complexes102. Within the same PRC 
pathway, USP11 was also picked up as an USP7 interactor82. This interaction has been picked 
up in a screen8, but whether it’s direct and what function it has is still under investigation.
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USP7 is also interacting with viral proteins without ubiquitin ligase activity . EBNA-1 (from 
Epstein-Barr virus; PDB: 1YY6) as well as vIRF-1 (PDB 4YSI), vIRF-4 (PDB:2XXN) and LANA 
(all from Karposi’s Sarcoma-associated Herpes Virus) bind USP7 at the TRAF domain (Fig. 
2a-b)103–105, and could therefore influence deubiquitination of targets like p53 and MDM2. 
Although the affinity of the TRAF is much higher for these viral interactors than for p53 or 
MDM2104, there seems to be no effect on p53 upon infection105. This could suggest that the 
viruses employ another cellular function of USP7. Interestingly, LANA and vIRF-4 seem to 
have a secondary interaction site on USP7, presumably on the CD104. This could mean that, 
apart from sequestering USP7, these viral proteins modulate USP7 activity. 
The USP7 interactor list furthermore contains various targets of its DUB activity as well 
as not fully characterized interactors. These targets imply USP7 in various pathways, such 
as DNA replication through the association with MCM-BP (PDB: 4KG9; Fig. 2a-b)25, or in 
the development of regulatory T cells by the deubiquitination of FOXP3106. Thus far, only 
information is available on such target-DUB interaction, but not whether such a complex 
regulates USP7 and these targets are therefore outside of the scope of this review. Obviously, 
as research progresses, these interactors could have an impact on (allosteric) regulation of 
USP7 activity.
USP7 inhibitors
Due to its importance in various pathways USP7 is an interesting target for drug development51. 
As USP7 is an important player in many pathways, disturbing one may lead to (undesirable) 
effects in the other107. Nevertheless, now that first-generation USP7 inhibitors have been 
developed108, they can also aid in understanding USP7 function109. These small molecule 
inhibitors are mostly discovered through DUB activity profiling110 and further developed to 
be specific for USP7111,112. Others approached the inhibitor search from the substrate point 
of view: by developing ubiquitin variants with increased affinity for the DUB, these could 
function as USP inhibitors113 with good specificity for USP7114.
The resulting inhibitors are promising but seem to have effects outside the targeted MDM2/
p53 pathway115,116. This shows that the different complexes of USP7 are targeted, resulting in 
potentially unwanted outcomes. Substrate-derived inhibitors could be a potential answer, but 
whether these can discern different USP7 complexes is yet unknown. Better understanding 
of the various complexes can aid in development of selective drugs directed to a subset of 
USP7 complexes. If one can selectively inhibit USP7 in one particular complex, it may result 
in better defined targeting. Using the described wealth of information on allosteric regulation 
of USP7 could allow inhibition of USP7 right where it is most needed.
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Conclusion and Outlook
In this review we described how USP7, one of the most studied DUBs, has a self-activating 
mechanism, one that can be allosterically modulated, either by inhibition or by stabilization 
of the active state. Apart from this type of regulation, USP7 also seems to be regulated by 
complex formation. These complexes can recruit USP7 to their preferred location, regulating 
USP7 through localisation. Many of these complexes contain E3 ubiquitin ligase activity, 
seemingly counteracting USP7’s DUB activity. Such a USP7/E3 ‘switch’ allows for rapid feedback 
upon cellular signals like DNA damage. Accessory proteins that associate with the complex, 
allow fine-tuning of the E3 and USP7 activity. These ternary complexes could be a way to 
selectively study or inhibit the various roles of USP7. 
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Abstract 
Ubiquitin conjugation is an important signal in cellular pathways, changing the fate of a target 
protein, by degradation, relocalisation or complex formation. These signals are balanced 
by deubiquitinating enzymes (DUBs), which antagonize ubiquitination of specific protein 
substrates.
Because ubiquitination pathways are critically important, DUB activity is often carefully 
controlled. USP7 is a highly abundant DUB with numerous targets that plays complex roles 
in diverse pathways, including DNA regulation, p53 stress response and endosomal protein 
recycling. Full-length USP7 switches between an inactive and an active state, tuned by the 
positioning of 5 Ubl folds in the C-terminal HUBL domain. The active state requires interaction 
between the last two Ubls (USP7-Ubl45) and the catalytic domain (USP7CD), and this can 
be promoted by allosteric interaction from the first 3 Ubl domains of USP7 (USP7-Ubl123) 
interacting with GMPS.
Here we study the transition between USP7 states. We provide a crystal structure of USP7-
CD123 and show that CD and Ubl123 are connected via an extended charged alpha helix. 
Mutational analysis is used to determine whether the charge and rigidity of this ‘connector 
helix’ are important for full USP7 activity.
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Introduction
The covalent attachment of ubiquitin (Ub) to lysines of target proteins is an important post-
translational modification1,2 that is carried out by a cascade of E1 activating enzymes, E2 
conjugating enzymes and E3 ligases3–5. Apart from mono-ubiquitination, ubiquitin can form 
chains, by further ubiquitination on any of its seven lysines or the N-terminus6. Different 
ubiquitination states, either mono-ubiquitination or different types of poly-ubiquitination, 
will have different signalling outcomes for the target protein; ranging from cellular location 
to proteasomal degradation7,8.
To reverse the ubiquitination, deubiquitinating enzymes (DUBs) can hydrolyse the bond 
between ubiquitin and the target lysine9,10. Besides functions in ubiquitin processing and at 
the proteasome, DUBs can antagonise the ubiquitination step and affect the cellular fate of 
the target protein11. Dysfunction of DUBs can cause an imbalance in cells and therefore DUBs 
play important roles in infectious diseases, cancer and neurological diseases12–14.
DUBs are specialized isopeptidases that hydrolyse the ubiquitin bond. In the human genome 
about 80 different DUBs have been identified providing specificity for different targets11,15. 
These are divided into five classes, based on their catalytic domain (CD) architecture. Next to 
this class defining catalytic domain, DUBs may have a series of regulatory domains16. These 
extra domains can confer substrate specificity, by recruiting the target, but may also influence 
the overall activity of the DUB17.
USP7, or HAUSP 18, is one of the first DUBs identified and remains one of the best studied 
ones19,20. USP7 is involved in many pathways as it deubiquitinates a wide range of targets. It 
functions in apoptosis and senescence through its deubiquitinating activity in the p53 pathway, 
primarily affecting MDM221,22, but also p5323 and TSPYL524. It acts on a large number of targets 
in chromatin and DNA regulation, such as H2B25, Chk126, Claspin27, UVSSA28, SCML229, DNMT130, 
BRCA1-A31 and RNF16832, but also interacts with FOXO433, PTEN34, MAGE-L235, GMPS25 and 
viral proteins like ICP0 and EBNA-136, making it an interesting but complex protein to study.
USP7 belongs to the family of ubiquitin specific proteases (USP), which have a papain-like 
catalytic domain (USP7-CD). USP7 is one of the larger USP family members with an N-terminal 
TRAF domain (Fig. 1a), which is critical for recruitment of its targets like p53 or MDM237,38, and 
on the C-terminal side five ubiquitin-like (Ubl) domains. These five Ubl domains together are 
dubbed HUBL (for HAUSP-Ubl) domain and denoted here as Ubl12345. Interestingly, proteins 
like GMPS, DNMT139 and ICP019,40 interact primarily with Ubl12, while others like MDM2 and 
p5341 seem to have a secondary binding site here, showing that different types of interaction 
and regulation may occur.
Structural analysis has revealed that the apo structure of USP7-CD has a catalytic triad that 
is not functional, as the distance between active site residues is too large42. In the presence 
of a covalently bound ubiquitin aldehyde, the catalytic triad is rearranged to generate a 
catalytically competent state of CD42. Interestingly, for full activity the C-terminal domains 
are required, as the CD on its own showed a hundred-fold decrease in activity compared to 
full-length or USP7-CD1234543. 
Faesen et. al. showed that USP7 exists in an equilibrium between the active and inactive 
state and that the active state requires the presence of the Ubl45 domain. Ubl45 can bind 
to the CD, which then promotes the interaction between a C-terminal peptide on Ubl45 that 
causes a rearrangement of the switching loop on CD and induces the rearrangement of the 
catalytic triad into an active state44. The equilibrium between the active and inactive state 
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can be modulated further by the binding of the allosteric activator GMPS25. This protein binds 
to Ubl123 but promotes the interaction between CD and Ubl45, thus shifting USP7 towards 
the active side of the equilibrium.
Structural studies have shown that the Ubl domains are arranged in a 2-1-2 fashion44. The 
crystal structure of the full HUBL domain showed that the 5 Ubl domains can exist in an 
extended state, but geometrical restraints indicate that this domain needs to rearrange to 
enable interaction with the CD. This conclusion was supported by SAXS and binding data. 
Since the first two (Ubl12) and last two (Ubl45) Ubl domains are connected to Ubl3 by small 
linkers, some flexibility between the domains was proposed. However, how this ‘folding 
back’ is achieved is not clear and structures are required that show the arrangement of these 
domains relative to the CD. 
Here we present a crystal structure of USP7-CD123 containing the CD and the Ubl domains 
1, 2 and 3. It shows that the catalytic domain is connected to the HUBL domain through a 26 
amino-acid α-helical linker. This apparently rigid linker shows how the first three Ubl domains 
are positioned relative to the catalytic domain. We studied the role of this connecting element 
in positioning of the C-terminal domains and were able to show that the rigidity, length and 
charges on this linker may affect the activity of USP7.
Materials and Methods
Constructs and mutations
USP7 constructs CD123 (residues 208-882) and CD12345 (res. 208-1102) were cloned into 
expression vector pGEX-6P-1 (GE Healthcare) using BamHI and NotI restriction sites based on 
the codon-optimized USP7 from Faesen et al, 2011. Mutations were introduced in CD12345 
using site-directed mutagenesis with overhanging primers. 
Protein expression and purification
USP7 constructs were expressed in Escherichia coli BL21(DE3) T1R cells using auto-induction 
medium overnight at 18°C 45. Cells were pelleted and resuspended in lysis buffer (50 mM 
HEPES pH7.5; 250 mM NaCl; 1 mM EDTA; 1 mM DTT). DNAseI and 0.1 mM PMSF were added 
prior to lysis using Emulsiflex. The lysate was cleared by centrifuging at 20k G and supernatant 
was applied to Glutathione Sepharose 4B beads (GE Healthcare). After washing the beads, 
the protein was eluted using 15 mM reduced glutathione and subjected to cleavage using 
3C protease and dialysis versus 10 mM HEPES pH7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT. 
Anion exchange on a PorosQ column (GE Healthcare) was performed using a salt gradient 
(50 to 500 mM NaCl; 10 mM HEPES pH7.5; 1 mM DTT). Protein fractions were pooled and 
concentrated, followed by size exclusion chromatography on a Superdex 200 column (GE 
Healthcare) equilibrated against 10 mM HEPES pH7.5; 100 mM NaCl; 1 mM DTT. If necessary, 
a GST FF column (GE Healthcare) was attached to the end of the gel filtration column to 
remove residual GST. The peak fractions were analysed by SDS-PAGE and pooled accordingly. 
Proteins were concentrated to 10 mg mL-1 for assays and up to 25 mg mL-1 for crystallization 
purposes. Generally, 1 litre of culture yields 2 mg of purified protein.
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Crystallization and Data collection
USP7-CD123 was used at a concentration of 25 mg mL-1 in a sitting drop vapour diffusion 
experiment using 96-well plates at 4°C. Crystallization plates were set up using Mosquito (TTP 
Labtech) with 0.1 µL of mother liquor (15% PEG-3350; 0.2 M Sodium citrate pH ~8.5) and 
0.1 µL of protein solution. Crystals appeared within one week and were flash-frozen in liquid 
nitrogen after being cryo-protected in mother liquor supplemented with 20% ethylene glycol.
X-ray diffraction data could be obtained from a single crystal to 3.4 Å on beamline ID 14-1 
at the ESRF, Grenoble, France. The crystal belongs to space group F222 and the data were 
processed using XDS 46, yielding statistics shown in Table 1.
Structure Determination
The structure of CD123 was solved by molecular replacement using PHASER47 with search 
models for the catalytic domain (PDB code 1NB842) and the Ubl-domains (2YLM44), split into 
separate searches for Ubl12 and Ubl3. The separate solutions were merged to one monomer 
in the asymmetric unit. In the resulting electron density map, the connector helix could be 
built manually using COOT48. The resulting structure was refined, using PROSMART geometric 
restraints from the higher resolution reference structures49, in iterative cycles of maximum-
likelihood restrained refinement in REFMAC from the CCP4 suite50,51. The model was further 
validated and optimised using MolProbity52 and PDB_REDO53. The final model had R
work 
and 
R
free
 values of 22.2% and 26.7% respectively.
Enzyme activity assays
The DUB activity of the USP7 variants was monitored by measuring the increase in fluorescence 
upon release of the Rhodamine fluorophore from quenched substrate Ub-Rho (UbiQ) using 
Pherastar plate reader (BMG LABTECH GmbH, Germany), with excitation wavelength 485 nm 
(±10 nm) and emission at 520 nm (±10 nm). For Michaelis-Menten analysis, 1 nM enzyme 
was used to react with concentrations of substrate as indicated. The initial rates were plotted 
against substrate concentration and fitted with a Michaelis-Menten model using non-linear 
regression in Prism 6 (GraphPad). These experiments were performed in triplicate on two 
different batches of protein.
Molecular weight determination using MALLS
Purified proteins were run on analytical gel filtration coupled to Multi-angle Laser Light 
Scattering (MALLS) detector MiniDawn Tri-star (Wyatt Technologies, USA). Molecular weights 
of corresponding peaks were determined with refractive index using manufacturer’s software 
(ASTRA).
Melting temperature assessment
Stability of wild type protein and mutants was tested using the Optim 1000 (Avacta, now 
Unchained Labs, USA). Using an excitation wavelength of 266 nm, scattering at 266 nm and 
fluorescence intensity over the spectrum between 300 nm and 400 nm were measured and 
analysed as function of the temperature using the manufacturer’s software. Barycentric 
fluorescence curves were plotted using Prism 6 (GraphPad) and used to obtain melting 
temperatures.
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Results
USP7-CD123 crystal structure
We were able to express and purify a USP7 construct comprising residues 208-882. This 
construct contains the catalytic domain (CD) and the first three Ubl domains, from here on 
referred to as CD123 (Fig. 1a). We obtained single crystals in a vapour diffusion setup at 
4°C with mother liquor of pH > 7, containing multivalent acids. During optimization sodium 
Connector Helix
Ubl3
Ubl2
Ubl1
USP ‘ngers’
B
Catalytic  Domain
1001 200 300 400 500 600 700 800 900 1000 1100
TRAF USP7CD 1 2 3 4 5
C223 H464 D481
1102
USP7CD 1 2 3 4 5 CD12345
USP7CD 1 2 3 CD123
FL
HUBL - structure 2YLM
Ubl12 Ubl45
A
208
208 882
538 562 664 682 771 793 882 894 975 986 1081
Figure 1. The crystal structure of USP7-CD123. A. Schematic overview of USP7 domains and constructs 
used. Also indicated are the catalytic residues and domain boundaries. The ‘connector’ helix, spanning from 
residue 538 to 562, is here defined as the full α-helix, stemming from the CD. The other domain boundaries 
are based on previously solved structures. Domain colours are used for all structural representation of 
CD123. B. The crystal structure of CD123 reveals a curved architecture of domains and a ‘connector’ 
α-helix that links the CD to Ubl1. 
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citrate was found to yield the best diffracting crystals, 
resulting in a dataset diffracting to 3.4 Å (Table 1). 
The crystal belonged to space group F222 with unit 
cell parameters a = 115.2, b = 195 and c = 219.8 
Å, with a rather high solvent content (68%) for a 
single monomer of 79 kDa (Table 1). The structure 
was solved by molecular replacement using apo 
USP7-CD (1NB842) followed by separate searches 
for Ubl12 and Ubl3 (2YLM44). After manual building 
of the connector helix, the model could be refined 
to R-values of R
work
 = 0.22 and R
free 
= 0.27 with good 
geometry (Table 1). The R-values are relatively good 
for a structure at this resolution, probably thanks to 
the external restraints generated by ProSmart from 
the higher resolution search models49. 
The failure of molecular replacement using Ubl123 
from the previous structure as a whole, already 
indicates a conformational change in CD123 with 
respect to the crystal structure of the extended HUBL 
(2YLM44). Indeed, the structural model for CD123 
shows the four domains in a curved, crescent-shaped 
conformation, where Ubl3 ‘bends’ inwards, back to 
the catalytic domain (Fig. 1b). This backward bending 
contrasts with the extended conformation of the 
HUBL domain, and results in a globular overall shape 
for CD123.
Structural analysis of USP7-CD123
As shown previously CD123 has the low activity that 
was observed for the catalytic domain alone (Fig. 
2b44). Accordingly, we observe that the catalytic 
triad is misaligned, with the active-site cysteine and 
histidine separated by more than 10 Å (Fig. 2a). The 
catalytic domain aligns much better with the apo 
structure of CD (1NB842) separately (RMSD 0.53 Å on 
322 Cα’s) than with the activated ubiquitin-bound 
CD (1NBF42) (RMSD 1.34 Å on 314 Cα’s). The main 
differences with the apo structure are in a series 
of loops, that could not be modelled confidently in 
this low resolution structure, and the relatively poor 
density in the β-strands of the fingers region, which 
is mobile in other USP structures54.
The overall arrangement of the Ubl123 is different from that observed in the extended state 
structure of the five Ubl domains (Figure 2c, 2YLM44). When aligning the first two Ubls, the third 
Ubl shows a 25° rotation with respect to the extended structure (Fig. 2c). Such an angle was 
Table 1. Data processing and refinement 
statistics for the crystal structure of 
USP7CD123. Values within parentheses 
are for the outer resolution shell
USP7-CD123
PDB accession code 5FWI
Space group F222
Cell dimensions
   a (Å) 115.18
   b (Å) 195.04
   c (Å) 219.78
   α (°) 90
   β (°) 90
   γ (°) 90
Monomers in ASU 1
Resolution (Å) 48.76-3.40
   Outer shell (Å) 3.67-3.40
Beamline ESRF ID14-1
Wavelength (Å) 0.97935
Observed reflections 77295 (15487)
Unique reflections 17198 (3504)
R
merge
0.061 (0.733)
Multiplicity 4.5 (4.5)
Completeness 99.9 (100)
Mean (I/σ(I)) 13.4 (1.9)
No of protein atoms 5352
R
work
 (%) 22.2
R
free
 (%) 26.7
RMSD from ideality
   Bond lengths (Å) 0.008
   Bond angles (°) 1.278
   Chiral volume (Å3) 0.071
Ramachandran plot
   Favoured (%) 634 (96%)
   Disallowed (%) 3 (0%)
Average B-values (Å2) 104.0
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also observed in the co-crystal structures of Ubl123 with an ICP0-peptide40 and the structure 
of HUBL with DNMT139. Both these structures could exhibit this rotation as consequence of 
binding of the protein partner, but the CD123 structure shows that the protein alone can 
have this flexibility. 
The bending of Ubl3 fits with the model 
proposed44, as this curving lessens the gap 
between the CD and the very C-terminus, 
reducing the distance between K882, the 
last residue of the construct crystallized, 
and C223, the active site, to 47Å. In this 
gap, the remaining Ubl45 domain of 45Å 
would fit perfectly (Fig. 2c), keeping in 
mind the extending, activating C-terminal 
peptide. As proposed earlier40, this distance 
could be further bridged by a hinge motion 
at the region between Ubl3 and Ubl4, an 
area notoriously flexible, as seen in the 
full-length degradation pattern (results not 
shown and 44).
USP7-CD is connected to the Ubl 
domains by an α-helix
A new finding in the CD123 crystal structure 
is the long α-helix connecting the catalytic 
domain to the Ubl domains (Fig. 1b). 
Previous structures have shown parts of 
the helix40,42, and the structure of CD123 
confirms these helical fragments. This 39 
Å helix (26 residues) connects the CD to 
the HUBL domains, and will be referred to 
as ‘connector helix’ from here onwards. 
The density for this part of the protein 
is relatively well-defined, most probably 
thanks to crystal packing and the rigidity 
in the element. Having two domains 
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Figure 2. Comparison of USP7-CD123 to USP7 variants. A. Structural alignment of the apo structure of 
USP7-CD (purple) and USP7-CD of USP7-CD123 (gold) yields an RMSD of 0.53 Å. Both have the misaligned 
catalytic triad, confirming their inactive state. B. Michaelis-Menten analysis of enzyme activities on 
minimal substrate Ub-Rho, comparing CD12345 with CD and CD123 shows that Ubl45 is necessary for 
full activity of USP7. Insert is a magnification of the larger figure. C. Superposition of the HUBL structure 
(2YLM) on either Ubl12 (dark grey) or Ubl3 (light grey) of the CD123 structure. The structural alignment 
shows an angle of 25°, emanating between Ubl2 and Ubl3. 
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connecting over such a length with a rigid α-helical element could imply that the helix has 
an important function in the protein. Therefore we analysed whether this connector helix 
was important for activity. 
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Figure 3. The connector helix is important for full activity of USP7. A. Mutations in the connector helix 
that affect its rigidity were introduced in two location AQK552PGP (purple) and EAH560PGP (green). B. 
Michaelis menten analysis of mutants that affect the charge or bending of the helix show similar K
M
-values 
as wild type CD12345, but yield differences in k
cat
. Curve colours are matched throughout the panels as 
indicated in panel D. C. Mutations in the connector helix that affect a charged patch were introduced. 
Zoom in on the connector helix and surroundings shows a charged patch on both the connector helix and 
the CD. D. Overview of the mutants made, serving as a legend to all panels in figure 3. E. Zoom in on the 
connector helix, showing the deleted helix turns on its N-terminal end (red and pink) and the C-terminal 
end (shades of green). F. Michaelis-Menten analysis for deletion mutants show little changes in K
M
-values, 
but indicate a decrease in k
cat
 upon removal of 2 helical turns of the connector helix.
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The connector helix is necessary for full USP7 activity
First we studied whether the rigid extended nature of the connector is important for activity. 
The connector helix’ rigidity can influence the correct positioning, because such an extended 
element will create distance between the CD and Ubl1. This distance could be necessary to 
position the activating C-terminal tail correctly for folding back onto the catalytic domain 
and promoting its activation. In order to investigate the role of the helix, we introduced two 
‘bending motifs’ by mutating stretches AQK552 and EAH560 (Fig. 3a) to proline-glycine-proline 
in the CD12345 construct, which contains the full HUBL domain.
These CD12345 mutants could be expressed and purified according to the wild type protocol, 
although both mutants eluted later from the gel filtration column (Supplementary Fig. 1a). 
The wild type construct dimerises at concentrations above 1 mg/mL, and with the introduced 
mutations the dimerization equilibrium seems to have shifted to higher concentrations 
(Supplementary Fig. 1b). Furthermore, melting temperature analysis (Supplementary Fig. 
1c) was performed, resulting in similar values, indicating the mutants are as stable as wild 
type protein.
Both AQK552PGP and EAH560PGP were analysed in a deubiquitination assay and compared 
to wildtype CD12345 (Fig. 3b). The K
M
 values were similar, but the k
cat 
rates showed interesting 
differences (Table 2). The mutant with the bend at the end of the connector helix (EAH560PGP) 
exhibited similar activity as wildtype. This would indicate that the HUBL domain has enough 
intrinsic flexibility to overcome such a bending disruption at the end of the extending connector 
helix. In contrast, the mutant with a bend in the middle of the helix (AQK552PGP) has lower 
activity, due to a lower k
cat
 (Table 2, Fig. 3b). The increased flexibility within the helix may 
have changed the spatial location of the Ubl domains with respect to the CD and this could 
explain why the activation by Ubl45 is affected.
A charged patch in the connector helix has influence on USP7 activity
We identified a cluster of charged residues in the connector helix (K554, R555 and R558) all 
pointing inwards, towards the catalytic domain. On the complementary surface of the catalytic 
domain a similar positive cluster of five lysines was identified (Fig. 3c). These positive surfaces 
(with distances between 4Å and 10Å) could repel the connector helix away from the catalytic 
domain. We wondered if this would be relevant for the activity of USP7. 
Table 2. Michaelis-Menten analysis of USP7-CD12345 constructs
kcat (s
-1) KM (µM) kcat / Km (µM
-1 s-1)
WT 2.80 ±0.04 8.80 ±0.32 0.32
AQK552PGP 1.69 ±0.02 8.48 ±0.28 0.20
EAH560PGP 2.45 ±0.03 9.47 ±0.31 0.26
KR554AA R558A 1.10 ±0.03 7.17 ±0.54 0.15
KR554AE R558E 1.46 ±0.05 9.75 ±0.78 0.15
Δ538-541 2.47 ±0.08 9.11 ±0.86 0.27
Δ538-545 1.54 ±0.09 11.86 ±1.61 0.13
Δ561-564 2.87 ±0.07 7.13 ±0.39 0.40
Δ557-564 1.03 ±0.02 6.04 ±0.34 0.17
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We made mutations in the active CD12345 construct that neutralised (KR554AA R558A) or 
reverted (KR554AE R558E) the charge on the linker. These could be expressed and purified in 
a similar fashion as wild type CD12345 (Supplementary Fig. 1a), indicating no drastic changes 
in fold. When comparing the mutants with wild type protein in a deubiquitination assay (Fig. 
3b), they showed reduced activity, indicating that the charge has a role in the activity of USP7. 
The K
M
-values are similar for the mutants and wild type, indicating that these mutants do not 
affect the binding of ubiquitin (Table 2). The values for k
cat 
are two-fold lower, which suggests 
that the charged patch influences the efficiency of the Ubl45 domain activation of the CD.
The connector helix has a minimum length to allow for full activity
Next to the helix’ rigidity and charged patch, the length could influence the positioning of 
Ubl45, and thereby the activation. Therefore, we investigated the length of the connector 
and its effect on the activity of the CD12345 construct. To this end we removed one or two 
α-helical turns (4 residues per turn) on the C-terminal (Δ561-564 and Δ557-564) as well as 
the N-terminal part (Δ538-542 and Δ538-546) of the helix (Fig. 3e).
These mutants could be expressed and purified using the CD12345 protocol and the gel 
filtration profiles indicated a monomeric species (Supplementary Fig. 1a). The activity assays 
yielded similar K
M
-values, however the activity of the mutants differed in k
cat 
(Fig. 3f and Table 
2), indicating that the effect is not on the final positioning, but on the efficiency of reaching 
this stage. In agreement with the findings for the mutant EAH560PGP, where the last helical 
turn is affected, deletion of one turn does not affect catalysis. Deletion of a second turn, 
whether at the start or the end of the helix, affects the activity as shown by the two-fold 
lower values k
cat
. 
Discussion and conclusions
The large number of important targets reported for USP7 indicates that it has a number of 
separately regulated functions in the human cell, but its exact molecular functioning remains 
elusive. Here we present a partial structure of USP7, which shows how previously solved 
crystal structures are connected and allows near full-length modelling. The crystal structure 
reveals a long extended α-helix that connects the CD to the HUBL domain. We studied the 
importance of this connector helix and found that it may play in a role in regulation of activity 
by positioning the C-terminal element.
In the mutational analysis, both the charged patch, the rigidity and the length of the connector 
helix play a role in activation. Mutations in the helical element lead to a modest decrease 
in k
cat
, but do not affect K
M
. The observed effect is analogous to the changes seen in the 
presence of the allosteric activator GMPS, but in the opposite direction25,44. In both cases the 
actual activation has not changed, but the equilibrium between the active and inactive state 
has shifted, in this case towards the inactive state. When this is disrupted, the equilibrium 
between active and inactive USP7 will shift as the efficiency of ‘folding back’ onto the CD of 
Ubl45 is somewhat disrupted (Fig. 4). 
The HUBL domain has some flexibility on its own, as USP7 activity remains similar for the 
mutant EAH560PGP and upon removal of an α-helical turn on either side of the connector 
helix. Only upon tampering with the charge or removing multiple turns the activity drops to 
roughly half the k
cat
. This suggests that the Ubl45 domain is still able to activate the catalytic 
domain, albeit less efficiently. The exact positioning of Ubl45 is still unknown, but our 
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mutational analysis shows that changes in the connector helix play a modest role in USP7 
activity, probably by less efficient positioning of Ubl45.
We know that the linker regions of HUBL are rather flexible, as they are susceptible to 
proteolysis in protein purification. The first linker, between Ubl12 and Ubl3, can allow Ubl3 
to make an angular motion of up to 35°40, but most of the kinking should take place in the 
second linker, between Ubl3 and Ubl45. This second pivot point should allow for another 50° 
to get Ubl45 towards the CD. Distance-wise our structure shows that it can fit, but the exact 
interaction spot on the catalytic domain is not known.
Our structure begins to show the flexibility of the linker between Ubl12 and Ubl3, in line 
with recent co-crystal structures of (parts of) the HUBL domain with DNMT1 and ICP039,40. 
The relative bending of Ubl3 in these structures could have been induced by binding of the 
protein partner. In the CD123 structure however, we don’t have a binding partner, suggesting 
that USP7 does not need a specific modulator for this ‘folding back’ motion. 
The HUBL domain is an important regulatory region in USP7. It contains the second binding 
site (Ubl12) of targets p53 and MDM, but where this interaction exactly takes place and 
whether this influences the activity on these targets is yet unknown. Ubl12 is known to bind 
GMPS, an allosteric activator, as well as DNMT139, URHF1 and ICP040. The co-crystal structure 
of the Ubls with the ICP0 interactor peptide (4WPH40) shows a similar bend of Ubl3 as we 
found in the structure of CD123 and this is also seen in the structure of the full HUBL domain 
with DNMT1 (4YOC39). However, the Ubl45 in this structure has an extended conformation, 
and how ‘closing’ of the gap towards the catalytic domain occurs, an important step in USP7 
self-activation, remains unclear.
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Figure 4. Model of USP7 activation. A. The model of USP7 self-activation shows an equilibrium between 
the inactive and active state, the transition requiring a rearrangement of the HUBL domain. B. A bend 
within the connector helix of USP7 could change the efficiency of the positioning of Ubl45, affecting the 
overall activity of USP7. C. Mutating the charged patch could have a similar effect, affecting the efficiency 
of the positioning of Ubl45 and thereby the USP7 self-activation. D. Shortening of the connector helix 
with two helical turns affects the self-activation, possibly due to the efficiency of positioning of Ubl45.
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The changes in k
cat
 observed upon mutation of the connector helix, and upon GMPS binding to 
Ubl12344 indicate that these regions can be allosterically modulated. One could imagine that 
binding of small molecules at these sites could have a function in regulation of USP7 activity. 
As the charged patch of the connector helix is required for full activity, this could be a good 
starting point for structure-guided inhibitor design in a USP7 specific manner, especially as 
USP7 is emerging as an important drug target55–59. Good understanding of the conformational 
changes and allosteric regulation of this critical DUB will be important to understand the 
effects of bound inhibitors. Our new structure will contribute to these efforts. 
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Supplemental figure 1. Quality control of USP7-CD12345 mutants. A. Gel filtration profiles for CD12345 
constructs indicate dimer formation for wild type CD12345 and charge mutants, but less so for the 
other mutants. Analysis was done on Superdex 200 16/60 during purification. B. MALLS analysis of WT 
CD12345 versus EAH560PGP shows that WT behaves as dimer and EAH560PGP is a monomer at ~6 mg 
mL-1. At lower concentrations WT is also monomeric as seen from the gel filtration profile, but no useful 
MALLS signal can be obtained at this concentration. All runs were performed on an analytical Superdex 
200 10/300 gel filtration column, the resulting molecular weight (by MALLS analysis) in the peaks are 
plotted on the right-hand axis. C. Analysis of the barycentric fluorescence curves show that the mutants 
have a similar melting temperature as wild type protein, indicating the mutations do not affect stability.
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Abstract 
USP7 is a highly abundant deubiquitinating enzyme (DUB), involved in cellular processes 
including DNA damage response and apoptosis. It has an unusual catalytic mechanism, where 
the low intrinsic activity of the catalytic domain (CD) increases when the C-terminal Ubl 
domains (Ubl45) fold onto the CD, allowing binding of the activating C-terminal tail near the 
catalytic site. Here we delineate how the target protein promotes the activation. Using NMR 
analysis and biochemistry we describe the order of activation steps, showing that ubiquitin 
binding is an instrumental step in USP7 activation. With chemically synthesised p53-peptides 
we identify how the correct ubiquitinated substrate promotes catalytic activity dramatically. 
This allows transient reaction kinetic modelling to define how the USP7 multistep mechanism 
is driven by target recognition. Our data show how this pleiotropic DUB can gain specificity 
for its cellular targets.
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Introduction
Ubiquitination is recognised as an important post-translational modification (PTM), influencing 
protein fate in every cellular process1,2. This modification of a target protein conjugates 
the C-terminus of ubiquitin (Ub) to a lysine residue on a target protein via an E1-E2-E3 
cascade3. As Ub has 7 lysines and an available amino terminus it can be ubiquitinated itself, 
resulting in poly-ubiquitination through 8 different possible linkages4. These different ubiquitin 
marks generate distinct signals that determine the fate of the target protein, ranging from 
proteasomal degradation to cellular relocalisation or recruitment of complex partners2,5,6.
Similar to other PTMs, ubiquitination can be reversed, modulating and fine-tuning the ubiquitin 
signal7. This deubiquitination is carried out by deubiquitinating enzymes (DUBs) that can 
hydrolyse the isopeptide bond between Ub and the target protein8. DUBs play a balancing 
role in ubiquitination: dysfunction can lead to serious diseases such as cancer9,10, and their 
activity is tightly controlled11.
One of the most abundant DUBs is Ubiquitin Specific Protease 7 (USP7, also known as 
HAUSP12). It has been assigned multiple critical functions ranging from DNA repair and 
apoptosis to suppression of regulatory T-cell function13,14. USP7 is shown to correlate with 
paediatric cancer15,16 and is actively targeted for cancer therapy17–19, primarily for its nuclear 
functions, while USP7 haploinsufficiency leads to a neurodevelopmental disorder20 through 
a cytosolic role. 
USP7 is found in a variety of protein complexes, many of which contain an E3 ligase and its 
target21. In these complexes both the E3 ligase and its substrate are targets of USP7, like the 
substrate pair of E3 ligase MDM2 and target p5322, the master regulator of the response to 
cellular stress23. This creates a situation where USP7 can either deubiquitinate and stabilise 
MDM2, promoting p53 ubiquitination and its proteasomal degradation24,25, or target p53 
by which the apoptotic pathway is activated26. The balance between these two targets is 
influenced by various other proteins shifting USP7 activity towards MDM227 or p5328. 
For the interaction with both MDM2 and p53, USP7 relies on its N-terminal TRAF (Fig. 1a) 
domain on USP7. This domain interacts with a TRAF recognition motif on the target proteins 
with a moderate affinity of ~10 µM29,30, but does not affect the actual hydrolysis of the ubiquitin 
isopeptide bond on a minimal substrate31.
The TRAF domain is connected to the adjacent catalytic domain (CD) through a flexible 
linker30, allowing the CD to find and cleave off the ubiquitin from the target (Fig. 1a). This 
catalytic domain alone has low intrinsic deubiquitinating activity while full-length USP7 is a 
much more active DUB32. Crystal structures of this CD show that the apo state of the enzyme 
has an inactive conformation, with a misaligned catalytic triad33. When ubiquitin is bound, 
the catalytic triad (C223, H464 and D481) realigns into an active conformation, involving 
significant changes in a loop above the active site. This ‘switching loop’ is essential for full 
activity of full-length USP731.
Located C-terminally of the CD are five ubiquitin-like (Ubl) domains which are essential for 
the increased activity of full length USP731,32. The three Ubl domains just downstream of the 
CD (Fig. 1a) do not influence the activity directly, but rather serve as a binding platform for 
interactors such as GMPS or DNMT131,34,35. The last two Ubl domains with the activating tail 
(Ubl45), however, are indispensable for full activity of USP7: Ubl45 readily activates the CD 
as does the very C-terminal tail by itself, at high concentrations36.
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The Ubl domain region can adopt an extended conformation, as seen in the crystal structure of 
Ubl12345 (PDB: 2YLM), but has considerable flexibility, as shown by small-angle X-ray scattering 
(SAXS)31. Detailed biochemistry combined with SAXS analysis led to a proposed mechanism 
where the Ubl domains curve and the Ubl45 domain ‘folds back’ onto the CD. The C-terminal 
tail then interacts with the ‘switching loop’, stabilising a catalytically competent conformation 
of USP7. Various mutations in either the tail or the loop substantiated this model31. The role 
of the C-terminal tail was further defined in a crystal structure of ubiquitin-bound CD linked 
to Ubl45. This showed how the C-terminal tail binds the CD, stabilising the ‘switching loop’36 
in the active conformation. Intriguingly in this analysis the C-terminal peptide alone, when 
directly linked can reconstitute much of the activation, but from the structure, it was unclear 
whether it was bound in cis or trans. This ambiguity prompted us to further investigate the 
role of the Ubl45 domain in this interaction and its effect on USP7 activity. 
Most molecular studies on DUB activity utilise minimal substrates, focussing on the role of 
the ubiquitin moiety, essentially the product of the reaction. In the last years the focus has 
therefore shifted towards Ub-chains4, uncovering chain-specificity of DUBs, which allowed 
relating them to distinct biological processes37. For USP7 the active conformation of the 
catalytic domain has only been observed when it was conjugated to ubiquitin33. Ubiquitin alone 
is not sufficient to induce the rearrangement and a fusion at its C-terminus, such as ubiquitin 
aldehyde or a ubiquitinated substrate, is required for proper active site rearrangement38. 
The roles of other substrate proteins, however have received relatively little attention in 
biochemical DUB analyses. Quantifying contributions of a realistic substrate requires a 
homogeneous, well-defined target. For p53, the interaction with USP7 has been described 
in detail29,39, allowing generation of synthetic mimics of the substrate. Using such ubiquitinated 
p53 mimics as model targets we can investigate the effect of a more realistic substrate on 
USP7 activity in an in vitro setting. 
Here we made use of chemical synthesis to generate well-defined tools to address how a p53 
model substrate interaction may modulate the activation process. Structural analysis suggests 
that a monomeric USP7 undergoes an activation process that can be further improved by 
binding to a valid substrate. Using the p53 model substrate and global modelling on the 
experimental data we could determine the order of events and quantify the steps involved 
in the USP7 ubiquitin hydrolysis cycle.
Figure 1. USP7 activation by the C-terminal tail happens in cis. A. Schematic domain representation of 
USP7 and constructs used in this study. Active site residues and domain names are indicated: TRAF; TRAF 
domain, CD; Catalytic domain, 1-5; Ubl domains 1 through 5, tail; The activating C-terminal peptide (res. 
1083-1102), marked in purple. The graphical representation of the constructs is used in other figures. 
B. Analysis of USP7 constructs on SEC-MALLS shows monomer/dimer equilibrium. CD45 (100 µL of 45 
µM) or FL (80 µL of 20 µM) were loaded on a Superdex200 gel filtration column. Absorbance at 280 nm 
(dark red: CD45; dark blue: FL) was monitored and eluted peaks were analysed for molecular weight (red: 
CD45; blue: FL) by in-line MALLS. For CD45 the molecular weights of the monomer (69 kDa) and dimer 
(138 kDa) are indicated with the dotted line. C. Activation of USP7CD by Ubl45 requires the very C-terminal 
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tail. 20 nM of CD was mixed with Ubl45 variants as indicated and tested for DUB activity using UbRho. 
D. 20 nM USP7CD was incubated with a titration range of Ubl45, and tested in a deubiquitination assay 
as in 1c. These initial velocities were plotted against the concentration to yield an apparent K
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, with the 
displayed standard deviation. E. 20 nM CD12345ΔC has similar activity to CD and can be activated by the 
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causes an inhibitory effect above 2 µM, therefore only lower concentrations were used to extrapolate a 
K
D,app
 (blue dashes). The red dotted lines indicate the activity of WT CD12345 for comparison.
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Results
USP7 activation requires the C-terminal tail in cis
The activation of USP7 requires interaction between the CD and the C-terminal peptide (see 
Fig. 1a for domain definitions and nomenclature). The details of this interaction were described 
in a recent crystal structure (PDB: 5JTV) of Ubl45 and CD36. This structure convincingly shows 
the binding of the activating C-terminal peptide, however the connection to Ubl45 was 
disordered making it difficult to decide whether the C-terminus of USP7 binds into the 
activation cleft in cis or in trans. 
When we analysed the ability of USP7 to form dimers in size-exclusion chromatography 
with multi-angle laser light scattering detection (SEC-MALLS), we observed no dimerization 
for FL (injected at 20 µM, peak elutes at ~4 µM) and only partially for the construct used in 
the crystallization experiment (injected at 45 µM, monomer peak elutes at ~7 µM) (Fig. 1b). 
This indicates that at the much lower concentration in cells (~0.3 µM40), USP7 is more likely 
to behave as a monomer. 
We then checked what concentrations of Ubl45 are needed for in trans activation of CD (Fig. 
1c). We find this is possible, but only occurs at high concentrations, with an apparent K
D
 of 110 
µM (Fig. 1d). Consistently, a construct lacking the C-terminal tail (CD12345ΔC) can be activated 
by a catalytically dead FL USP7, (CD12345C223A) only at similarly high concentrations, with an 
apparent K
D
 of 60 µM (Fig. 1e). Both these apparent in trans activation constants are orders 
of magnitude higher than the concentrations (1 to 20 nM) that are sufficient for USP7 activity 
assays of full-length or CD-Ubl45 constructs31. We therefore conclude that although trans 
activation of USP7 is possible at high concentrations, it is not the predominant mechanism 
of its self-activation. 
Definition of the interaction interface between CD and Ubl45
These results suggest that the interaction of CD and Ubl45 likely takes place in cis. The 
interaction of the C-terminal peptide with CD, as determined by Rougé et. al. in the crystal 
structure36, is indisputable, but the positioning of the Ubl45 core did not seem as well-defined. 
We therefore wanted to investigate this interaction further, using solution methods. In an 
attempt to explore the role of the tail in the interaction and identify the interaction site on 
Figure 2. Interaction between Ubl45 and CD identified in solution using NMR. A. The peak dispersion 
and resolution in the 1H-15N correlation spectrum of Ubl45 (45 µM; 25 kDa; coloured blue) indicates a 
well-folded protein. Assignments are indicated, those for the crowded regions, indicated in grey, are shown 
in Supp. Fig. 1a. B. The addition of 450 µM CD prompted very little chemical shift perturbations (CSPs). 
The biggest observed CSP of 0.019 ppm for Y1093 is illustrated in this zoom. C. Upon titration of CD the 
peaks in the Ubl45 spectrum show significant decrease in intensity. Here the intensity ratios between the 
apo spectrum (1:0) and the highest titration (1:10) are plotted against the residue numbers. The average 
is indicated by a dotted line, while residues that were found in the crystal structure to interact (see D) 
are highlighted in the bar graph. D. Structure and intermolecular interface in the Ubl45-CDUb structure 
(PDB: 5JTV 36), showing contacts between both the tail and the core of Ubl45 to CD. Ubl45 residues that 
are within 4 Å of CD are shown as sticks and indicated. E. The same intensity plot as in C, but now done 
for the titration with CDUb indicates that the tail now does get immobilised.
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the Ubl45 core in solution, we used NMR spectroscopy to map the binding interface (Fig. 2, 
Supp. methods), starting by assignment of the backbone resonances of Ubl45 (Supp. Fig. 1a). 
The resulting predicted secondary structure in solution matches that of the crystal structure 
(PDB: 5JTV; Supp. Fig. 1b), indicating that NMR conditions allow functional interaction analysis.
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We titrated the unlabelled CD (42 kDa) into labelled Ubl45 (25 kDa) up to a ratio of 1:10 and 
followed changes in peak position or intensity (Fig. 2a-b). Upon addition of CD, we observe 
only very minor chemical shift perturbations (CSPs) (Fig. 2b), but a marked decrease in 
intensity for residues in the core of the Ubl45 domains (Fig. 2c). The amount of peak intensity 
decrease agrees well with the formation of a 67 kDa complex with affinity as determined 
by SPR (see below and Supp. Fig. 2a). Under these conditions, residues with large changes 
in their chemical environment upon binding are expected to show an even more dramatic 
intensity loss (Supp. Fig. 2c). From the absence of such effect for residues that are predicted 
to be in the interface based on the crystal structure (Fig. 2d) or for any other site on the core 
surface, we conclude that the Ubl45 core is not involved in a single, specific interaction with 
CD. Only a few, very minimal CSPs are observed, localized to C-terminal tail residues, with the 
strongest shift seen for Y1093 (Fig. 2b). The tail residues however remain sharp and intense 
peaks throughout the titration, indicating that the tail is not immobilized on the CD surface.
As the tail is immobilised in the crystal structure, which was solved in the presence of ubiquitin 
we decided to assess the influence that ubiquitin would have on this interaction. Because 
ubiquitin monomers bind poorly to USP7 CD38, we first generated a covalent complex between 
CD and Ub, using a suicide probe, ubiquitin-propargyl (Ub-PA41) to generate CDUb. Upon 
titration of CDUb onto Ubl45, the effect of binding is only apparent through peak intensity 
decrease. Upon addition of CDUb, the Ubl45 peak intensity decrease is now nearly directly 
proportional to the equivalents of CDUb added. At 30% of CDUb added, peak intensity for 
all Ubl45 residues, including the C-terminal residue has been reduced by ~30% (Fig. 2e). 
This indicates that Ubl45 forms a tight complex with CDUb in which the tail, particularly the 
C-terminal residues are immobilized. The absence of CSPs indicates that the free protein is 
in slow exchange with the complex (75 kDa) (see also Supp. Fig. 2c).
Together, these results suggest that while the Ubl45 binds to CD, it does so in multiple, weak 
binding modes predominantly involving the Ubl45 core to form a dynamic complex. Our 
data further suggest that the presence of ubiquitin or a ubiquitinated target may induce the 
specific binding mode of the C-terminal tail as observed in the crystal structure.
Figure 3. Affinity of CD for Ubl45 increases with Ub present and is dependent on C-terminal tail. A. 
SPR binding results indicate a weak affinity of USP7CD for either Ubl45 or Ubl45ΔC. CD was immobilized 
through GST on the chip and tested for binding with Ubl45 or Ubl45ΔC. Equilibrium binding values were 
plotted against concentration and fitted to get an estimated K
D
. Responses were normalised using the 
B
max
 and the standard deviation for resulting values is given. B. The increased binding between Ubl45 
and CDUb depends on the C-terminal tail. Ubl45 or Ubl45ΔC was immobilized on the chip and the covalent 
CDUb complex was flown over. A fit was made using the equilibrium binding values yielding a K
D
 of 590 
nM for Ubl45, whereas no binding could be observed for Ubl45ΔC. Normalisation was carried out using 
B
max
. C. Comparison of the affinity of Ubl45 for CD or CDUb shows a remarkable increase. Specified curves 
from Fig. 3a and 3b are replotted to exemplify the change in K
D
. D. The C-terminal tail was immobilized 
using biotin and CD or CDUb was flown over to confirm that the tail interacts with the transition state 
(CDUb) only and not the apo CD. E. Overview of affinities between Ubl45 and CD show that Ub enhances 
the binding of the tail. The values for the upper two rows are determined using SPR, see A-D. The values 
79

A
4
5
4
5
CD
OR
10 100
0.0
0.5
1.0
Concentration (µM)
N
or
m
al
iz
ed
 re
sp
on
se
 (R
U
)
KD 280 µM±40
KD 420 µM±40
Ubl45
Ubl45∆C
0.01 0.1 1 10 100
0.0
0.5
1.0
Concentration (µM)
N
or
m
al
iz
ed
 re
sp
on
se
 (R
U
)
KD 280 µM±40
KD 0.59 µM±0.03
Ubl45 vs CDUb
CD vs Ubl45
C
4
5
CD
Ub
4
5
CD
B
4
5
4
5
OR
CD
Ub
0.01 0.1 1 10 100
-0.5
0.0
0.5
1.0
Concentration (µM)
N
or
m
al
iz
ed
 re
sp
on
se
 (R
U
)
Ubl45∆C
Ubl45
KD 0.59 µM±0.03
D
OR
CD
Ub
CD
0.01 0.1 1 10 100 1000
0
50
100
150
200
250
Concentration (µM)
R
es
po
ns
e 
(R
U
)
CD
CDUb
KD 2.6 µM±0.4
E
Δ


+
280. ±40
0.59 ±0.03
420. ±40
2.6±0.4
110. ±20 ~1000.
N.D.
N.D.
N.A. *
S
P
R
A
ct
(Apparent) affinities in µM
Determined by SPR and activity assay (Act)
F
100 1000
40
60
80
100
120
Concentration (µM)
P
ol
ar
is
at
io
n 
TA
M
R
A
U
b 
(m
P
)
CD
CD12345
CD12345∆C
101
KD ~100 µM
KD ~150 µM
KD ~270 µM
G
10 15 20 25
0.0
0.2
0.4
0.6
0.8
1.0
0 5
Concentration UbRho (µM)
In
iti
al
 v
el
oc
ity
 v
0 (
s-
1 )
10 15 20
0.00
0.02
0.04
50
Concentration UbRho (µM)
CD12345∆C
CD
CD12345
kcat (s-1)KM (µM)
5.6
18.9
4.7
±  1.1
±19
±  0.2
0.02
0.07
1.1
±0.002
±0.04
±0.02
in the last row have been derived from activity assays, see Fig. 1d and 36 for the estimated affinity of the 
C-terminal tail (*). N.A.: not applicable; N.D.: No binding detected. F. The presence of the Ubl45 domain is 
essential for increased affinity of CD for ubiquitin, but not the C-terminal tail. The affinity for ubiquitin was 
measured in an FP assay where TAMRA-labelled ubiquitin was incubated with various USP7 constructs. 
G. Steady state kinetics analysis of USP7 constructs indicates that the C-terminal tail mainly affects the 
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cat
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Interaction between Ubl45 and CD does not require the tail
For full activity the C-terminal tail is essential, but its affinity for the catalytic domain could only 
be measured indirectly in activity assays. In surface plasmon resonance (SPR) experiments, 
interaction was not detectable31, but in an activation assay, the apparent K
D
-value was 
estimated at ~1000 µM36. This is one order of magnitude weaker than the apparent K
D
 
determined for Ubl45 (110 µM, Fig. 1d), in line with our NMR result that suggested that the 
Ubl domains contribute to the binding and activation of the catalytic domain. To investigate 
the interaction between Ubl45ΔC and the catalytic domain we immobilised GST-USP7CD on 
the SPR chip, flowing over the tailless construct Ubl45ΔC. We were able to detect binding at 
high concentrations. Extrapolation of the curve, suggests a K
D 
 of 420 µM (Fig. 3a), similar to 
that observed for the C-terminal peptide interaction in the activity assay. This suggests that 
both Ubl45ΔC and the tail bind weakly to the CD.
We then tested the affinity of CD for Ubl45 including the tail, and get an approximate K
D
 of 
280 µM (Fig. 3a), comparable to the tailless construct. This suggests that the C-terminal tail 
is not the main driving force for the interaction between the CD and Ubl45 as the affinity is 
similar with or without the tail. This result is in agreement with the lack of binding between 
the C-terminal peptide and CD observed in the NMR experiment (Fig. 2c) and earlier data31, 
but seems at odds with the activating role of the tail in the activity assay. The NMR experiment 
seemed to suggest that ubiquitin needs to be present for immobilization of the tail on CD. 
Interaction between C-terminal tail and CD requires Ub 
To quantify this effect of ubiquitin on the binding of the activating, C-terminal tail, we used 
the covalently coupled ubiquitin to the catalytic cysteine in the CD (CDUb). As CD on its own 
has low activity, the reaction between Ub-PA and CD had to be driven to completion using 
the trans activation of Ubl45. After incubation however, Ubl45 could not be separated from 
CDUb on gel filtration (Supp. Fig. 3a) requiring additional ion exchange chromatography, 
indicating that complex formation between CDUb and Ubl45 was tighter than expected, as a 
complex with a K
D 
of 280 µM (Fig. 3a) generally dissociates on such gel filtration experiments.
We quantified the interaction by SPR flowing CDUb over GST-immobilised Ubl45 (Fig. 3b). 
Data analysis in EvilFit42 identified a K
D
 of 0.59 μM ±0.03 with a k
off
 of 0.8 s-1 (Supp. Fig. 3b) 
for the interaction between CDUb and Ubl45. The presence of ubiquitin in CD therefore 
increased the affinity four hundred-fold compared to CD only (Fig. 3c). As the C-terminal tail is 
necessary for activation, we hypothesised that it would directly facilitate the interaction with 
the intermediate, ubiquitin-bound, state. To test this, we immobilised the tailless construct 
(Ubl45ΔC) in our SPR experiment setup and flowed over CDUb with concentrations up to 
80 µM (Fig. 3b). We could not detect any binding of Ubl45ΔC in this experiment, suggesting 
that the Ubl domains can no longer bind ubiquitin-bound catalytic domain, contrary to apo 
CD (Fig. 3a). This would mean that, after ubiquitin binding, the increased activity depends 
exclusively on the C-terminal tail. 
In agreement to this, the immobilised tail peptide (residues 1083-1102) interacted with CDUb, 
with a K
D
 of 2.6 µM, but showed no binding to the CD alone (Fig. 3d). This is analogous to 
what we found for Ubl45 (Fig. 3b) and in line with our NMR experiments where the tail did 
not show clear binding to CD alone (Fig. 2b). 
Our results are in line with previously published NMR data that showed that a linked Ub 
is necessary to induce rearrangement of the catalytic site38. The binding of ubiquitin to CD 
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apparently facilitates binding of the C-terminal tail (Fig. 3d). Together, these data explain 
how CD can still be activated by the C-terminal tail on its own, albeit with a lower resulting 
activity than the FL construct36. We conclude that once the ubiquitin-bound intermediate 
state is achieved, the C-terminal tail is sufficient for self-activation.
Ubl45ΔC promotes ubiquitin binding
Knowing that the C-terminal tail has high affinity for CD only after ubiquitin binding (Fig. 3e), 
we wondered if Ubl45ΔC might affect the Ub binding. Such an outcome is consistent with our 
previous results indicating that in full-length USP7 self-activation increases the catalytic rate 
(k
cat
) but also the K
M  
(which is, on a minimal substrate, dominated by the affinity to ubiquitin), 
from >>35 µM to roughly 4 µM31. It may also explain why direct linkage of the C-terminal 
peptide to the CD almost, but not completely recapitulates the full length activity36. 
We therefore tested ubiquitin binding qualitatively in a fluorescence polarization (FP) assay, 
following polarisation of TAMRA-labelled Ub upon incubation with various USP7 constructs 
(Fig. 3f). In this assay we see the increased affinity for ubiquitin in the presence of the Ubl45 
domain (when comparing CD12345 with CD only) even when the tail is absent (comparing 
CD12345ΔC to CD). The data indicate that the presence of the C-terminal tail does not affect 
the CD affinity for Ub, in line with its lack of affinity for CD observed in the NMR (Fig. 2b) and 
SPR experiments (Fig. 3d). 
We could confirm the Ubl45-induced increase in affinity of CD for Ub by analysis of the steady 
state kinetics of these constructs in activity assays (Fig. 3g). When we fit Michaelis-Menten 
curves for CD, CD12345 and CD12345ΔC we could see that presence of the C-terminal tail 
dramatically increases k
cat
31, whereas the Ubl45ΔC is responsible for the increase in K
M
 (compare 
CD and CD12345ΔC in Fig. 3g).
A multi-step mechanism for USP7 activity
These data suggest that USP7 is likely to follow a multi-step mechanism during its catalytic 
cycle. In the first step, binding of ubiquitin is facilitated by the core of Ubl45, which does not 
involve the C-terminal tail. After binding of ubiquitin, conformational changes align the catalytic 
triad33. In this state, the affinity of the CD for Ubl45 is decreased (Fig. 3e), but the affinity for 
the tail is dramatically increased, allowing optimal orientation of the activating C-terminal 
tail to form the activated state. This mechanism is reminiscent of the classical induced fit in 
enzymology, where binding of the substrate can activate the enzyme: here, ubiquitin-induced 
binding of the C-terminal peptide stabilizes the active CD conformation and promotes fast 
hydrolysis of substrate, which is observed as an increase in k
cat
. 
Next, we wanted to address the role of the target protein in the USP7 mechanism. To study 
whether interactions with a ubiquitinated target protein would affect USP7 activation we 
make use of a chemical biology approach.
Role of the target p53
We chose p53 as our model target protein (Fig. 4a), which has six lysines near the C-terminus 
that can be ubiquitinated39 as well as motifs that can be recognized by the USP7 TRAF 
domain29,43. We made a synthetic toolbox of ubiquitinated C-terminal p53 peptides44 and 
initial tests on these conjugates indicated that all six lysines could be cleaved by USP7.
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We generated two versions of the ubiquitinated p53 peptides with K382 as the ubiquitination 
site, either with the TRAF recognition motif (p53Ub, res. 357-389) or without this region 
(p53shortUb, res. 368-389, Fig. 4a). The ubiquitin attachment was varied to allow different 
assays: a suicide version with a vinylamide (VA) linkage (I)45 that can bind covalently, like the 
better-known vinyl methyl ester46,47, a non-hydrolysable triazole linkage (II) 48 and a cleavable 
native isopeptide linkage (III)44,49, for both the short and long versions of the peptide (Fig. 4b). 
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Figure 4. Development of synthetic p53-derived substrates for USP7. A. Schematic domain structure 
of p53 with transactivation domain (TAD), core region, tetramerization domain (TET) and C-terminal 
region indicated (CT). Close-up of CT highlights lysines (bold) known to be ubiquitinated39 and the TRAF 
recognition motif (underlined)29,43. K382 (red) is used as target lysine in the synthetic p53Ub reagents, 
underneath the sequence coverage of the peptides is indicated. B. Three synthetic p53Ub-peptides are 
generated with different linkage types: covalently-binding (vinylamide linkage, (I)), uncleavable (triazole 
linkage, (II)) and cleavable (native linkage, (III)). C. The affinity of USP7 for the covalent-binding p53Ub
VA
 
increases if the TRAF domain is present. USP7 constructs with and without TRAF domain have been 
incubated with the probe for 15 minutes at RT and analysed on a Coomassie gel. D. The affinity of Ubl45 
for the substrate-bound TCD is similar to CDUb (2.9 µM compared to 0.59 µM, Fig 3c). Around 50 units of 
Ubl45 were immobilized on the chip before a titration range of p53Ub-bound TCD was flown over. Their 
equilibrium binding values were plotted and fitted to get the K
D
-value.
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Using the p53Ub
VA
 suicide probes we were able to assess the role of the TRAF interaction in 
substrate binding. Although both short and long versions of the probe reacted readily with 
CD12345 (Fig. 4c), the full-length USP7, which contains the TRAF domain, showed increased 
complex formation, specifically for the p53Ub peptide that has the TRAF recognition sequence. 
This indicates that the TRAF recognition sequence promotes the USP7 interaction with the 
model substrate. In the remainder of this report we will focus on the long peptide.
Next, we used the p53Ub
VA
 probe to generate a non-hydrolysable complex with TCD, a 
construct that lacks all Ubl domains (Fig. 1a) to address whether the p53 interaction affects 
the interaction of CD with Ubl45. Using SPR, the complex was flowed over immobilised Ubl45 
and we could determine the affinity between Ubl45 and TCD-p53Ub (Fig. 4d, Supp. Fig. 
3d). With a K
D
 of 2.9 µM it is similar to the affinity found for the C-terminal tail interacting 
with CDUb (2.6 µM, 
Fig. 3d). Apparently the 
presence of the TRAF-p53 
interaction does not further 
change the interaction with 
Ubl45. This is in line with 
the fact that the presence 
of the TRAF domain does 
not affect activity on a 
minimal substrate31 or the 
association of the activating 
Ubl45 domain.
A second p53 
interaction
To further investigate the 
role of the p53 peptide 
interaction with the TRAF 
domain in the activation 
process, we decided to 
look at the affinity between 
USP7 and the model target. 
As previous reports have 
alluded to an additional 
binding site (other than 
TRAF) for the USP7 targets 
p53 and MDM2 in the 
C-terminal domains of 
USP750, we first assessed 
the binding of the peptide 
to USP7 constructs in a FP 
assay (Fig. 5a). These direct 
binding assays with TAMRAp53 
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peptide confirmed the presence of an additional p53 binding site and map it to the Ubl45 
domains, without requiring the C-terminal tail (compare FLΔC and TCD45 to TCD). Interestingly, 
this additional site depends on the TRAF domain since CD12345 alone does not bind the 
peptide at these concentrations (Fig. 5a). These results suggest an extended binding interface 
between the TRAF domain and the p53 peptide that is aided by Ubl45, but the hypothesis 
of a second, very weak, binding site within Ubl45 cannot be excluded.
To then assess a potential increase in affinity for the ubiquitinated substrate, we used the 
non-hydrolysable compound (Fig. 4b; p53Ubinh) as inhibitor in an activity assay, on minimal 
substrate UbRho (Fig. 5b). We found that both TRAF domain (compare TCD and CD) as well 
as Ubl12345 improve the IC
50
 independently (Fig. 5c). However, the full-length construct 
displays a further avidity effect, resulting in an IC
50
 of 16 nM, ~60-fold better than either TCD 
or CD12345. This underlines that the TRAF domain, CD and Ubl12345 all contribute to the 
effective substrate (p53Ub) recognition and that the sum of these interactions yields a tight, 
effective interaction.
Visualisation of the multi-step enzymatic mechanism
As both the ubiquitin acceptance (aided by Ubl45) and the target recognition positively 
influence deubiquitination, we wanted to explore how these collaborate during the 
deubiquitination process and whether there is a defined order of events. To this end, we 
utilised the synthetic ubiquitinated p53 target with a native linkage (Fig. 4b; p53Ub) and a 
fluorophore at the N-terminus of the p53 peptide to allow tracking of substrate and product44. 
We monitored the substrate during its hydrolysis in an FP assay where 100 nM of TAMRA-
labelled reagent is incubated with various USP7 constructs (Fig. 6b for FL, Supp. Fig. 5-7b for 
TCD, CD12345 and CD). Both FL and CD12345 could readily hydrolyse the substrate, resulting in 
a drop of the FP signal. The other two constructs, CD and TCD, required higher concentrations 
in order to see a decrease in FP signal, while the TCD construct actually started out with an 
increased signal (Supp. Fig. 5b). This increased signal would be a result of binding, as the TRAF 
domain increases the affinity for the p53-substrate but the rate of catalysis is still low for TCD. 
Although these experiments efficiently monitored substrate hydrolysis, we were interested 
in the early events that could not be caught in our plate reader setup.
To get insight into the very early phase of the reaction, we decided to use a stopped-flow setup 
(Fig. 6c,d). We followed the reaction by fluorescence polarization, which is sensitive to the size 
of the complex (as this affects the tumbling rate and thus polarisation), and by fluorescence 
Figure 5. The p53-derived tools stress the importance of both the TRAF and Ubl45 domain. A. Binding 
of the TAMRA-labelled p53 peptide is determined by incubating 25 nM of TAMRAp53 with a dilution series 
of various USP7 constructs in FP assays. The obtained K
D
 values for each USP7 construct are stated and 
indicate that in presence of the TRAF domain, the Ubl12345 domain affects recognition. B. The non-
hydrolysable p53Ub construct acts as an inhibitor for USP7 in deubiquitination assays. USP7 constructs, 
corrected for their activity (CD12345: 0.35 nM, TCD: 200 nM, CD: 75 nM, USP7FL: 0.35 nM) were incubated 
with increasing amounts of p53Ubinh and analysed for activity in a deubiquitination assay using a single 
concentration of UbRho. The raw data indicate that both the TRAF domain and the C-terminal Ubl domains 
increase the affinity towards the p53 construct. For clarity’s sake a limited number of concentrations is 
shown. C. The observed activity for USP7 constructs after incubation with p53Ub
inh
 (see B), is plotted 
against the concentration of inhibitor used. Fitting yielded IC50 values and standard deviation as shown.
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intensity, which responds to changes in local conformation affecting the fluorophore. As these 
experiments were performed under near-equimolar amounts of enzyme and substrate, we 
also measured binding to the product TAMRAp53 peptide in this stopped-flow setup (Fig. 6e,f).
In the stopped-flow anisotropy data we could detect an increase in signal when we titrated 
FL into TAMRAp53Ub (Fig. 6c). After this binding phase (0.02-0.2 s) we observe a decrease in 
anisotropy, indicating a second phase (0.2-2 s) indicative of hydrolysis. The signal however does 
not drop below baseline for the highest concentration, indicating retention of the product, 
in line with our p53 peptide binding data (Fig. 6e). 
For the constructs CD and CD12345 we can hardly detect the TAMRAp53Ub binding phase 
(Supp. Fig. 6c, 7c) or the decrease in anisotropy, indicating that these require the presence 
of the TRAF domain. When it is present, in TCD, the binding and the decrease are visible 
(Supp. Fig. 5c), but the decrease only occurs after a lag phase (>5 s), indicating the presence 
of intermediate states between binding and hydrolysis.
This step is more explicitly visualised in the intensity data from these stopped-flow 
experiments. For TCD, with the long delay between binding and hydrolysis (Supp. Fig. 5c), 
we see a significant decrease in intensity in this delay (Supp. Fig. 5d), which we interpret as 
a conformational change in the protein (see Supp. methods). For full-length USP7 a minor 
intensity increase (Fig. 6d) occurs, with a slight delay (0.05-0.5 s) relative to the binding 
phase. This suggests that a further conformational change affects the intensity signal, which 
we interpret as binding of the C-terminal tail read out by rearrangement of the TAMRA label. 
The non-synchronicity of the events in the anisotropy and intensity experiments suggests 
that multiple steps are involved in the hydrolysis mechanism.
Kinetic analysis of USP7 activity on p53 model substrate
To model these multiple steps we proceeded to describe every phase, with as few reaction 
steps as possible. We imported the raw stopped-flow, FP and activity data into KinTek51 and 
let the program scale the data based on the negative controls (Supp. methods). This rendered 
the data interpretable by KinTek modelling which we performed by using a minimal set of 
reaction equations. To be able to model the non-synchronous changes in the FP and intensity 
signals we decided to introduce intermediate steps in the reaction (Fig. 6h). These include 
binding events (Steps 1, 6 and 7), conformational changes (Steps 2, 3 and 5) and the enzymatic 
hydrolysis (Step 4). The introduction of these steps allowed KinTek to fit the data, obtaining 
rate constants (k
f
 and kr) for every step of the mechanism (Fig. 6h).
For the shorter constructs, introduction of one intermediate step between the binding (Step 1) 
and the hydrolysis step (Step 4, Supp. Fig. 5, 6, 7) was sufficient to fit the experimental traces. 
For the full-length construct however we required a second intermediate step to match the 
model to the experimental data. The order of release of the reaction products p53 and Ub 
could not be determined based on activity data alone. Therefore we used their respective 
affinities (Fig. 3f and Fig. 5a) to set the order of release. This order, with later release of the 
p53 peptide, also allowed adding the secondary binding site to the model, as induced by 
Ubl45 (Fig. 5a), which fitted well in the stopped-flow data (Fig. 6e,f).
The modelling of the experimental curves allowed us to tease apart the various steps that USP7 
performs in catalysis and reveals how the different domains affect the target processing. For 
instance, the intensity decrease observed upon p53Ub binding by the TCD construct (Supp. 
Fig. 5d) is not seen for FL (Fig. 6d). We can interpret this absence as an effect of the ‘folding 
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back’ of the Ubl domains towards the CD 31 and changing the p53 interaction50. Likewise, the 
long delay time seen for TCD is much shorter for constructs that still contain the Ubl domains. 
As these domains activate CD, it seems reasonable to assume the delay time in TCD is required 
to remodel the catalytic site into an active conformation33 without help of the Ubl domains.
The KinTek analysis results in a model where we can quantify each component (Fig. 6g) and 
reaction kinetics (Fig. 6h). In the first step, anisotropy changes are interpreted as binding of 
substrate p53Ub (Step 1; Fig. 6h), followed by multiple changes in intensity, interpreted as 
conformational changes (Step 2 and 3). This is then followed by the phase where the intensity 
shoots up and the anisotropy decreases (Step 4), interpreted as hydrolysis and release of the 
ubiquitin product. Further intensity changes (Step 5) take place before p53 peptide release 
returns USP7 to the ground state (Step 6).
Validation and evaluation of the kinetic model
Our kinetic model fully agrees with the order of events observed in NMR and SPR analysis in 
Fig. 2-3. We decided to test if this could be used quantitively as an independent control. We 
applied the model to fit the experiments done on the minimal substrate UbRho (Fig. 6a, Supp. 
Fig. 5a, 6a, 7a). Besides validating the kinetic model, this would also allow better definition 
of the rate constants by co-refining the values within KinTek. The intermediate states were 
used in the fitting, making a direct comparison between the ubiquitinated target protein and 
the minimal substrate possible. For the FL construct the efficiency of the reaction precluded 
fitting the intermediate steps in the minimal substrate analysis, so we only used steps 1, 4 
and 7 (Fig. 6h).
Figure 6. Global fitting of activity and affinity data of USP7 allows determination of a quantitative 
kinetic model for USP7 enzymatic activity. Icons in each panel indicate the substrate used. The lines 
describe the fit of the data in the various experiments performed. A. Minimal substrate activity assay of 
USP7FL (1 nM), using a dilution range of UbRho. B. FP enzyme activity assay on TAMRAp53Ub (100 nM). The 
amounts of USP7 are indicated. After conversion to p53Ub amounts (lower panel) a delay time (DT) was 
introduced. C. Stopped-flow FP enzyme activity assay on TAMRAp53Ub (50 nM), the anisotropy signal allows 
observation of the early binding and hydrolysis phases. Areas marked in grey were not included in the 
fit as they represent the mixing time (<0.001 s) or a timescale where bleaching effects start to dominate 
(>10 s). D. Intensity readings of the experiment in C indicates a change in chemical environment upon 
binding of substrate. E. Like C for using peptide only (25 nM p53) shows equivalent binding phases as the 
full substrate. F. Intensity readings of the experiment in E. G. Behaviour of p53-substrate states during 
overall model in an equimolar (1 to 1; 50 nM) ratio of enzyme and substrate. Intermediate states as in H. 
Model used for KinTek fitting with kinetic constants obtained. USP7FL indicated as USP7, intermediates 
with # or *. For binding steps (Step 1, 6 and 7) on-rates are in µM-1s-1 and off-rates in s-1. Rates for 
conformational changes (Step 2, 3 and 5) are in s-1. The forward reaction for enzymatic hydrolysis (Step 
4) is in s-1, but the reverse step (labelled with θ) was assumed irreversible (fixed at 0 µM-1s-1). Equation 
constants with matching Greek characters (α, β, γ and δ) were linked in the refinement. The on-rate for 
binding steps (labelled with ε) is diffusion-controlled, determined separately and fixed during modelling. 
These on- and off-rates reflect the optimal ratio that models the individual steps, since the experiment 
does not have sufficient resolution to fully resolve rates. For both UbRho and p53Ub the resulting steady 
state parameters were calculated to allow for a direct comparison (last column).
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USP7FL
Figure 7. Kinetic model for USP7 mechanism on p53Ub. The kinetic model (right hand equations) and 
their interpretation are depicted schematically. The weak affinity between Ubl45 and CD suggests that 
free USP7 is in equilibrium between an ‘open’ and ‘closed’ state31. The p53Ub substrate is bound by TRAF 
and CD, as well as an additional binding site that depends on the Ubl domains (1). Ubiquitin binding 
induces a rearrangement of the catalytic triad33 (2), which dramatically increases the affinity the activating 
C-terminal tail, but diminishes the contact between CD and Ubl45. Binding of the tail peptide (3) stabilises 
the active state. This promotes the hydrolysis of the isopeptide bond, allowing Ub release (4). This in turn 
diminishes affinity for the C-terminal tail, causing its release (5) and the subsequent release of the p53 
peptide (6) to return USP7 to the ground state.
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The validity of the fitted constants was then analysed using the FitSpace module of KinTek52. 
Here we found that only TCD and FL data had sufficient amplitudes to allow for a full statistical 
analysis (Supp. Fig. 8a,c). To avoid overfitting within this analysis we linked rate constants 
(Supp. Fig. 8a,c; left panel), testing the statistical relevance for their ratios rather than their 
absolute values. The overall result indicated a well-constrained model where Step 2, the 
catalytic rearrangement, is the rate-limiting step. Finally, we converted the rate constants 
into steady-state kinetics parameters using the appropriate formula for one (Supp. Fig. 8d) or 
two (Supp. Fig. 8b) intermediates53 (Supp. Fig. 5g, 6f, Fig. 6h). This yielded K
M
 and k
cat 
values 
similar to those determined previously31, and validated the descriptions used in our modelling.
USP7 activity is driven by target recognition
The conversion to steady-state parameters allows for easy comparison of USP7 activity on 
minimal substrate and the p53 model substrate. Interestingly, on the p53Ub substrate k
cat
 is 
slightly diminished as soon as a TRAF domain is present, but this is offset by the improved 
target recognition (here expressed as K
M
) leading to substantially increased processivity. These 
findings indicate that, although studies on a minimal substrate are essential in studying the 
enzymatic mechanism, using a realistic substrate can give better understanding of the working 
of a DUB and its possible regulation.
Discussion
Updated model for the USP7 mechanism of action
Here we studied USP7 self-activation by its C-terminal peptide and its target protein. We 
show that although trans activation by self-association is possible at high concentrations, the 
normal USP7 self-activation happens in cis. We show that interaction of Ubl45 with the CD 
promotes ubiquitin binding and only this promotes the correct positioning of the C-terminal 
peptide next to the catalytic site. Thus self-activation takes place in multiple distinct steps. 
Next we showed how the substrate protein strengthens activation and provided a kinetic 
model for the cooperative activation process. 
The combination of our findings allows us to generate an updated model for the USP7 mode 
of action (Fig. 7). Ubiquitinated targets associate initially with the TRAF domain (Step 1, Fig. 
7) and this binding is improved by the additional p53 binding site, induced by presence of the 
Ubl domains (Fig. 5c). The target association brings the attached ubiquitin in close proximity to 
the catalytic domain, overcoming its poor affinity for ubiquitin, enhanced by the Ubl45 domain 
(Fig. 3f). The binding of ubiquitin into the active site (Step 2) not only induces rearrangements 
of the catalytic triad33, but also reduces intramolecular interaction with Ubl45 (Fig. 3e) and 
promotes binding of the activating C-terminal tail, through a dramatic increase in affinity (Fig. 
3) where it stabilises the active conformation (Step 3). In this activated state the hydrolysis 
of the isopeptide bond (Step 4) occurs much faster than for CD only31. 
After hydrolysis, release of products takes place, which we modelled according to their 
respective affinities. In full-length USP7 the leaving ubiquitin has a poor affinity compared 
to the p53 peptide (Fig. 5c), so we expect Ub to leave first (Step 4), leaving p53 bound to 
USP7, enabling a change due to the additional binding site (Step 5). The p53 release (Step 6) 
is modelled here as the last step in order to let USP7 return to the ground state, but given 
the tight interaction (160 nM) and the protein concentrations found in cells the p53-USP7 
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complex may last longer in vivo. Another ubiquitinated substrate or additional regulatory 
step could be required to perturb this complex and release p53. 
Model implications
With this model we assumed a sequential order of reactions (Supp. methods) and we could 
not model all steps explicitly (Supp. Fig. 7). Nevertheless, the modelled intermediate steps 
agree very well with our SPR experiments that were not used for the model (Fig. 3). Based on 
the model we can separate intermediates in both time and place, allowing to connect species 
tested by SPR to states found in the kinetic model. Thus we see that Ubl45ΔC is responsible 
for the increased K
M
 whereas the C-terminal tail for the faster k
cat
31.
It is clear from our data that USP7 activation follows a multistep activation scheme that 
generates high specificity for the target. As USP7 interacts with many different targets21, such 
a mechanism could make sure activity is targeted to the right substrate at the right time. Our 
results indicate that the substrate recognition collaborates with the intrinsic self-activation.
The complexity of the self-activation provides regulatory opportunities through external 
factors. One example is hyperactivation by GMPS 31, but other binding partners, such as ICP0 
and DNMT135,54 and/or post-translational modifications may further affect activity.
Interestingly, the p53 peptide collaborates with the C-terminal domains through the additional 
binding site that we quantified. An earlier report suggested binding in the Ubl domains to both 
p5350 and MDM236, but whether such a bipartite binding of substrates by USP7 is a common 
theme in other substrates remains to be investigated. Further definition of the different 
interactions would be needed to explain why USP7 usually prefers MDM2 over p5325,55.
Our data provide opportunities for specific targeting in drug discovery programmes: both 
the secondary substrate binding site and the self-activation by Ubl45 are allosteric sites of 
interest. Working out the specifics of the interaction, using our NMR backbone assignment 
for Ubl45 and the recent assignment of CD56, can be helpful in this process. Better molecular 
understanding of this interaction would help to design inhibitors specifically targeted at USP7 
self-activation.
In this study we employed both a model substrate and the minimal substrate to assess the 
USP7 mechanism of action. The usefulness of the ubiquitinated model substrate is not only 
illustrated by our findings on the activity effect of the TRAF domain, it also allowed us to 
monitor intermediate steps of the reaction and the order in which they occur. Combining these 
chemical ubiquitin tools with a domain-by-domain approach we could pinpoint what part of 
USP7 is important in which part of the hydrolysis cycle. The results highlight the importance 
of the target protein and hopefully these insights will allow for the development of more 
specific USP7 inhibitors, targeting USP7 activity on specific substrates. 
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Materials and methods
Constructs and mutations
USP7 constructs (Fig. 1a) are from31, cloned from the codon-optimized sequence, (Addgene, 
#63573). USP7-TCD was cloned into pGEXNKI-GST-3C using ligase independent cloning57. 
Constructs lacking the C-terminal tail were made by introducing a stop codon at residue 
1083 using site-directed mutagenesis. Mutation constructs were introduced using partially 
overlapping primers and Phusion Flash polymerase (Thermo Fisher). All clones were sequence-
verified.
Protein expression
USP7 constructs that included the TRAF region were expressed in Escherichia coli BL21 Rosetta2 
(DE3) using Terrific Broth medium and overnight induction using 0.2 mM IPTG at 18°C. Other 
USP7 constructs were expressed in E. coli BL21 cells using overnight auto-induction58 at 18°C.
Isotope-labelled USP7-Ubl45 intended for interaction analysis by NMR was expressed in E. 
coli BL21 cells using M9 minimal medium supplemented with 15NH4 Cl (CortecNet), glucose, 
vitamin mix and micronutrient mix59. For three-dimensional NMR experiments 13C-glucose 
(CortecNet) was used. To acquire deuterated sample, D
2
O (CortecNet) was used to make the 
medium. Cells were grown in 5 mL LB from a single colony and transferred to a 50 mL minimal 
medium preculture after washing to grow overnight at 37°C. The preculture was dispensed 
in 4 L minimal medium and cells were grown until OD600 reached 0.6. Protein expression was 
then induced overnight at 18°C by addition of 0.2 mM IPTG.
Protein purification
Proteins were purified as described previously34. In short, proteins were isolated from the 
lysate using Glutathione Sepharose 4B beads (GE Healthcare). After elution the GST tag 
was removed under dialysis using 3C protease and the sample was subsequently applied to 
PorosXQ anion exchange (Thermo Fisher). After analysis appropriate fractions were pooled, 
concentrated and further purified on a Superdex gel filtration column (GE Healthcare). The 
peak fractions were pooled, concentrated up to 10 mg mL-1 and flash frozen.
MALLS experiments
Purified protein was run on a Superdex 200 gel filtration column (GE Healthcare) using GF 
buffer (20 mM HEPES 7.5, 100 mM NaCl, 1 mM DTT) in line with a MiniDawn Tristar (Wyatt 
Technologies) Multi-Angle Laser Light Scattering (MALLS) detector, connected to a Shodex RI 
101 (SHOWA DENKO K.K.) refractive index detector. Wyatt Technologies software (ASTRA) was 
used to determine the corresponding peaks’ molecular weight based on the refractive index.
Deubiquitination assays on a minimal substrate
Enzyme activity of USP7 was measured using the fluorescence of rhodamine upon cleavage 
of the quenched minimal substrate UbRho (Ubiquitin-Rhodamine110Gly, Ub-Rh110Gly; UbiQ, 
the Netherlands). Experiments were performed in running buffer (20 mM HEPES 7.5, 100 mM 
NaCl, 1 mM DTT, 1 mM EDTA and 0.05% v/v Tween-20). Protein samples were prepared at 
2X concentration and added to 8 µM UbRho just before measuring, reaching an end volume 
of 20 µL in the plate. 
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The release of rhodamine was measured at the emission wavelength of 520 nm (±10 nm) after 
excitation at 485 nm (±10 nm) in a Pherastar plate reader (BMG LABTECH GmbH, Germany). 
Either the raw data were plotted directly in Prism 7 (GraphPad), or the slopes were converted 
to initial velocity values for plotting against the titration range. Assays were performed three 
times with two different protein batches.
For steady-state kinetics analysis a single concentration of USP7 constructs (CD, CD12345 and 
CD12345ΔC) was incubated with a dilution range of UbRho and assessed for activity using the 
same experimental setup as described above. The initial velocities were determined using the 
linear slope of the reaction and plotted against the concentration UbRho used. Using Prism 
7 the data were fitted using the Michaelis-Menten equation, yielding the reported steady 
state kinetics parameters.
For kinetics analysis in KinTek, a concentration series of UbRho was used with USP7 constructs 
FL, (1 nM), TCD and CD (both 20 nM). To get resolution at the earliest time points the assay 
was performed using the injector, injecting the enzyme into the UbRho solution followed by 
direct detection (as described above). The resulting values were converted to rhodamine 
concentrations before being loaded into KinTek.
NMR experiments
All NMR experiments were carried out on Bruker Avance III HD spectrometer operating at 850 
MHz 1H Larmor frequency and equipped with a cryoprobe. All NMR spectra were processed 
using Bruker TopSpin or NMRPipe 60. NMR samples for assignment contained 180 µM USP7-
Ubl45 with either uniform 1H, 15N, 13C or fractional 2H, uniform 15N, 13C labelling in 50 mM 
HEPES pH 7.5, 100 mM NaCl, 7% D
2
O and 1 mM DTT (NMR buffer). Backbone resonances 
of Ubl45 were assigned to 84% completeness, using 3D TROSY HNCO, HN(CA)CO, HNCA, 
HNCOCA, HNCB, HNCOCB, HNCACB, and CBCA(CO)NH spectra. Assignment was done using 
CCPN61. The program TALOS62 was used to analyse the secondary structure based on the 
assigned backbone chemical shifts. 
Titration of 1H15N-labelled Ubl45 (45 µM) with either USP7CD (using Ubl45:CD molar ratios 
of 1:0, 1:1, 1:5 and 1:10) or USP7CDUb (using ratios of 1:0.1 and 1:0.3) were performed after 
extensive dialysis of the proteins to NMR buffer. We monitored residue-specific intensity 
change and chemical shift perturbations (CSP) of Ubl45 amide backbone resonances in 2D 
1H15N TROSY spectra. The CSPs were calculated from the perturbations in the 1H (Δδ
H
) and 
15N (ΔδN) dimensions as the weighted average (composite) CSP in ppm according to
63. The 
intensity changes were plotted against residue number for the end point of both titrations.
Generation of covalent Ubiquitin-USP7 complexes
120 µM CD was incubated overnight with an excess of Ub-PA64 and Ubl45 (both 150 µM) 
under dialysis (against 20 mM HEPES pH7.5, 50 mM NaCl, 2 mM DTT), yielding 80% of the 
CD reacted with the ubiquitin probe. The sample was subjected to anion exchange (PorosXQ) 
and gel filtration (Superdex 75) to remove unreacted ubiquitin and Ubl45. Fractions were 
concentrated for use in affinity assays. For USP7-TCD a similar approach was used, only 
substituting p53Ub
VA
 for Ub-PA, resulting in 100% reaction.
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Surface Plasmon Resonance assays
All Surface Plasmon Resonance (SPR) experiments were carried out on a Biacore T200 machine 
(GE Healthcare) at 25°C. A polyclonal GST antibody from the GST capture Kit (GE Healthcare) 
was covalently bound on a CM5 sensor chip via amino coupling. 200 units of GST-tagged USP7 
constructs were immobilised on the test flow cell, whilst the blank flow cell had an equal 
amount of GST only immobilised. The C-terminal peptide (residue 1083-1102) was synthesized 
with a biotin at the N-terminus and immobilized up to ~30 RU on a SA chip. A concentration 
series of USP7 constructs with or without covalently bound ubiquitin probe was tested for 
binding using running buffer (20 mM HEPES 7.5, 100 mM NaCl, 1 mM DTT, 1 mM EDTA and 
0.05% v/v Tween-20) supplemented with 1 mg mL-1 BSA and 1 mg mL-1 dextran.
Interaction values (K 
D
) were determined by plotting steady-state equilibrium values against 
the concentration and fitting these with 1:1 stoichiometry using Prism 7 (Graphpad). For easy 
comparison purpose, responses were normalised using B
max
. For binding curves with detectable 
dissociation and a K
D
 below 10 µM we used EvilFit 42 to determine kinetic rate constants. All 
experiments were performed at least in duplo and representative curves are shown.
Synthesis of p53-conjugated ubiquitin reagents
Both ubiquitin and the C-terminus of p53 were produced synthetically by solid phase 
peptide synthesis, for the native reagent the p53 peptide was N-terminally labelled with 
5-carboxytetramethylrhodamine (TAMRA). The peptide was linked to ubiquitin using click 
chemistry or native chemical ligation49 to yield the non-hydrolysable48, natively linked44 and 
covalently binding45 p53Ub and p53shortUb probes. Details are available in the Supplemental 
methods section.
Fluorescence Polarization binding assays
To measure the affinity for ubiquitin, N-terminally tetramethylrhodamine (TAMRA) labelled 
ubiquitin was incubated with a titration range of each USP7 construct. All assays were 
performed in running buffer (20 mM HEPES 7.5, 100 mM NaCl, 1 mM DTT, 1 mM EDTA and 
0.05% v/v Tween-20) on a Pherastar plate reader (BMG LABTECH GmbH, Germany), using 
excitation wavelength 540 nm (±20 nm) and detection of polarization at 590 nm (±20 nm). 
The anisotropy of TAMRAUb was calibrated at 35 mA, any change in anisotropy upon USP7 
interaction was calculated using MARS data analysis software (BMG LABTECH GmbH, Germany) 
and plotted using Prism 7 (GraphPad).
The affinity between the USP7 constructs and a TAMRA-labelled p53 peptide (TAMRAp53) 
was measured on a ClarioStar plate reader (BMG LABTECH GmbH, Germany). Assays were 
performed in triplo using the same running buffer and wavelength filters (Ex. 540 ±20 nm, 
Em. 590 ±20 nm). TAMRAp53 anisotropy was calibrated to be 35 mA and changes in anisotropy 
were plotted and fitted in Prism 7 to obtain affinities.
The p53 FP binding assay was repeated for USP7FL using a stopped-flow setup. 25 nM of 
TAMRAp53 was incubated with a concentration range of USP7 in running buffer. The binding was 
monitored using an excitation wavelength of 548 nm on a TgK Scientific instrument (model 
SF-61DX2) equipped with photomultiplier tube R10699 (Hamamatsu) and Kinetic Studio was 
used to merge ten separate, sequential injections for each protein concentration.
94
Chapter 3. USP7 activity mechanism
USP7 inhibition assays
USP7 constructs were incubated for 30 minutes in assay buffer (50 mM Tris-HCl pH 7.6, 100 mM 
NaCl, 2 mM cysteine, 1 mg mL-1 CHAPS) with various concentrations of the non-hydrolysable 
p53Ubinh construct, prior to assessment in a deubiquitination assay. To account for difference 
in activity, protein concentrations were adapted for FL (0.35 nM), CD12345 (0.35 nM), TCD 
(200 nM) and CD (75 nM), whilst the substrate (UbRho) concentration was kept constant at 
0.4 µM. Protein samples and substrate were prepared at 4x the final concentration. The initial 
raw velocities were derived and plotted against the titration range of inhibitor reagent. Using 
Prism 7 the data were fitted to yield IC
50
-values.
Fluorescence Polarization activity assays
Various USP7 constructs at indicated concentrations were incubated with 100 nM of TAMRA-
labelled, natively linked p53Ub (TAMRAp53Ub) to trace the binding and hydrolysis of the reagent. 
Assays were performed in assay buffer (20 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mM DTT and 
1 mg mL-1 CHAPS) on a Pherastar plate reader measuring at 590 nm after excitation at 540 nm. 
The FP signal for TAMRAp53Ub only was used as a starting baseline, whilst the TAMRA-labelled 
p53-peptide represents the fully cleaved reagent.
The fluorescence polarization activity assays were repeated in a stopped-flow setup. USP7 
constructs at three concentrations (50 nM, 25 nM and 12.5 nM) were incubated with 50 nM 
of TAMRAp53Ub to trace the binding and hydrolysis of the reagent. TAMRAp53Ub was monitored 
in running buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT and 0.05% v/v Tween-20) 
using an excitation wavelength of 548 nm on a TgK Scientific instrument (model SF-61DX2) 
equipped with photomultiplier tube R10699 (Hamamatsu), the manufacturer’s software 
(Kinetic Studio) was used to merge the ten measurements performed for each concentration. 
KinTek modelling
All data used were imported into KinTek with concentrations in µM and time in seconds: for 
minimal substrate activity curves, converted to released rhodamine, could be loaded into 
KinTek directly. The curves resulting from USP7 inhibition assays were read with a delay time 
of 120 seconds. The FP activity assay data from the stopped-flow instrument could also be 
read-in directly. With the data for every construct imported, the model (Fig. 6h) was fitted per 
construct in separately for each experiment. When the fits proved stable, reaction constants 
were linked and a global fit was performed. The resulting values were then statistically tested 
using the FitSpace module of the Kintek software. For detailed information see Supp. Methods.
Data availability
NMR assignments for Ubl45 (residues 890-1102) have been deposited in the Biomolecular 
Magnetic Resonance Bank (BMRB; www.bmrb.wisc.edu) under accession number 27627. 
Other datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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Supplemental Methods: NMR assignment 
To characterize the weak interaction between USP7-Ubl45 and USP7CD in trans we used 
solution NMR spectroscopy to map the binding interface at the residue-level. We isotope-
labelled the smallest of the two domains, Ubl45, including the C-terminal peptide, and first 
assessed the quality of its NMR spectrum. The 1H-15N correlation spectrum of the 25 kDa 
Ubl45 domain, spanning from residue 889 until 1102, shows the dispersion and number of 
peaks that is expected for a well-folded domain of this size (Fig. 2a). We could confidently 
assign resonances for 84% of the residues present in the construct (Supplemental Fig. 1a). 
The assigned backbone chemical shifts were used to predict the secondary structure using 
the TALOS-N webserver62: the identified secondary structure matched the crystal structure 
of Ubl45 (PDB: 5JTV) very well (Supplemental Fig. 1b). 
Next, we titrated in the unlabelled interaction partner CD and followed the chemical shift 
perturbations (CSPs) for the assigned Ubl45 residues. The titration was performed using 
Ubl45:CD ratios of 1:1, 1:5 and 1:10 where the Ubl45 concentration is kept constant at 45 
µM and the highest concentration of CD is 450 µM. Binding is apparent from the overall loss 
in peak intensities for residues in the folded core of the protein (Fig. 2c). Due to the large 
size of the complex (60 kDa) resonances of the bound state are severely broadened. This is 
not the case for the tails of Ubl45, indicating that they remain flexible. 
The tails did show the same uniform broadening however when titrating in covalently linked 
CDUb (Fig. 2e). Again we kept the concentration of Ubl45 constant at 45 µM, titrating in CDUb 
in an 0.1 and 0.3 ratio, as the determined affinity is in the low micromolar range (Fig. 3). The 
resulting intensity plot for the Ubl45 residues show a decrease correlated to the fraction 
of CDUb titrated in. Furthermore, we can now see that, unlike the CD only titration, the 
intensities belonging to both termini decrease, uniformly with the core domain. This could 
be due to the overall tighter binding, restraining the flexible termini, or to the interaction of 
the termini with the CDUb.
Supplemental Methods: chemical synthesis 
Fmoc solid phase peptide synthesis 
Peptides were synthesized on a Syro II MultiSyntech Automated Peptide synthesizer by 
standard 9-fluorenylmethoxycarbonyl (Fmoc) based solid phase peptide chemistry on a 25 or 
50 µmol scale. Starting with the pre-loaded Fmoc amino acid resin (Applied Biosystems), each 
successive amino acid (Novabiochem) was coupled in 4 molar excess for 45 min with PyBOP 
and DiPEA. Deprotection of the Fmoc group was achieved with 20% piperidine in NMP (2×2 
and 1×5 min). Peptides were cleaved with TFA/H
2
O/phenol/iPr3SiH (90.5/5/2.5/2 v/v/v/v) 
for 3 hrs., precipitated in cold n-hexane/diethyl ether and washed 3× with diethylether. The 
pellet was dissolved in H
2
O/CH3CN/formic acid (65/35/10; v/v/v) and lyophilized. The purity 
of the peptides was determined by LC-MS analysis and peptides were purified by RP-HPLC 
where appropriate.
p53Ub and p53shortUb 
p53 peptides (residues 357-389 and 368-389) containing an thioLys at position 382 and a 
5-carboxy-TAMRA at the N-terminus were synthesized according to the procedure described 
above. Ub was coupled to the peptides by native chemical ligation: To 0.1 M sodium phosphate 
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pH 8.0 were added: 5 mM MgCl
2
 (from 0.2 M aq. stock), 150 mM NaCl (from 5 M stock), 50 
mM MESNa (from 2 M stock), 5 mM ATP (from 0.5 M aq. stock), Ub (50 μM) and TAMRA-
thiolysine modified p53 peptide (250 μM). After adjusting the pH to 7.5 – 8.0 using 1M NaOH, 
E1 enzyme (150 nM, UBE1, Boston Biochem) was added and the ligation mixture was incubated 
at 37°C for 6 hrs. Next, 20 mM VA-044 (from freshly prepared 0.1 M stock in buffer), 40 mM 
GSH and 0.25 M TCEP (0.5 M stock, pH 7.0) were added to the crude ligation mixture. The 
pH was corrected to 7.0 using 1N NaOH and the reaction mixture was incubated at 37°C for 
6 hrs. The constructs were purified by RP-HPLC on a Shimadzu LC-20AD/T using a C8 Vydac 
column (Grace Davison Discovery SciencesTM). Column mobile phases: A= 0.05% aq. TFA and 
B= 0.05% TFA in CH3CN. T= 40°C. Flow rate= 5 mL min
-1. Gradient: 30→75%B over 18 min. 
p53Ubinh and p53shortUbinh
p53 peptides (residues 357-389 and 368-389) containing an azido-ornithine at position 382 
were synthesized according to the procedure described above. Ub was coupled to the peptides 
by the copper-catalyzed alkyne-azide cycloaddition (CuAAC or ‘click’) reaction: Ub-PA and the 
azido-modified p53 peptide were dissolved in warm DMSO at a concentration of 50 mg mL-1. 
1 eq. of the p53 peptide was mixed with 0.9 eq. of Ub-PA (typically 90 µL) in 1 mL 8M urea, 
100 mM phosphate buffer pH 7. To the resulting solution 10 μL of catalyst solution containing 
20 mg mL-1 Cu(I)Br in MeCN and 50 mg mL-1 TBTA-analogue in MeCN (2:3, v/v) was added 
followed by a short vortex, repeated in 5 minute intervals 5 times in total. After reactions 
were finished, as judged by LC-MS (~ 1 hr.), the reaction was quenched by the addition of 
100 μL of 0.5 M EDTA, pH 7.0. The product was purified using RP-HPLC on a Waters Atlantis 
T3 C18 30x250 5μm. Column Mobile phases: A= 0.05% aq. TFA and B= 0.05% TFA in CH3CN. 
Flow rate= 18 mL min-1. Gradient: 20→32%B over 20 min.
p53UbVA and p53shortUbVA
p53 peptides (residues 357-389 and 368-389) containing a Dab(Alloc) at position 382 were 
synthesized according to the procedure described above. The resin was treated with Pd(PPh3)4 
(0.35 eq) and Ph3SiH (20 eq) in DCM (2x 20 min) and shaken overnight at room temperature 
with 4-((tert-butoxycarbonyl)amino)-3-(tert-butyldisulfanyl)butanoic acid (3 eq), PyBOP (3 eq) 
and DiPEA (6 eq). After extensive washings (3× NMP, DCM and Et
2
O) the resin was treated 
with TFA/H
2
O/phenol/iPr3SiH (90/5/2.5/2.5 v/v/v/v) for 3 hrs. followed by precipitation in 
cold Et
2
O/pentane 3:1 v/v. The crude peptide was lyophilized and purified by HPLC. Ub
75
SEt 
was coupled to the peptides by native chemical ligation: To a solution of the p53 Dab mutant 
in 0.15 M sodium phosphate buffer (pH 7) containing 6M Gdn·HCl and MPAA (250 mM), a 
solution of Ub
75
SEt in 0.2 M sodium phosphate buffer (pH 7) containing 6M Gdn·HCl and MPAA 
(250 mM) was added and the mixture (conc.: 50 mg mL-1) was incubated at 37°C overnight. 
Next, TCEP was added to reduce the MPAA disulfide. The product was purified using RP-HPLC 
on a Waters Atlantis T3 C18 30x250 5μm. Column Mobile phases: A= 0.05% aq. TFA and B= 
0.05% TFA in CH3CN. Flow rate= 18 mL min
-1. Gradient: 20→40%B over 25 min.
TAMRAp53 peptide
p53 peptide (residues 357-389) with a 5-carboxy-TAMRA at the N-terminus was synthesized 
according to the procedure described above. LC-MS analysis was performed on a system 
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equipped with a Waters 2795 separation Module (Alliance HT), Waters 2996 Photodiode Array 
Detector (190−700 nm) and a Micromass LCT-TOF Premier mass spectrometer. Samples were 
run over an XBridge BEH300 C18 column (5 μm, 4.6×100mm, T= 40°C). Samples were run at 
0.8 mL min-1 using a gradient of two mobile phases: A= 1% acetonitrile and 0.1% formic acid 
in water; B= 1% water and 0.1% formic acid in acetonitrile. Gradient 30−60%B over 6.5 min.
Supplemental Methods: Global modelling of enzymatic activity
All the acquired data for USP7 activity on the model substrate p53Ub were loaded into KinTek51 
per construct. Here we describe the corrections applied to the data before introduction and 
how we defined our observables. We also state our assumptions and what steps were taken 
to condense the model in order to be dependent on the least amount of variables.
KinTek observables definition and data treatment
The minimal substrate data (panel A in Fig. 6, S4, S5, S6) were obtained using an injector in our 
plate reader set up, so no time delay had to be introduced. The raw data could be converted 
to amounts (µM) using a calibration curve and then directly read into KinTek.
The FP data on the model substrate from the plate reader (panel b, upper) required a delay 
before introduction into KinTek. This delay was estimated for each experiment by co-fitting the 
curves using Prism 7 to determine point “0”. The curves were corrected for a drift using the null 
experiment and subsequently normalised (panel b, lower). Fittable data (with good amplitudes) 
were then read into KinTek, omitting concentrations within two orders of magnitude to the 
substrate concentration due to their lack of signal at the early time points. We defined the 
observed curves as amount of uncleaved substrate (p53Ub) and the bound fraction of product 
(USP7.p53), although this is a minor influence, all scaled by a defined factor c of 1000 that 
converted the used 0.1 µM substrate to 100%.
In the stopped-flow FP activity anisotropy data (panel c) the raw data were read-in as is. For 
data quality purposes we excluded the early time points (<0.001 s) due to the low signal to 
noise ratio as well as the late time points (>10s), as we observed bleaching of the fluorophore. 
Here we scaled the observables using factor a determined from the null experiment as this 
curve represents the appropriate signal for the amounts in the reaction. We noticed how 
the curves, especially for full-length, represented four different phases (Fig. 6c; description 
c) below), so we accounted for these with four different USP7 states each with their own 
scaling factor (FP1-4) that converged in the initial fitting of the experiment.
For the intensity signal accompanying the anisotropy data (Fig. 6d), the overall signal 
differences were less than 10 percent (before the 10 s mark), allowing use of the obtained 
anisotropy signal without correction68. To use the intensity signal, we subtracted the baseline 
(null experiment) and normalised using the early time points (<0.005 s), setting these to an 
arbitrary 100. We then applied the same observables as for panel c, now scaling them with 
a defined factor b of 2000 (100 / 0.05 µM). We found that the intensity of the free substrate 
and product did not differ from their initial bound state (USP7.p53Ub and USP7.p53), but 
that there are two different USP7 states in the hydrolysis. These observations have been 
described with their own scaling factors (I1-I3).
For the constructs TCD and FL affinity for the p53 peptide product was high enough to be 
relevant (Figure 5c). For TCD, this value (2 µM) is far weaker than the 50 nM used in the 
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stopped-flow experiments, so introduction of the fitted FP data from Figure 5c was sufficient 
input. For the full-length construct however, the K
D
 (160 nM) was much closer to the used 
concentration, so we performed a separate stopped-flow experiment for the p53 product, to 
fit the data within the KinTek model. We pre-treated the anisotropy data similarly as in panel 
c, but now only for the product states, and a defined scaling factor q of 3.4 that related the 
used amount (25 nM) to the obtained signal in the null curve.
In panel f we used the intensity data belonging to the p53 product stopped-flow. The data 
are corrected just as in panel d, and the observables now only pertain to the product and 
its complexes. As the used concentration is two-fold lower (0.025 µM) the scaling factor r is 
now 4000.
 a) Rho
 b) c*(p53Ub+(USP7.p53+USP7*.p53))
c) a*(p53Ub + FP1*(USP7.p53Ub) + FP2*(USP7*.p53Ub 
+ USP7#.p53Ub) + FP3*p53 + FP4*(USP7.p53+USP7*.
p53))
d) b*((p53Ub + USP7.p53Ub) + I1*(USP7*.p53Ub) + 
I2*(USP7#.p53Ub) + I3*(p53+USP7.p53+USP7*.p53))
e) q*(p53 + P1*(USP7.p53+USP7*.p53))
f) r*(p53 + USP7.p53+(P2*USP7*.p53))
Reaction assumptions and rate determination
We fitted every experiment separately, to obtain good estimations for the scaling factors. 
We then determined the on-rate, which is diffusion-limited and should be shared over all 
experiments. To this end we used all stopped-flow anisotropy data, as these experiments 
have a direct indication of the association. We were able to pinpoint this rate at 179 µM s-1, 
well within the range considered reasonable for diffusion69. Furthermore, we assumed an 
irreversible reaction, so only hydrolysis of the substrate (k4), locking the reverse reaction 
(k-4) at 0. For the model, we started out with as few steps as possible (binding, catalysis and 
release; Fig. 6h), only adding intermediates when the data required them.
Remarks on USP7 CD
For CD we found that the amplitudes for the stopped-flow data were too small, making them 
unusable for KinTek fitting. Therefore, we used only the minimal substrate (Supp. Fig. 6a) and 
plate reader FP enzyme activity data (Supp. Fig. 6b) for fitting and included data from TCD 
for step 3 (Supp. Fig. 6e), assuming that the observed conformational changes are the same.
Remarks on USP7 TCD
The stopped-flow data for TCD indicated a delay phase (0.1-5 s), which we modelled as a 
conformational change step (Step 2), based on the intensity data (Supp. Fig. 4d). The data 
could be fitted with one state, which did not change shape, thus the observables description 
for c) could be condensed, merging the FP1 and FP2 terms. Furthermore, the FP4 term seemed 
to have a minor effect only after 10 s, prompting us to omit the term in the fit. Similarly, 
we condensed the terms for the accompanying intensity experiment. With the data we 
modelled both the minimal and the model substrate with the same set of reactions, linking 
106
Chapter 3. USP7 activity mechanism
the conformational change step (Step 2) as well as the catalytic step (Step 4). Assuming a 
similar reaction for both substrates resulted in a good fit and values stated in Supp. Fig. 4g.
Remarks on USP7 CD12345
The data for CD12345 had low amplitudes, indicative of the low affinity for the substrate. 
This resulted in high sigma values in the modelling. Just as in the TCD case, we had to model 
one intermediate step for reasonable fits. Therefore we condensed the observable terms 
in a similar fashion as for TCD. Furthermore, as there is no detectable binding of p53 to the 
construct (Supp. Fig. 5c) we did not require the p53 product retaining line in the model.
When attempting to link the found values for the p53 substrate with the minimal substrate we 
found the catalytic rates non-comparable, possibly due to interaction with the p53 peptide. We 
therefore could not assume a similar catalytic rate and constraining the fits was not possible 
through this linking. Combined with the low amplitudes, the less constrained values were 
not converged enough to be assessed by the statistical analysis.
Remarks on USP7 FL and statistical analysis
In the fitting of the FL construct two intermediate steps, instead of one, were required. As 
both TCD and CD12345 needed one intermediate, the requirement for two in the FL construct 
added up. We modelled these steps as two separate distinct steps, assumed to be sequential. 
Furthermore, at the product release steps we had to add a conformational change step upon 
binding of the p53 product (Step 5) to satisfy the p53 peptide stopped-flow data (Fig. 6f).
After fitting all the experimental data using the model description (Fig. 6h), we performed 
the statistical analysis using the FitSpace module of KinTek52 on the fitted data for TCD and 
FL (Supp. Fig. 7). The analysis showed us that some variables are heavily dependent on one 
another, but we could constrain their values by linking their ratios. Our data unfortunately do 
not have the resolution to pinpoint on- and off-rates for each step. The resulting values should 
therefore rather be interpreted as the optimal ratio to model the reaction or intermediate 
steps. 
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Supplemental figure 1. Related to Figure 2; A. The 1H-15N correlation spectrum of Ubl45 with assignments 
indicated. The zoom shows the crowded central region. Smaller crosses are unassigned peaks. B. Secondary 
structure of Ubl45 obtained from NMR backbone shifts. The coloured blocks on the first row represent 
the Ubl domains 4 (yellow) and 5 (red) and the C-terminal tail (purple). The secondary structure from the 
crystal structure, as determined by DSSP65 for PDB: 5JTV, is depicted just below. The primary sequence 
is shown on the third row with tag residues in italics, assigned/unassigned residues in black/grey font 
and highly flexible residues shown with cyan background. The last row shows the secondary structure as 
determined from obtained chemical shifts (HN, N, Cα, Cβ, CO) using the TALOS-N webserver62. 
Supplemental Figures
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Supplemental figure 2. Quantitative analysis of USP7 Ubl45–CD NMR titration data. 
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Supplemental figure 2. Related to Figure 2; Quantitative analysis of USP7 Ubl45–CD NMR titration data; 
A. The overall peak intensity for Ubl45 residues in the folded core without chemical shift perturbations (blue) 
matches the expected values (grey) based on the affinity determined by SPR (Fig. 3A, main text). The core 
peak intensity was derived from the average intensity over 93 residues (all with no or minimal chemical 
shift changes), excluding the 50% most intense peaks. For residues without chemical shift perturbations 
(CSPs), peak intensity is determined by both the population of free (red) and bound (black) states. Notably, 
because of the significantly larger size of the complex (67 kDa) compared to the free protein (25 kDa), 
signals from the bound state will have a ~2.5 times larger line width in each dimension66,67 and will thus 
contribute less to the peak intensity. In addition, the dynamic exchange between free and bound state 
critically determines the observed peak shape and peak intensity, even for residues without chemical 
shift perturbation. In the limit of slow exchange, the signals of free and bound states add independently 
and a peak intensity of 50% of the initial value is expected. In the limit of fast exchange, both free and 
bound states have the same population-weighted relaxation rates and thus the same linewidths, which 
is significantly larger than the pure free state line width. Thus in this limit a final peak intensity of 25% is 
expected. B. Given the fact that the observed peak intensity decrease match well with the expectations 
for the formation of a 67 kDa complex, this indicates that the Ubl45-CD complex behaves as a globular 
assembly rather than two separate domains flexibly linked by the C-terminal tail. C. Simulated NMR 
peak trajectories (left) and peak intensity ratios (right) as function of chemical shift perturbation and off-
rate (k
off
). The simulated system is based on the Ubl45-CD interaction, using the appropriate molecular 
weights for the free protein and complex, the experimentally used titration scheme, and the affinity as 
determined by SPR. The CSP between free and bound state (indicated with a black circle) was systematically 
varied between 0 and maximally 0.5 ppm for 1H and 2 ppm for 15N. The titration was simulated for three 
combinations of on- and off-rates as indicated. Extrapolating from the experimentally observed off-rate 
for the Ubl45–CDUb interaction (K
D
 1 µM, k
off
 1 s-1, Fig. 3c and S3b), the most likely scenario corresponds to 
k
off
 300 s-1 and k
on
 1∙106 s-1, which matches well with diffusion-controlled on-rate for biomolecular systems. 
At this off-rate, only small CSPs can be observed and residues with large chemical shift changes will show 
a strong reduction in peak intensity, beyond what is expected based on the amount of free protein. Higher 
off-rates will allow to observe larger CSPs. For very slow off-rates (< 10 s-1) the free state and bound state 
become essentially isolated species and the observed peak will no longer encode properties of the bound 
state. The bound state will have peak intensity corresponding at most to ~10% (60% population of peak 
broadened 2.5 times in each dimension) of the apo state peak in the limit of no exchange and thus hardly 
observable in practice because of additional exchange broadening. The experimentally observed peak 
intensity ratio at position of the apo peak (42%) is best reproduced using a k
off
 of 50 s-1 (k
on
 2∙105 s-1). Still, 
also for this slow exchange a large decrease in peak intensities (down to 10%) is expected for residues 
with large CSPs. The grey area indicates the expected peak intensities for residues without CSP from the 
slow to fast exchange limit. Peak intensities at the free state chemical shift position in the apo and 10 
equivalent added spectrum are indicated as I
0
 and I
10
, respectively. In cases a CSP can be observed the 
actual intensity ratio will be higher, at most equal to the zero ppm CSP case; these are marked with a *.
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Supplemental figure 3. Related to Figure 3 and Figure 4d; A. Co-elution of CDUb and Ubl45 on Superdex75 
gel filtration indicates a strong affinity. After incubation of CD and Ub-PA with Ubl45 to generate covalently 
bound CDUb, the product co-elutes with Ubl45 on gel filtration. The fractions indicated in the filtration 
profile are run on SDS-PAGE and imaged using the StainFree approach on the imager. B. The SPR curves 
from BiaCore were fitted using EvilFit to obtain both K
D
 and k
off 
values for the interaction between Ubl45 
and CDUb. For every fitted interaction, the left panel shows the fit of the curves (rainbow-coloured) with 
the residuals displayed below. The right panel shows the heat map of the fitted values for K
D
 and k
off
. C. 
The SPR curves from the interaction between the C-terminal peptide and CDUb fitted using EvilFit. D. The 
raw SPR data of the interaction between TCD-p53Ub and Ubl45 (Fig. 4d) fitted using EvilFit.
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Supplemental figure 4. Related to Figure 5 and Figure 6b; A. The inhibition assay (see Fig. 5a) was 
repeated using the short non-hydrolysable p53Ub substrate, showing less inhibition when the TRAF motifs 
are left out. B. The initial velocities for the assay in A. are plotted against the used inhibitor concentration, 
yielding IC
50
-values as stated in the adjacent table. C. The FP-assay as done in figure 6b is performed using 
TAMRAp53Ub
short 
for the various protein constructs. The used protein concentrations are stated, they differ 
between constructs to cope with their difference in activity.
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Supplemental figure 5. Global fitting of TCD data using KinTek. 
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Supplemental figure 5. Related to Figure 6; Global fitting of TCD data using KinTek is displayed in a 
similar fashion as figure 6. Icons in each panel indicate the substrate used. Non-fitted are indicated in 
their panel. A. Minimal substrate activity assay of TCD (20 nM). B. FP enzyme activity assay on TAMRAp53Ub 
(100 nM) in plate reader setup. The used amounts of TCD are indicated in the legends. C. Stopped-flow 
FP enzyme activity assay on TAMRAp53Ub (50 nM), showing anisotropy signal allows observation of the 
binding and hydrolysis phases. D. The intensity signal for the experiment in C indicates a change in 
chemical environment upon binding of substrate. E. The end-point FP experiment measuring the affinity 
of TCD for the p53 product (Fig. 5c) was used to determine product binding of Step 6. F. Upon fitting of all 
experiments described here the fraction of each p53-substrate state could be modelled in an equimolar 
(1 to 1) setting. G. The model description used in KinTek to fit all the data. The intermediate state of TCD 
is indicated with an asterisk (TCD*). The forward and reverse rates reflect the optimal ratio that models 
the individual steps, since the experiment does not have sufficient resolution to fully resolve rates. The 
independently determined diffusion rate (ε) and the irreversible reaction (θ) have been fixed, whilst values 
with identical superscript identifiers (α,β,γ,δ) have been co-refined.
Supplemental figure 6. Related to Figure 6; Global fitting of CD12345 data using KinTek is displayed in a 
similar fashion as figure 6. Icons in each panel indicate the substrate used. A. Minimal substrate activity 
assay of CD12345 (1 nM). B. FP enzyme activity assay on TAMRAp53Ub (100 nM) in plate reader setup. 
The used amounts of CD12345 are indicated in the legends. C. Stopped-flow FP enzyme activity assay on 
TAMRAp53Ub (50 nM), showing anisotropy signal allows observation of the binding and hydrolysis phases. D. 
The intensity signal for the experiment in C indicates a change in chemical environment upon binding 
of substrate. E. Upon fitting of all experiments described here the fraction of each p53-substrate state 
could be modelled in an equimolar (1 to 1) setting. F. The model description used in KinTek to fit all the 
data. The intermediate state of CD12345 is indicated with a pound sign. The independently determined 
diffusion rate (ε) and the irreversible reaction (θ) were introduced as fixed values, whilst values with 
identical superscript identifiers (α,β,γ,δ) were co-refined.
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Supplemental figure 6. Global fitting of CD12345 data using KinTek.
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Supplemental figure 7. Related to Figure 6; Global fitting of CD data using KinTek is displayed in a similar 
fashion as figure 6. Icons in each panel indicate the substrate used. Non-fitted are indicated in their panel. 
A. Minimal substrate activity assay of CD (20 nM). B. FP enzyme activity assay on TAMRAp53Ub (100 nM) 
in plate reader setup. The used amounts of CD are indicated in the legends. C. Stopped-flow FP enzyme 
activity assay on TAMRAp53Ub (50 nM), showing anisotropy signal allows observation of the binding and 
hydrolysis phases. D. The intensity signal for the experiment in C indicates a change in chemical environment 
upon binding of substrate. E. The model description used in KinTek to fit all the data. The intermediate 
state of CD indicated with an asterisk, is included based on the findings for TCD (Supplemental Fig. 4). 
These rates (β) were fixed in the refinement, just as the determined diffusion rate (ε) and the irreversible 
hydrolysis reaction (θ).
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Supplemental figure 8. Related to Figure 6 and Figure S5; A. The statistical analyses as performed by the 
FitSpace module of KinTek. The equation constants (left panel) were linked were applicable and labelled 
(b,c,d or o). The statistical analyses of these constants are depicted in the heat plots (right panel). Constants 
that are marked with an x were locked during fitting and analysis of USP7 FL. B. To calculate steady state 
parameters from the KinTek fits the depicted formulas are used (top panel). The relationship of the used 
constants is drawn schematically in the simplified reaction scheme (lower panel). C. The same analyses 
as in A. performed for the TCD construct. D. The calculation of steady state parameters for reactions with 
one intermediate state (lower panel) requires the formulas depicted (top panel).
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Ubiquitination, and thereby deubiquitination, plays an important role in virtually every 
process of the cell. Its dysregulation can therefore have detrimental effects on cell survival. 
Knowledge on how these processes take place on a molecular level will therefore increase 
our understanding of the workings of the human cell. Furthermore, it can provide a starting 
point for drug development to intervene in certain diseases, such as Alzheimer’s disease1 
or cancer2,3.
In this thesis we describe the activation mechanisms of the deubiquitinating enzymes (DUB) 
USP7 and its homologue USP40. The findings pertain not only to these two DUBs, but could 
represent a general mode of activation for (a subclass of) USP enzymes. Moreover, this 
activation mechanism indicates a potential window for specific inhibition as the self-activation 
of these enzymes does not rely on the conserved USP-fold. Insights obtained from the research 
described in this thesis would help to develop such specific inhibitors and could help in 
studying other (deubiquitinating) enzymes.
USP7 activation mechanism
In chapter 2 and chapter 3 we have investigated the activity of USP7 in great detail. Using 
protein crystallography we could elucidate a partial structure of the catalytic domain (CD) 
and the first three Ubiquitin-like (Ubl) domains4. This structure on its own did not directly 
provide insight into the mechanism of action of USP7, but did supply an essential piece to 
merge the structures solved previously into one full-length model. The full-length model 
shows how the 7 different domains are arranged spatially. 
As is often the case with multi-domain proteins, USP7 requires multiple domains for its full 
activity. For every separate domain a global function had been described previously, but in 
chapter three we have tried to identify, quantitatively where possible, the contribution of each 
domain to the deubiquitinating activity of USP7. For USP7 to reach its full activity, it requires 
the last two Ubl domains (Ubl45) with the very C-terminal tail5. When these are present, both 
the affinity and processivity for a minimal substrate increase6. The K
M
 improves five-fold, while 
k
cat
 goes up roughly twenty-fold. Using biochemistry, combined with biophysical techniques 
like nuclear magnetic resonance (NMR) and surface plasmon resonance (SPR), we were 
able to tease apart the effect of the Ubl domains and the very C-terminal tail. In a nutshell, 
the Ubl45 domains can bind the CD, thereby changing its conformation and increasing the 
affinity for ubiquitin. Once ubiquitin is bound in CD, it will adopt an active state7 and now the 
C-terminal tail can bind, which stabilises the active form, allowing for rapid hydrolysis. This 
state has been captured in a crystal structure by Rouge et. al.8.
For the enzyme to get from the open state to the closed, activated state however, the 
C-terminal domains will have to curve dramatically. Although such big movements are not 
unheard of for conformational changes in proteins9, it is the first DUB described to have this 
rearrangement. Interestingly, the second step where the tail binds is heavily dependent on the 
presence of ubiquitin. Such behaviour is reminiscent of the classic ‘induced fit’ theorem10,11, 
where the substrate induces a rearrangement into the active state.
This particular activation mechanism could also have consequences for the design of a potential 
inhibitor of the enzyme. The ubiquitin/proteasome system (UPS) has been an interesting 
target for the development of drugs12, as it is involved in many facets of cell biology. USP7 
has received particular interest due to its multifaceted role in the cell (see chapter 1) and 
its name ‘guardian of the genome’13 due to its interaction with p53 and its E3 ligase14. The 
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development of inhibitors for these deubiquitinating enzymes is usually done using activity 
profiling of various small compounds15. Promising leads are then combined to create better 
inhibiting compounds, which are then assessed for specificity against a panel of other DUBs16,17. 
Quite often this results in compounds that compete with Ub for binding in the active site18–20, 
as the activity profiling assays are done on a minimal substrate. As we show in chapter 3, the 
additive effect of the realistic target is rather large, so these types of inhibitors would require 
very tight binding affinities. This could potentially be achieved by adding a TRAF binding motif 
to the compounds (along the lines of the non-hydrolysable probe in chapter 3), but how this 
would work out for the pharmokinetics remains to be seen.
The USP7 activation mechanism actually presents a potential to circumvent this problem. 
As the enzyme relies heavily on the self-activation by the tail, inhibiting this interaction 
would create a non-competitive inhibitor. Some studies have already yielded such allosteric 
inhibitors21,22 and they resulted in low nanomolar inhibitors. As USP7 plays a role (see chapter 
1) in many cellular processes however, an USP7 inhibitor will target more pathways than 
initially anticipated and could results in off-target effects. Hopefully these inhibitors can 
be further developed to successfully modulate USP7 activity, there where it is needed. The 
current progress of developing non-competitive, allosteric inhibitors is however promising. 
Targeting the catalytic domain only could yield dual-specific inhibitors, as is illustrated nicely 
with the cross-reactivity of USP7 and USP47 for various inhibitors17. Perhaps mimicking the 
biological target could not only increase the affinity of inhibitors, but also further specify the 
drugs towards one particular (state of) enzyme.
A new subclass of USPs
Cross-reactivity between close homologs is not unheard of17 and is not too surprising to 
find this between USPs. This class of DUBs contains 54 members in humans and all share 
the same catalytic domain. The catalytic domain on its own often has no specificity towards 
ubiquitin chains23. The deubiquitinating specificity of USPs is largely dependent on the 
accessory domains, which for USPs are present in high numbers and varieties24,25. To further 
understanding of their influence, each of these domains separately would need to be analysed 
in context of the CD. As this would present a huge amount of work, it is appealing to postulate 
some generalities and, based on these, divide the USPs in subclasses.
In this thesis two DUBs with C-terminal Ubl domains have been investigated. USP7, the main 
player in this thesis, has a quintet of Ubl domains of which the last two, including a twenty-
residue tail, enhance its deubiquitinating activity dramatically. As we show in chapter 4, USP40 
has a similar make-up, with now six Ubl domains in the C-terminal half. And, as with USP7, the 
latter two, again including a possibly flexible tail, greatly enhance the activity of the USP40 
catalytic domain. Such a shared self-activation mechanism would put the two DUBs within 
the same subclass, from both a functional and structural point of view.
To identify other members of this class one could look at sequence conservation and structural 
similarities. Unfortunately, sequences of a Ubl domain can vary widely, despite their structural 
homology26,27. BLAST searches using the final two domains therefore yield very little useable 
results while searches that use full-length sequences of USP7 or USP40 place emphasis on 
the catalytic domain. The latter search yielded a list of USPs, with some of them containing 
a (predicted) Ubl-domain. This limits the potential candidates for the new subclass, although 
this approach could miss others, due to difficulty in predicting Ubl domains26. More in-depth 
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analysis of these USP sequences readily shows three different positions in relation to the 
catalytic domain, perhaps indicating three different subclasses. Indeed USP4, USP11 and 
USP15 have previously been grouped together28 as they all share the internal Ubl domain 
as well as an activation mechanism that involves the N-terminal DUSP-Ubl 28. Moving on to 
the group with C-terminal Ubl domains, we see that USP7 and USP40 are accompanied by 
USP47 and USP48, and we could propose that these four make up the new subclass of USPs 
that can get self-activated trough their C-terminal Ubl domain.
For USP40 this activation has been shown in chapter 4, while for USP7 the self-activation has 
been described by us and others5,6,8. The role of Ubl domains in USP47 and USP48 require 
experimental validation. Although USP47 has been produced and tested in vitro no in-depth 
activation experiments have been performed29. For USP48 a thorough assessment of its 
activity on histone H2A was done30. This study not only unearthed its target preference, 
it also indicated that for full activity it requires the putative Ubl domain located near its 
C-terminus. This reduction in activity upon omission of the Ubl domain is reminiscent of the 
requirement of Ubl45 in USP7 self-activation and could imply that USP48 follow a similar 
activation mechanism.
One other requirement for the activation mechanism as presented for USP7 however, is the 
presence of a ‘switching loop’ in the catalytic domain. This ‘switching loop’ acts through a 
rearrangement of aromatic residues6, but whether there are e.g. obligate tryptophan positions 
in this loop is not yet known. Alignment of all USP domains revealed that USP48 lacks a loop 
altogether in this place, but both USP40 and USP47 contain an aromatic motif like USP731. 
This would suggest that, although only three members large, this subset of USPs activate 
itself in a similar way. Such a conserved mechanism would not only be interesting from an 
evolutionary point of view; if it is indeed conserved, the findings described in this thesis could 
help investigations on these DUBs as well.
External USP modulators
The conservation within this subclass is not limited to the C-terminal Ubl-domain and the 
proposed activation mechanism. All group members have a series of duplicated domains 
between the catalytic domain and the activating Ubl. For USP7, USP47 and USP40 these Ubl 
domains are sometimes grouped per two and can mediate protein-protein interactions: the 
interactions of Ubl123 of USP7 have been described in chapter 1. The presence of these 
domains between CD and the activation domain prompts to speculate about the effect on 
DUB activity upon binding an interactor.
Unfortunately binders in this region have only been described for USP7. And although many 
have been found, very few have been investigated for in vitro activity modulation. GMPS32 
is the one exception and for this protein an activity-enhancing effect on USP7 has been 
observed6. The proposed mechanism for this hyper-activation revolves around the active 
conformation of USP7 and its stabilisation by GMPS through the intermediate Ubl domains. 
Thus far no co-crystal structure of this complex has been solved so how GMPS would keep 
USP7 in de active, bend form remains unknown thus far. Other binders of Ubl123 however 
have been solved and especially the viral protein ICP0 seems to create a bend within the Ubl 
domains33. This could indicate an activating role for the protein, but no studies on this have 
been published. Another co-crystal structure, the one with DNMT134, shows an extended 
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form of the five Ubl domains, suggesting the opposite effect, but whether DNMT1 inhibits 
USP7 activity is yet to be uncovered.
The list of USP7 Ubl123 interactors is long, and for some hits a function could already be 
implied. Secondary proteins can use the interaction to recruit USP7 to a complex or site of 
interest. For example, UHRF1 can recruit USP7 to protect the DNA methylation maintenance 
complex from getting ubiquitinated and degraded35,36. Such recruitment, or scaffolding, 
would not necessarily influence the activity, but does localise the DUB to a place in need. 
Finding such interactors for the other members of the subclass would therefore not only be 
interesting from a mechanistic point of view, but could shed some light on the biology of 
these, fairly unstudied, USPs. Thus far USP40 or USP47 have only been marginally implied in 
certain pathways and their biological target has yet to be discovered.
USP target specificity
As we have discussed in chapter 3, next to the internal (and external) domains, the actual 
target of the USP plays a big role in DUB activity. USP21 for instance readily cleaves most 
ubiquitin linkages37 except K6-linked ubiquitin chains, as these chains sterically hinder the 
catalytic domain38. For USP40 we see a similar behaviour, but now with K27 chains. The 
inability of the enzyme to cleave K27 diubiquitins could rise from a similar steric hindrance 
or from binding the ubiquitin with the free carboxyterminus. A structure of USP40CD alone 
or in complex with K27 diubiquitin would definitely help to gain insight. Not being able to 
process a certain ubiquitin chain could also have implications on a biological level. Thus far 
K27 chains have not been studied that extensively, but one can imagine K27 linkages serving 
as a protective cap, not allowing USP40 to digest the preceding chain.
In chapter 3 we have looked at the contribution of a target on USP7 activity. We showed that, 
independent from the activating tail the recognised p53 sequence can enhance the activity 
roughly four hundred-fold, and roughly fifteen-fold in the full-length setting. These data give 
good insight to how deubiquitination specificity is obtained: under normal circumstances the 
DUB has moderate activity, but is able to increase it when the ubiquitinated target is present. 
This not only is an elegant way of target-regulated DUB activity, it opens up this specific 
DUB activity to regulation. By e.g. phosphorylation of either the TRAF recognition motif on 
p53 or the TRAF domain itself the activation effect can be diminished and USP7 remains a 
moderately active DUB. This type of DUB regulation might make the USP7-MDM2-p53 switch 
act when necessary.
Investigations into DUB mechanisms, or enzymes in general, might benefit greatly from using 
more realistic substrates in the assays. Finding the proper substrate and eventually generating 
derivatives that allow for biophysical examination from this substrate however can be a rather 
daunting task. For the case described in chapter 3 both the binding and ubiquitination sites 
of p53 were previously determined, which allowed the chemists to generate the realistic 
substrate tools to study USP7. These studies can generate more biological insight as one 
mimics physiological circumstances. Studying USP mechanisms using more realistic substrates, 
alongside a minimal one, gives more information about the intrinsic regulation and can open 
new therapeutic avenues. 
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A. Summary
The human cell contains a lot of different proteins that need to collaborate to keep the cell 
healthy and in working order. In order to facilitate these collaborations and make changes 
to the way the proteins interact, the cell employs modifications such as ubiquitination. This 
attachment of a ubiquitin molecule can change the function of the protein after cellular 
events like damage on the DNA or send the signal that the protein is no longer required and 
needs to be degraded. As ubiquitination is involved in many cellular signals, its dysfunction 
can have adverse effects and lead to diseases.
To keep the system in balance, the ubiquitin modification can also be taken off, by so-called 
deubiquitinating enzymes (DUBs). As these enzymes exert control over the ubiquitination 
pathway through countering the ubiquitination state of targeted proteins, they can potentially 
be used for human intervention. By selectively inhibiting DUBs one could potentially battle 
diseases such as cancer. To acquire proper inhibitory drugs however, knowledge of the 
mechanistic workings of these enzymes is a key requirement.
In this thesis we investigated the molecular mechanism of a subset of USPs (Ubiquitin-Specific 
Proteases), a class of DUBs. Our findings describe how USP7, one of the subset members, 
can get activated by its biological target, sketching a role for its biological partner proteins. 
Furthermore, we describe on a molecular level how the domain structure of USP7, but also 
the paralogue USP40, aids in the intrinsic activity by activating the enzyme. We show that this 
self-activation is a conserved mechanism, yielding valuable information for the development 
of inhibitory molecules, but altogether also providing insight into the biological workings and 
role of these USP enzymes.
Review on USP7 regulation
USP7 interacts with a plethora of proteins, some of them targets of the enzyme, others 
interactors with a potential to modulate the enzyme activity. In chapter 1 we review 
the activation mechanism of USP7 (in-depth investigated in chapter 3) and describe a 
comprehensive list of validated USP7-interacting proteins. These interactions can link USP7 
to various cellular pathways, but also represent a potential for regulating its activity, through 
e.g. recruiting USP7 to a specific site or affecting the intrinsic deubiquitination speed. We 
describe that, next to the activating GMPS protein, DNMT1 could have an effect on USP7 
activity as both bind on the C-terminal part of USP7, possibly affecting the activating domain.
Another striking find is the abundance of E3 ubiquitin ligases that have been reported to 
interact with USP7. As these proteins are responsible for the last step in the attachment of a 
ubiquitin onto a target protein, the co-occurrence with a DUB seems counterintuitive at first. 
However, the presence of one unit that can both add and remove ubiquitin would allow for 
quick switching between two states of the target protein. A good example is p53, a protein 
that can trigger cell apoptosis, which gets ubiquitinated by MDM2 and deubiquitinated by 
USP7. With MDM2, USP7 and p53 existing in a complex, the cell can quickly switch between 
the ubiquitinated or unubiquitinated state of p53 and thereby decide upon cell death or 
survival. If one understands this switch better and were able to modulate it explicitly in cancer 
cells, this would be a great step forward for cancer treatments.
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Structure of USP7
Important information in the development of drugs often comes from acquired crystal 
structures. As such there have been many attempts to crystallise USP7, unfortunately only 
resulting in partial structures. We were able to crystallise a construct of USP7 that allowed to 
‘merge’ the available structures of USP7 into a full-length model, painting a picture of what 
USP7 could look like.
Furthermore, this structure exposed a very long α-helical linker between the catalytic domain 
and the activating Ubl domains. We could show that this linker is important to obtain proper 
interaction in ubiquitin hydrolysis between the catalytic domain and the activating one.
Mechanism of USP7
This activation mechanism is one topic in chapter 3, where we looked into the self-activation 
of USP7 with molecular detail. USP7 has a domain architecture in which the catalytic domain, 
where the actual hydrolysis happens, is flanked by a TRAF domain at the N-terminus and five 
Ubiquitin-like (Ubl) domains at the C-terminus. The last two of these, including a flexible tail 
at the very C-terminal, are required in the self-activation of USP7.
Using biochemistry, NMR and biophysical methods we showed how the Ubl domain affect the 
catalytic activity in two distinct steps.  The Ubl domains themselves, without the tail, interact 
with the catalytic domain and thereby increase its affinity for ubiquitin. When the catalytic 
domain, which normally has an unproductive conformation, binds ubiquitin, it rearranges and 
thereby changes the interaction with the activating Ubl45 domain. Instead of the Ubl domains, 
now the C-terminal tail plays the main role, it can bind the rearranged catalytic domain and 
stabilise this catalytically competent state. This stabilisation results in an increase in rate, 
overall resulting in faster hydrolysis of the ubiquitin bond. This self-activation mechanism 
makes the full-length protein a hundred-fold more active than the catalytic domain only.
Influence of a substrate
The domain at the N-terminus, the TRAF domain, can also play a role in the activity of the 
enzyme. This domain is required for the interaction with ubiquitinated proteins and in chapter 
3 we can confirm this using the model substrate p53. We also show that this particular 
interaction also aids in the processing of the substrate, by making use of novel chemical tools 
and computational modelling of acquired biophysical data. Overall the activity on the p53 
substrate is fifteen-fold higher, than the activity observed for the minimal substrate that is 
often used in these DUB studies. As these more realistic substrates represent biology much 
better, their usage could give more insight in the enzyme mechanisms.
162
Addendum. A. Summary
USP40 has a similar mechanism
For USP40, a close paralogue of USP7, however we mainly used the aforementioned minimal 
substrate, as for this DUB no targets are currently known. We used a bioninformatics approach, 
backed up with biochemistry and biophysical assays to confirm that USP40 shares the same 
activation mechanism as USP7. It uses its last two Ubl domains (Ubl56 in this case) and the 
flexible C-terminal tail to increase the affinity for ubiquitin and the rate of hydrolysis. Whilst it 
shares a lot with USP7, USP40 differs on certain aspects. The inability to efficiently cleave K27-
linked diubiquitin might perhaps be the most interesting point. We show that this substrate 
competes with minimal ubiquitin substrate and can inhibit USP40. This inhibitory mechanism 
could be of interest to those studying K27 chains and our research lays the groundwork for 
a better understanding of the K27-DUB interaction.
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B. Samenvatting
De menselijke cel is een complex systeem, duizenden verschillende eiwitten moeten nauw 
samenwerken om alles draaiende te houden. Eiwitten, en de processen waar ze bij betrokken 
zijn, zijn streng gereguleerd, alles moet op het juiste moment en de juiste plaats gebeuren 
om de cel gezond te houden. Om de werking, locatie of concentratie van specifieke eiwitten 
te beïnvloeden maakt de cel gebruik van labels, ook wel post translationele modificaties 
genoemd. Eén zo’n modificatie is ubiquitinatie, waarbij het kleine eiwit ubiquitine als label 
wordt vastgemaakt. Het ubiquitine label heeft een aantal verschillende functies, die afhangen 
van waar, hoe en hoeveel van het label is vastgemaakt. Ubiquitinatie kan worden gebruikt als 
signaal dat een eiwit moet worden afgebroken, het kan eiwitten activeren of juist deactiveren, 
eiwit-eiwit interacties versterken of juist verbreken of zorgen dat een gelabeled eiwit naar een 
bepaalde plaats in de cel wordt gestuurd, bijvoorbeeld naar het DNA als daar een beschadiging 
is opgetreden. Al deze regulatie is van cruciaal belang om de processen in de cel goed te laten 
verlopen, een probleem met ubiquitinatie kan desastreuze gevolgen hebben voor de cel en 
zelfs leiden tot het ontstaan van kanker.
Voor de juiste regulering van deze processen is het niet alleen belangrijk dat het ubiquitine 
label aan eiwitten kan worden vastgemaakt, maar ook dat het op specifieke momenten 
weer verwijderd kan worden. Het verwijderen van ubiquitine wordt uitgevoerd door 
deubiquitinerende enzymen (DUBs). Door het tegengaan van het ubiquitinesignaal oefenen 
deze enzymen controle uit over het lot van de eiwitten die ze deubiquitineren. Als deze 
gebalanceerde ubiquitinesignalering misgaat kan dat ziektes veroorzaken zoals kanker of 
Alzheimer. DUBs zijn daardoor een interessant doelwit voor medicijnen tegen deze ziektes. 
Gedetailleerde kennis van de structuur en het werkingsmechanisme van deze DUBs komt erg 
van pas bij de ontwikkeling van specifieke en effectieve enzymremmers. 
In dit proefschrift hebben we gekeken naar het moleculaire mechanisme van twee 
deubiquitinerende enzymen uit de klasse van de Ubiquitine-Specifieke Proteases (USPs). 
Door middel van biochemische en structuurbiologische experimenten achterhalen we het 
mechanisme van USP7 en USP40. In deze thesis worden de stappen van het enzymatische 
mechanisme beschreven, identificeren we welke residuen essentieel zijn en vinden we een 
activerende rol voor het C-terminale gedeelte van het enzym. Hiermee wordt een moleculaire 
basis gelegd voor enzymremmers voor USPs.
De cellulaire rol van USP7
Het mechanisme achter de enzymatische activiteit van het deubiquitinerende enzym USP7 
is het hoofdthema van dit proefschrift. USP7 speelt een rol in veel verschillende processen 
in de cel en is een onderdeel van uiteenlopende signaleringscascades. De bekendste rol van 
USP7 is de deubiquitinatie van p53, een tumor suppressie eiwit, dat door deubiquitinatie 
wordt gespaard van degradatie en daardoor celdood kan induceren. Het enzym is hierdoor 
onmisbaar voor de ontwikkeling van cellen en een slecht functionerend USP7 kan leiden 
tot neurologische defecten zoals autisme en ontwikkelingsstoornissen. Daarbovenop speelt 
USP7 ook een rol bij het herkennen en repareren van schade aan het DNA. Het enzym heeft 
dan ook interacties met een groot aantal andere eiwitten. Sommige van deze eiwitten zijn 
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een doeleiwit van USP7 en worden door USP7 gedeubiquitineerd. Anderen kunnen juist de 
activiteit van USP7 beïnvloeden of werken samen met USP7. In hoofdstuk 1 geven we een 
overzicht van de eiwitinteracties die USP7 maakt en gaan we in op de mogelijke effecten van 
deze interacties op de activiteit van USP7. 
Kristalstructuur van USP7
Zoals hiervoor al besproken is het deubiquitinerende enzym USP7 een interessant doelwit 
voor het ontwikkelen voor medicijnen. Kennis van de moleculaire structuur van USP7 kan 
daarbij een grote rol spelen, er zijn daarom al veel pogingen gedaan om de structuur van USP7 
op te lossen. Tot nu toen zijn er echter alleen gedeeltelijke structuren beschikbaar waarin 
slecht enkele domeinen te zien zijn. 
USP7 bestaat uit zeven domeinen (zie Figuur 1 van Hoofdstuk 1): een TRAF-domein, waarmee 
(geubiquitineerde) doeleiwitten worden herkend, een katalytisch domein, waarin de hydrolyse 
van de ubiquitinebinding plaatsvindt, vijf ubiquitine-achtige (Ubl) domeinen en een flexibele 
staart aan de C-terminus. Vooral de laatste twee Ubl domeinen (Ubl45), inclusief de flexibele 
staart, zijn erg belangrijk voor de activatie van USP7.
In hoofdstuk 2 presenteren wij de structuur van het katalytisch domein en de eerste drie Ubl-
domeinen van USP7. Hoewel dit weer een gedeeltelijke structuur betreft, is onze structuur 
zeer waardevol voor het begrijpen van de structuur van het hele eiwit. Onze structuur vormt 
namelijk een brug tussen de eerder gepubliceerde structuren, waardoor hij gebruikt kan 
worden om de losse structuren aan elkaar te koppelen en een model te maken van heel 
USP7 (Hoofdstuk 1 Figuur 1). Bovendien laat onze structuur een lange α-helix zien tussen het 
katalytische domein (CD) en de activerende, ubiquitine-achtige (Ubl) domeinen. Deze linker 
is van belang om het activerende domein op de juiste plek te brengen ten opzichte van het 
CD en beïnvloedt daarmee de activiteit van USP7.
Activatie van USP7
Naast het ophelderen van de structuur hebben we gekeken naar het katalytische mechanisme 
van USP7 en de functies van de verschillende domeinen. De essentiële stap van het katalytische 
mechanisme van USP7 is de activatie. USP7 is in staat tot zelfactivatie, een proces waarbij 
verschillende delen van het eiwit betrokken zijn. Met biochemische experimenten hebben wij 
aangetoond dat het katalytisch domein op zichzelf niet heel erg actief is; het verwijderen van 
ubiquitine van een modelsubstraat gaat zeer langzaam. Als de laatste twee Ubl domeinen en 
de flexibele staart (Ubl45) aanwezig zijn, wordt deze activiteit ruim honderd keer verhoogd. 
In hoofdstuk 3 laten wij met behulp van NMR en biofysische methoden zien dat Ubl45 
het katalytisch domein in drie stappen activeert. Allereerst hebben de Ubl domeinen, 
maar niet de staart, een interactie met het katalytisch domein, waardoor de affiniteit voor 
ubiquitine wordt verhoogd. De volgende stap is de binding van ubiquitine, dit zorgt voor een 
conformatieverandering in het katalytisch domein. Deze conformatieverandering verhoogt 
de affiniteit van het katalytisch domein voor de flexibele staart van Ubl45. De derde stap 
is de binding van de flexibele staart. Deze binding stabiliseert de actieve conformatie van 
het katalytisch domein, waardoor het volledige eiwit zo’n honderd keer actiever is dan het 
katalytische domein alleen.
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De invloed van het substraat op de enzymactiviteit
Naast de Ubl-domeinen, die een rol spelen in de zelfactivatie, en het katalytisch domein, 
heeft USP7 ook nog een TRAF-domein. Dit domein is verantwoordelijk voor de interactie 
met doeleiwitten en is daardoor belangrijk voor de activiteit bij natuurlijke substraten. In 
hoofdstuk 3 onderzoeken we hoe de interactie van het TRAF-domein met p53, een doeleiwit 
van USP7, de activiteit van USP7 beïnvloedt.
Om dit te bestuderen hebben we met innovatieve synthetische technieken een modelsubstraat 
van geubiquitineerd p53 gemaakt. Door een deel van dit natuurlijke doeleiwit chemisch na te 
maken verkregen we een homogeen substraat waar makkelijker studies aan gedaan kunnen 
worden. Met dit realistische modelsubstraat hebben we vervolgens de activiteit geanalyseerd 
van verschillende combinaties van USP7 domeinen. Door deze opgedane biofysische data te 
modelleren kregen we vervolgens informatie over de invloed van de verschillende domeinen 
en tonen we aan dat het TRAF-domein essentieel is voor de herkenning van doeleiwit p53. 
Bovendien ontdekten we dat de activiteit van USP7 grofweg vijftien keer hoger is door de 
betere herkenning en binding van het substraat is wanneer we de p53 herkenningssequentie 
gebruiken in het modelsubstraat. 
USP40 en USP7 delen het activatiemechanisme
USP40 is een deubiquitinerend enzym uit dezelfde eiwitfamilie als USP7. Over USP40 is echter 
een stuk minder bekend in de literatuur. Zo is bijvoorbeeld niet bekend wat de natuurlijke 
doeleiwitten zijn voor USP40. Om toch onderzoek te kunnen doen naar de activiteit van USP40 
en het werkingsmechanisme te kunnen bestuderen hebben we gebruik gemaakt van een 
modelsubstraat zonder een herkenningssequentie van een doeleiwit. Met dit substraat konden 
we verschillende USP40 domeinen en combinaties daarvan testen op deubiquitinatieactiviteit. 
De resultaten hiervan, tezamen met onze bioinformaticastudie leidden tot de conclusie dat 
USP40 een vergelijkbaar activatiemechanisme heeft als USP7. Ook bij USP40 vinden we dat 
de laatste twee Ubl-domeinen en de flexibele C-terminus essentieel zijn voor de volledige 
activiteit van het enzym. Ook konden we, aan de hand van de conservatie ten opzichte van 
USP7, de essentiële residuen identificeren.
Met deze kennis hebben we ook gekeken naar de specificiteit van USP40 ten opzichte van 
verschillende types ubiquitineketens. Hieruit blijkt dat USP40, in tegenstelling tot USP7, 
maar moeilijk K27 ketens knipt en dat deze ketens zelfs een inhiberend effect hebben. Onze 
resultaten laten zien dat USP7 en USP40 volgens hetzelfde mechanisme werken, maar dat 
ze toch verschillen in katalytische specificiteit.
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C. Stellingen
1. USP7 activiteit kan worden beïnvloed door al zijn domeinen. (dit proefschrift)
2. Het TRAF domein van USP7 is van belang voor de herkenning van het 
doeleiwit, maar beïnvloedt daarmee ook de enzymatische activiteit. (dit 
proefschrift)
3. De zelf-activatie van een USP domein door een  peptide aan de C-terminus 
is een algemeen principe voor een subgroep van USP enzymen. (dit 
proefschrift)
4. Door het bestuderen van USP7 activiteit op verschillende, realistische, 
biologisch relevante substraten kan achterhaald worden hoe USP7 in de 
cel functioneert. (dit proefschrift)
5. Het modelleren van experimentele data helpt enorm om verschillende 
datasoorten kwantitatief te combineren en daarmee mechanismestappen 
te deconvolueren. (dit proefschrift)
6.  “Volledige kennis van iets veronderstelt ook de kennis van zijn oorzaak.” 
(Baruch Spinoza)
7. De biochemie zou enorm geholpen zijn met het standardiseren van 
eiwitnamen en het uitbannen van alternatieve benamingen.
8. De huidige (bio)fysische en (bio)chemische technieken complementeren 
elkaar en enkel door meerdere methoden te gebruiken kan een 
werkingsmechanisme worden ontrafeld.
9. Het bestuderen van gerelateerde, maar biologisch minder interessante, 
eiwitten kan waardevolle informatie opleveren voor het relevantere 
doeleiwit, en de biologie in het algemeen.
10. Als domeinen in een eiwit wel samenwerken om een activatiemechanisme 
te vormen, waarom competeert men dan om dit te begrijpen?
11.  “Als je ouder wordt, wordt je velletje dunner maar je huid dikker” (Pim van 
Dijk; 06-05-2013)
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